Myo1d inhibitor and use thereof

A novel small molecule compound targeting MYO1D degrades multiple GFRs via TPD, addressing drug resistance and metastasis in cancer therapies by inhibiting MYO1D, enhancing the efficacy of anti-EGFR drugs and providing a therapeutic strategy for GFR-overexpressing cancers.

WO2026240631A2PCT designated stage Publication Date: 2026-11-19IND FOUND OF CHONNAM NAT UNIV +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/097018
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current cancer therapies face challenges such as drug resistance, dose-limiting toxicity, and metastasis due to issues with targeting single growth factor receptors (GFRs), necessitating a strategy to inhibit multiple abnormally activated targets simultaneously.

Method used

Development of a novel small molecule compound that targets the molecular motor MYO1D, anchoring GFRs to the plasma membrane, using Targeted Protein Degradation (TPD) to degrade multiple GFRs via the Ubiquitin-Proteasome System, thereby inhibiting their function and overcoming resistance to existing anti-GFR drugs.

Benefits of technology

The compound effectively reduces the growth and invasiveness of cancer cells resistant to GFR inhibitors by degrading GFRs, enhancing the efficacy of anti-EGFR drugs and providing a novel therapeutic approach for GFR-overexpressing cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026097018_19112026_PF_FP_ABST
    Figure KR2026097018_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a MYO1D inhibitor and use thereof and, more particularly, to a novel compound that inhibits the activity of MYO1D, and a composition for preventing, ameliorating or treating cancer in which a growth factor receptor is overexpressed, a disease or disorder caused by overexpression of a growth factor receptor, or a neurodegenerative disease, the composition comprising same.
Need to check novelty before this filing date? Find Prior Art

Description

MYO1D Inhibitors and Their Uses The present invention relates to MYO1D inhibitors and their uses. The inhibitors described herein may be useful for treating cancers with GFR overexpression, diseases or disorders caused by GFR overexpression, or degenerative brain diseases by inhibiting the MYO1D-GFR interaction that fixes or maintains GFR (growth factor receptor) on the plasma membrane, thereby inducing GFR degradation. In particular, the present invention relates to compounds and pharmaceutical compositions that inhibit MYO1D, methods for preventing, improving, or treating cancers with GFR overexpression, diseases or disorders caused by GFR overexpression, or degenerative brain diseases, and the uses of such compounds. Despite recent advancements in cancer treatment, there remains a significant need to identify ideal targets within cancer cells and develop optimal approaches aimed at them. The identification and targeting of ErbB mutations have brought about a paradigm shift in the field of oncology, leading to significantly improved treatment outcomes (Lim et al., 2018). However, the efficacy of most cancer therapies eventually diminishes due to issues such as drug resistance, dose-limiting toxicity, and metastasis. Resistance to anti-growth factor receptor (GFR) drugs, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), remains a critical barrier, and a better understanding of resistance mechanisms is required (Passaro et al., 2017; McLoughlin et al., 2020). In activated signaling pathways, since tumors rely on both wild-type and mutant GFR signaling pathways, drugs that disrupt a single target may not be sufficient (Tortora et al., 2008). Strategies to simultaneously inhibit multiple abnormally activated targets are emerging as attractive therapeutic methods. In the ErbB family, the EGFR (ErbB1) and ErbB2 (HER2) pathways are functionally linked and play a crucial role in the onset and progression of lung cancer. Furthermore, c-Met and VEGF are known to contribute to the acquisition of resistance to anti-EGFR drugs. Therefore, simultaneously inhibiting multiple GFRs can disrupt the molecular feedback loops that induce resistance to existing anti-ErbB drugs (Husain et al., 2017; Eskilsson et al., 2018). To this end, the use of highly selective multi-target drugs or new classes of anti-GFR drugs with different molecular mechanisms may be considered. Targeted Protein Degradation (TPD) is a drug development strategy that utilizes small molecules to rapidly destroy disease-causing proteins via the Ubiquitin-Proteasome System (UPS), and it has been rapidly advancing recently (Sasso et al., 2023). This approach is attracting attention as a novel therapeutic targeting various diseases caused by the abnormal expression of pathological proteins, such as cancer, inflammatory, and immune diseases (Li et al., 2021; Zhong et al., 2022). Molecular Glue Degraders (MGDs) are compounds that facilitate the interaction between two proteins or molecules within a cell; they form novel recognition interfaces on the surface of E3 ligases, serving to tightly bind disease-causing proteins (neosubstrates) to E3 ligases for ubiquitination and subsequent degradation (Oleinikovas et al., 2024). Thalidomide and its derivatives are known as representative MGDs that induce target proteins to be degraded through the ubiquitin-proteasome system by reprogramming the E3 ubiquitin ligase cereblon (CRBN). The molecular motor MYO1D plays a role in anchoring wild-type and mutant EGFR to the plasma membrane, and it has been revealed that knocking down MYO1D via si-MYO1D RNA treatment can inhibit the growth, invasion, and downstream signaling of lung cancer and glioblastoma cells expressing EGFR or ErbB2 mutations (Ko et al., 2019; 2021). This suggests that MYO1D acts as a novel regulator that maintains EGFR levels at the cell surface by anchoring EGFR to the plasma membrane, thereby mechanically preventing the translocation of dephosphorylated receptors into the cytoplasm before binding to their corresponding ligands. Furthermore, clinical data showing high MYO1D immunohistochemical staining in tumor growth and advanced colorectal cancer (CRC) stages in mouse tumor models suggest that the tumor-promoting function of MYO1D is enhanced in tumors overexpressing EGFR (Ko et al., 2019). Furthermore, these data suggest that MYO1D may act as an oncogene that promotes tumorigenesis in tumor tissues overexpressing ErbB family proteins. Recently, Mu et al. (2022) reported that SPAG6 (sperm-associated antigen 6), one of the most significantly increased SPAG genes in acute myeloid leukemia (AML), interacts with MYO1D, translocating MYO1D to the cell membrane to increase the expression of EGFR family proteins and promote AML progression. They also suggested that SPAG6 or MYO1D could be new target genes for AML treatment. Furthermore, it has been reported that MYO1D is a potential prognostic biomarker in patients with triple-negative breast cancer (TNBC) and could be a new target for TNBC treatment (Li et al., 2024). Therefore, blocking MYO1D function could be a new approach to inhibit downstream signaling of wild-type and mutant EGFR in TKI-resistant cancer cells and enhance the effects of existing anti-EGFR drugs. Accordingly, the inventors synthesized a new small molecule compound for degrading and inhibiting the function of the molecular motor MYO1D, and discovered that the synthesized new small molecule compound can degrade the molecular motor MYO1D and inhibit its function, thereby degrading multiple GFRs, which can inhibit the growth of solid tumor cells that are resistant to drugs that inhibit GFR activity, and can resolve problems caused by GFR overexpression, and thus completed the present invention. One object of the present invention is to provide a novel compound having excellent MYO1D inhibitory activity, an optical isomer thereof, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomeric isomer thereof, or a pharmaceutically acceptable salt thereof. Another object of the present invention is to provide a novel compound having activity to degrade GFR and GFR mutants with excellent MYO1D inhibitory activity, an optical isomer thereof, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomeric isomer thereof, or a pharmaceutically acceptable salt thereof. Another objective of the present invention is to provide a pharmaceutical composition for preventing, improving, or treating cancer with GFR overexpression, diseases or disorders caused by GFR overexpression, or degenerative brain diseases, comprising as an active ingredient a novel compound having excellent MYO1D inhibitory activity and activity to degrade EGFR and EGFR mutations, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomer, or a pharmaceutically acceptable salt thereof. Another objective of the present invention is to provide a use of the said compound for the manufacture of a drug for preventing, improving, or treating cancer in which GFR is overexpressed, diseases or disorders caused by the overexpression of GFR, or degenerative brain diseases. Another objective of the present invention is to provide a method for preventing, improving, or treating cancer with GFR overexpression, diseases or disorders caused by GFR overexpression, or degenerative brain diseases by administering the compound. In one aspect of the present invention, the present invention provides a compound represented by the following formula 1, an optical isomer thereof, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomeric variant thereof, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] In the above formula, A is a substituted or non-substituted C6-C 12 It is an aryl, a substituted or unsubstituted 5-12 member heteroaryl, or a substituted or unsubstituted 7-20 member heterobicycle; Z is S or C; R1 and R2 are each independently H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C1-C6 alkylamine, substituted or unsubstituted C3-C 20 Cycloalkyl, substituted or unsubstituted C6-C 12 Aryl, substituted or unsubstituted 5-12-membered heteroaryl, substituted or unsubstituted 5-12-membered heterocycloalkyl, substituted or unsubstituted C9-C 20 It is a 7- to 15-membered heterobicycle of a bicycle, substituted or non-substituted, or, R1 and R2 form a 5-20-membered heterocycloalkyl group together with the bonded N, wherein the heterocycloalkyl group may be unsubstituted or substituted. In one aspect of the present invention, a pharmaceutical composition comprising the compound of Formula 1, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomer, or a pharmaceutically acceptable salt thereof is provided, and a pharmaceutical / medicinal use, e.g., as a drug for the prevention, improvement, or treatment of cancer in which GFR is overexpressed, diseases or disorders caused by GFR overexpression, or degenerative brain diseases. In one aspect of the present invention, a combination agent or use for the prevention, improvement, or treatment of cancer with overexpression of GFR, a disease or disorder caused by overexpression of GFR, or a degenerative brain disease is provided, characterized by comprising a pharmaceutical composition comprising the compound of Formula 1, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomer, or a pharmaceutically acceptable salt thereof, and other additional therapies. The MYO1D inhibitors according to the present invention, i.e., compounds that inhibit the activity of MYO1D, bind to Ecm29 like molecular glue, first targeting the molecular motor MYO1D, and then acting by degrading various GFRs (growth factor receptors) through the proteasome. The strategy of functionally blocking MYO1D at the plasma membrane via TPD (Targeted Protein Degradation) is an attractive therapeutic approach to overcome acquired resistance to existing EGFR-TKIs, and is effective in reducing mutant EGFRs at a stage prior to their activation by binding to a ligand. Furthermore, compared to existing RTK-TKIs or RTK monoclonal antibody therapies, the action of the compounds according to the present invention, which block MYO1D and degrade RTK (GFR), presents a novel anti-RTK strategy for RTK-overexpressing cancers. Therefore, the compounds according to the present invention will be very useful for the prevention, improvement, or treatment of diseases such as cancer with RTK(GFR) overexpression, diseases or disorders caused by RTK(GFR) overexpression, or degenerative brain diseases, either alone or in combination, by targeting MYO1D. Figure 1 shows the results of analysis using a NanoBiT analysis system constructed to search for small molecule compounds that inhibit MYO1D-EGFR interaction. Specifically, a total of eight combinations were formed by subcloning expression plasmids of MYO1D and EGFR into LgBiT or SmBiT, respectively, and these combinations were transfected into HEK 293T cells. The MYO1D-EGFR interaction activity of each combination was analyzed by luminescence measurement using the Nano-Glo Live Cell reagent. Figure 2 shows the luminescence signals in the NanoBiT analysis system of compounds selected to inhibit increased invasiveness caused by MYO1D, after screening a total of 8,000 types of small molecules twice in a NanoBiT analysis system constructed to search for small molecule compounds that inhibit MYO1D-EGFR interactions, selecting about 250 compounds that inhibit reporter activity by more than 50% and showed no significant cytotoxicity compared to the solvent (vehicle) treatment group, and then performing an invasion analysis on Caco2 / p and Caco2 / MYO1D colorectal cancer (CRC) cells with increased invasiveness caused by MYO1D. Figure 3 compares the inhibitory effects of knockdown treatment with MYO1D and selected MYO1Di-B014 compounds on the invasiveness of Caco2 colorectal cancer (CRC) cells increased by overexpressed MYO1D. Caco2 / p and Caco2 / MYO1D CRC cells were transfected with si-scr or si-MYO1D for 48 hours (left) or treated with 0.1% DMSO (vehicle) or 5 μM MYO1Di-B014 for 48 hours (right), and then subjected to Transwell invasion analysis. Figure 4 shows the inhibitory effect of MYO1Di-B014 compound on cell survival at different concentrations in Caco2 CRC cells. For Caco2 / p and Caco2 / MYO1D CRC cells, the vehicle (Con) or MYO1Di-B014 compound at specified concentrations was treated daily for 2 or 3 days, and the degree of cell proliferation was evaluated via MTT assay. Figure 5 shows the decrease in expression of various GFRs in CRC cells after treatment with MYO1Di-B014. Caco2 / MYO1D cells were treated with 1 μM or 5 μM of MYO1Di-B014, and after 48 or 72 hours after treatment, the cells were collected and lysed, and the expression of target proteins such as EGFR, HER2, c-Met, VEGFR1, and MYO1D was analyzed using antibodies. Figure 6 illustrates the comparison of the inhibitory effects of various GFR expression on H1975 / OR cells following knockdown treatment with MYO1D and treatment with MYO1Di compounds. H1975 / OR cells were transfected for 48 hours with a mixture of scrambled siRNA (si-scr) or siRNA targeting MYO1D (mixed with si-MYO1D, si-MYO1D #1, and independent siRNA #2) (left), or treated daily with 5 μM or 10 μM MYO1Di-B014 for 2 days (right). After transfection or treatment, cells were collected, lysed, and target protein expression analyzed with antibodies. Figure 7 shows the effect of MYO1Di-B014 treatment on reducing the invasiveness of H1975 / OR non-small cell lung cancer (NSCLC) cells. After treating H1975 / OR cells with 0.1% DMSO (vehicle) or 1 μM or 5 μM MYO1Di-B014 for 48 hours, a Transwell invasion assay was performed. Figure 8 shows the effect of MYO1Di-B014 treatment on the survival inhibition of H1975 / OR cells. Cell proliferation was evaluated by MTT assay after treating H1975 / p or H1975 / OR cells with vehicle (Con) and 10 μM osimertinib (OS) for 48 hours, or with the specified concentration of MYO1Di-B014 compound daily for 2 or 3 days. Figure 9 illustrates the survival inhibitory effect of MYO1Di-B014 on Caco2 / EGFR-L858R-T790M-C797S cells. After treating Caco2 / EGFR-L858R-T790M-C797S cells daily with the vehicle (Con) or the specified concentration of MYO1Di-B014 compound for 1, 2, or 3 days, cell proliferation was measured via MTT analysis. An asterisk (*) indicates a statistically significant difference between the vehicle group and the treatment group at each time point (**P < 0.01; ***P < 0.001). Figure 10 illustrates the inhibition of survival by MYO1Di-B014 in U87 glioblastoma cells expressing wild-type or mutant EGFR. Cell proliferation was evaluated by MTT assay after treating U87 cells expressing vsvg (empty vector), WT-EGFR (wild-type EGFR), or EGFRvIII (exon 2-7 deleted EGFR construct, a form in which exons 2–7 of the extracellular domain are deleted) with 0.1 μM afatinib (48 hours) or vehicle (Con) or specified concentrations of MYO1Di-B014 (daily for 3 days). Figure 11 shows the effect of MYO1Di-B014 on survival inhibition in BaF3 progenitor B cell lines expressing mutant EGFR. BaF3 cells, which are mouse IL-3 dependent progenitor B cell lines expressing EGFR-Δ19 / T790M, EGFR-L858R / T790M, or EGFR-L858R-T790M-C797S (WT-EGFR), were treated with 10 μM osimertinib (48 hours), vehicle (Con), or specified concentrations of MYO1Di-B014 (daily for 3 days), and cell proliferation was evaluated by MTT assay. Figure 12 illustrates the survival inhibitory effect of MYO1Di-B014 on HER2-overexpressing H1975 cells. H1975 / p or H1975 / HER2 cells were treated with 10 μM osimertinib (48 hours), vehicle (Con), or specified concentrations of MYO1Di-B014 (daily for 3 days), and cell proliferation was measured by MTT assay. HER2-HA expression was confirmed in H1975 / p or H1975 / HER2 cells by immunoblot analysis with specified antibodies (right). Figure 13 illustrates the inhibitory effect of MYO1Di-B014 on long-term survival in Caco2 cells expressing mutant EGFR or MYO1D. Caco2 / p, Caco2 / EGFR-L858R-T790M-C797S, or Caco2 / MYO1D cells were treated daily for 14 days with the vehicle (Con) or the specified concentration of the MYO1Di-B014 compound, and long-term survival was evaluated by clonogenic analysis. After 14 days, adhered cells were stained with trypan blue. EGFR, c-Met, and MYO1D expression in lysates collected after 14 days of treatment of Caco2 / MYO1D cells were confirmed by immunoblot analysis (right). Figure 14 compares the inhibitory effect of MYO1D on cell invasiveness increased by MYO1D against various synthetic analogues of the MYO1Di compound. The derivatives of the MYO1Di compound were designed based on MYO1Di-B014 and have a structure capable of linker binding. After treating Caco2 / MYO1D cells with the vehicle or MYO1Di derivatives at a concentration of 1 μM for 48 hours, a transwell invasiveness assay was performed. Figure 15 shows the number of invasive cells counted in five randomly selected regions in an experiment on the inhibitory effect of MYO1Di derivatives on cell invasiveness increased by MYO1D. An asterisk indicates a statistically significant difference between the treatment group and the control group (*P < 0.05; **P < 0.01; ***P < 0.001). Among these, four compounds (e.g., MYO1Di-B066) that showed an inhibitory effect similar to MYO1Di-B014 are indicated by arrows. Figure 16 shows the concentration-dependent results of the inhibitory effect of MYO1Di-B066 on Caco2 / MYO1D cell proliferation. After treating Caco2 / MYO1D cells daily with vehicle (Con) or MYO1Di-B066 at specified concentrations for 1, 2, and 3 days, cell proliferation was measured by MTT assay. Figure 17 is a figure comparing the inhibitory effects of MYO1Di-B014 and MYO1Di-B066 on GFR expression. Caco2 / MYO1D cells were treated daily with the vehicle or 10 μM concentrations of MYO1Di-B014 or MYO1Di-B066 for 1, 2, and 3 days, and the expression of EGFR, ErbB4, c-Met, and MYO1D at each time point was measured by immunoblot analysis using the indicated antibodies. Figure 18 compares the inhibitory effects of MYO1Di-B066 and MYO1Di-B066 combined with a linker on cell invasion. Caco2 / MYO1D cells were treated with 1 μM MYO1Di-B066 (B66) or 1 μM MYO1Di-B66-linker-Ac (B66-linker), and a Transwell invasion assay was performed in the same manner as in Figure 15. The chemical structure of MYO1Di-B066, with the linker-binding site indicated by an arrow, is presented (right). Figure 19 shows the silver-stained gel of proteins pulled down using a chemical probe to confirm that Ecm29 is a MYO1Di binding protein. Proteins pulled down from Caco2 / MYO1D cell lysates using either bead only (Affigel only) or the MYO1Di-B066 chemical probe (B66-Affigel) were separated by SDS-PAGE and stained with Coomassie blue. Bands showing differences between the two groups (indicated by numbers) were excised, and protein identification was performed using Matrix-assisted Laser Desorption / Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF). Some of the identified proteins are listed in the table on the right. Figure 20 shows the results of detecting proteins pulled down from Caco2 / MYO1D cell lysates using a specific antibody with the MYO1Di-B066 chemical probe (B66-Affigel), and from this, it can be confirmed that the MYO1Di-B066 compound binds not only to Ecm29 but also to MYO1D. Figure 21 shows the results of analyzing the expression levels of Ecm29 and MYO1D in various CRC cells. One-fifth of the Caco2 / MYO1D cell lysate was used as a positive control for MYO1D. Figure 22 confirms that the inhibitory effect of MYO1Di-B014 on cell survival depends on Ecm29 expression. Caco2 / MYO1D cells were transfected with si-scr or si-Ecm29 for 24 hours and plated in a 96-well plate (5 × 10⁻⁶ 3 cells / well) were re-inoculated and cultured for 24 hours. Subsequently, the vehicle (Con) or MYO1Di-B014 at specified concentrations was treated daily for 3 days, and cell proliferation was evaluated by MTT assay. Figure 23 shows that the expression of EGFR and MYO1D, which was reduced by MYO1Di-B014 after knockdown treatment of Ecm29, was restored to basal levels. After treating the si-RNA pre-treated Caco2 / MYO1D cells used in Figure 22 with vehicle (Con) or 10 μM MYO1Di-B014 daily for 3 days, the expression of EGFR and MYO1D was measured by immunoblot analysis. Figure 24 illustrates that MYO1D is not a binding partner of Ecm29 in the normal state (untreated with the compound). Each cell lysate prepared from Caco2 / p or Caco2 / MYO1D-Myc cells was immunoprecipitated (IP) with an anti-Myc antibody, followed by immunoblotting (IB) with anti-Ecm29 or anti-Myc antibodies to analyze the interaction. A Caco2 / p-derived cell lysate (WCL) was included as a positive control for Ecm29. Figure 25 shows the results of immunoblot analysis confirming the expression of MYO10, MYO1B, and MYO1D after treating Caco2 / MYO1D cells daily with vehicle (Con) or MYO1Di-B014 at specified concentrations for 3 days. From the above results, it can be confirmed that MYO1Di-B014 does not affect the expression of MYO10 and MYO1B, which are normal binding partners of Ecm29. Figure 26 shows a schematic diagram (top) of the Ecm29 fragment mutation representing the N-terminal region (1-881 aa, No) and C-terminal region (882-1846 aa, Co), and the results of immunoblotting analysis using an anti-His antibody on the expression of His-tagged Ecm29 N-terminal (No) or C-terminal (Co). After transfecting Caco2 / MYO1D cells with No or Co, the beads were mixed with either Affigel alone (Affigel only) or the MYO1Di-B066 chemical probe (B66-Affigel). The pulled-down proteins were separated by SDS-PAGE, and immunoblotting was performed using anti-His, anti-Ecm29, and anti-MYO1D antibodies to detect possible interactions between the MYO1Di compound and its binding sites. A red asterisk indicates that Ecm29 No is the binding partner of the MYO1Di compound. From these results, it was found that MYO1Di-B014 binds to the N-terminal region of Ecm29. Figure 27 shows a schematic diagram (top) of the Ecm29 N-terminal segments represented by the left segment (1-307 aa, Cut-1), middle segment (308-648 aa, Cut-2), and right segment (649-881 aa, Cut-3), and the results of immunoblotting analysis with an anti-His antibody regarding the expression of His-tagged Cut-2 or Cut-3 in Caco2 / MYO1D cells. After transgenerating His-tagged Cut-2 or Cut-3 into Caco2 / MYO1D cells, a pull-down was performed by mixing with Widman (Affigel only) or MYO1Di-B066 chemical probe (B66-Affigel), and after separation by SDS-PAGE, immunoblotting was performed with anti-His, anti-Ecm29, and anti-MYO1D antibodies (same method as in Figure 26). The red asterisk indicates that Ecm29 Cut-2 is a binding partner of the MYO1Di compound. From this, it was found that MYO1Di-B014 is bound to the middle region of the N-terminus (308-648 aa, including the 5th-7th HEAT repeats). Figure 28 shows the results of immunoblot analysis of the expression levels of EGFR, c-Met, VEGFR1, 2, 3, IGF1R, FGFR, MYO1D, and Ecm29 with designated antibodies at each time point. Caco2 / MYO1D cells were treated daily with the vehicle or MYO1Di-B014 compound at a concentration of 10 μM for 1, 2, and 3 days, and immunoblot analysis was performed at each time point to show the temporal flow of the action of MYO1Di-B014 on the expression levels of Ecm29, MYO1D, and various GFRs. Figure 29 shows the results of immunoblotting the cell proteins with anti-HA, anti-Ecm29, or anti-MYO1D antibodies after transfecting Caco2 / MYO1D cells with an empty vector or ubiquitin-HA and treating them daily with 10 μM of MYO1Di-B014 compound for 3 days, then separating the cells with anti-Ecm29 antibody (left) or anti-MYO1D antibody (right) using a 6% SDS-polyacrylamide gel. Figure 30 shows the results of transfecting Caco2 / MYO1D cells with an empty vector or ubiquitin-HA, treating them daily with 10 μM of MYO1Di-B014 compound for 1, 2, and 3 days, and then immunoprecipitating cell samples at each time point with anti-Ecm29 antibody (left), anti-MYO1D antibody (center), or anti-EGFR antibody, separating them on a 6% SDS-gel, and performing an immunoblot with an anti-HA antibody. Figure 31 is a schematic diagram illustrating the mechanism of action in which the MYO1Di compound binds to Ecm29 to induce the molecular motor MYO1D into the E3 ligase / 26S proteasome complex, which consequently dismantles various GFRs from the cell membrane and leads to degradation. Figure 32 is a schematic diagram of the experimental protocol for an allograft colorectal cancer mouse model including the MYO1Di-B014 treatment schedule. Figure 33 shows the change in tumor growth (volume) after intraperitoneal (ip) injection of vehicle or MYO1Di-B014 (20 and 40 mg / kg) for 12 days in CT-26 / iRFP / wild-type tumor-grafted mice. An asterisk (*) indicates statistical significance between the MYO1Di-B014 treatment group and the vehicle treatment group. Figure 34 shows the change in tumor weight after intraperitoneal (ip) injection of vehicle or MYO1Di-B014 (20 and 40 mg / kg) for 12 days in CT-26 / iRFP / wild-type tumor-grafted mice. An asterisk (*) indicates statistical significance between the MYO1Di-B014 treatment group and the vehicle treatment group. Figure 35 shows the total tumor fluorescence intensity after intraperitoneal (ip) injection of vehicle or MYO1Di-B014 (20 and 40 mg / kg) for 12 days in CT-26 / iRFP / wild-type tumor-grafted mice. An asterisk (*) indicates statistical significance between the MYO1Di-B014 treatment group and the vehicle treatment group. Figure 36 shows the change in body weight of mice after intraperitoneal (ip) injection of vehicle or MYO1Di-B014 (20 and 40 mg / kg) for 12 days in CT-26 / iRFP / wild-type tumor-grafted mice. Figure 37 shows the tumor photographs (top) and tumor fluorescence images (bottom) obtained for each group after injecting vehicle or MYO1Di-B014 (20 and 40 mg / kg) intraperitoneally (ip) for 12 days in CT-26 / iRFP / wild-type tumor-grafted mice. Figure 38 shows the results of measuring fluorescence reporter activity after treatment with novel compounds using 293T cells transfected with a NanoBiT system-based TH-MYO1D / KD-EGFR plasmid. An asterisk (*) indicates a compound that strongly inhibits MYO1D-EGFR interaction. Figure 39 compares the TNBC cell survival inhibitory effects of MYO1Di-B014, MYO1Di-B38, and MYO1Di-B68. Triple-negative breast cancer (TNBC) cells derived from 4T1 mice were treated daily for 3 days with the vehicle (Con) or the indicated concentrations of MYO1Di-B014, MYO1Di-B38, and MYO1Di-B68. Cell proliferation was measured by the MTT assay. Figure 40 compares the cell survival inhibitory effects among MYO1Di-B014, MYO1Di-B38, and MYO1Di-B68. Caco2 / MYO1D cells were treated daily for 3 days with the vehicle (Con) or specified concentrations of MYO1Di-B014, B38, and B68. Cell proliferation was evaluated via MTT assay (top), and the expression of EGFR and MYO1D was confirmed by immunoblot analysis (bottom). Figure 41 shows the inhibitory effect of MYO1Di-B014, MYO1Di-B038, and MYO1Di-B068 on the invasion of H1975 / OR cells. Figure 42 is a schematic diagram of the experimental protocol for an allograft colorectal cancer mouse model including a MYO1Di-B68 or MYO1Di-B38 treatment schedule. Figure 43 shows changes in tumor growth (volume) after intraperitoneal (ip) injection of vehicle or MYO1Di-B68, MYO1Di-B38 (10 and 20 mg / kg, respectively) into CT-26 / iRFP / wild-type tumor-grafted mice for 14 days. Figure 44 shows the change in body weight of mice after intraperitoneal (ip) injection of vehicle or MYO1Di-B68, MYO1Di-B38 (10 and 20 mg / kg, respectively) into CT-26 / iRFP / wild-type tumor-grafted mice for 14 days. Figure 45 shows the total tumor fluorescence intensity after intraperitoneal (ip) injection of vehicle or MYO1Di-B68 and MYO1Di-B38 (10 and 20 mg / kg, respectively) for 14 days in CT-26 / iRFP / wild-type tumor-grafted mice. These are expressed as mean ± standard error (SEM). An asterisk (*) indicates statistical significance between the vehicle treatment group and the MYO1Di treatment group: *P<0.05; **P<0.01; ***P<0.001; NS is not significant. Figure 46 shows tumor weights after intraperitoneal (ip) injection of vehicle or MYO1Di-B68 and MYO1Di-B38 (10 and 20 mg / kg, respectively) for 14 days in CT-26 / iRFP / wild-type tumor-grafted mice. These are expressed as mean ± standard error (SEM). An asterisk (*) indicates statistical significance between the vehicle treatment group and the MYO1Di treatment group: *P<0.05; **P<0.01; ***P<0.001; NS is not significant. Figure 47 illustrates a comparative analysis of various GFR expressions in tumor tissues between the 20 mg / kg MYO1Di-B68 treatment group and the control group (vehicle treatment group) after intraperitoneal (ip) injection of vehicle or MYO1Di-B68 and MYO1Di-B38 (10 and 20 mg / kg, respectively) for 14 days into CT-26 / iRFP / wild-type tumor-grafted mice. The expression of EGFR, HER2, c-Met, VEGFR1&2, MYO1D, and Ecm29 was confirmed by immunoblot analysis in tumor tissues collected from each group. The expression levels of each protein were quantified by densitometry and expressed in arbitrary units (arbitrary score, mean ± SEM, n=6). An asterisk (*) indicates a statistically significant difference between groups (*P<0.05). Figure 48 is a schematic diagram of the experimental protocol for an intrasplenic injection-based liver metastasis CRC model including the treatment schedule of the MYO1Di compound. An experimental liver metastasis model was established by injecting cells stably expressing CT-26 / iRFP / KITENIN-V5 into the spleen of allogeneic mice, followed by splenectomy. Subsequently, for 2 weeks, mice were administered a single dose of 5-FU (100 mg / kg), or a vehicle, MYO1Di-B68, or MYO1Di-B38 (10 and 20 mg / kg, respectively) daily via intraperitoneal injection (ip). Figure 49 shows the total fluorescence signal of iRFP expressed in liver tumor nodules after daily intraperitoneal injection (ip) of 5-FU (100 mg / kg) or vehicle, MYO1Di-B68, or MYO1Di-B38 (10 and 20 mg / kg, respectively) for 2 weeks in an experimental liver metastasis model. Figure 50 shows the results of evaluating the degree of liver metastasis in each group by measuring and quantifying the total fluorescence signal of iRFP expressed in liver tumor nodules after daily intraperitoneal (ip) injection of 5-FU (100 mg / kg) or vehicle, MYO1Di-B68, or MYO1Di-B38 (10 and 20 mg / kg, respectively) for 2 weeks in an experimental liver metastasis model. The results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference between the groups (**P<0.01). Figure 51 compares the inhibitory effects of MYO1Di-B014 on TNBC cell survival. Human TNBC cell lines MDA-MB-231, MDA-MB-468, and HCC1806 were treated daily for 3 days with either the vehicle (Con) or the specified concentration of MYO1Di-B014 compounds. Cell proliferation was evaluated via the MTT assay (left). GFRs (EGFR, etc.) and MYO1D expression were confirmed by immunoblot analysis (right). Additionally, for MDA-MB-231 cells, long-term viability (clonogenic assay) was evaluated after daily treatment with the vehicle (Con) or MYO1Di-B014 for 14 days (same method as in Figure 13). Figure 52 compares the inhibitory effects of MYO1Di-B68 and MYO1Di-B68-Na on human TNBC cell survival. MDA-MB-231 and MDA-MB-468 cells were treated daily for 3 days with the vehicle (Con), MYO1Di-B68, or MYO1Di-B68-Na compounds. Cell proliferation was evaluated by the MTT assay (left). GFRs and MYO1D expression were confirmed by immunoblot analysis (right). Figure 53 compares the cancer cell survival inhibitory effects of MYO1Di-B68 and MYO1Di-B68-Na. HCC1806 human TNBC cells or Caco2 / MYO1D colon cancer cells were treated daily for 3 days with the vehicle (Con) or indicated concentrations of MYO1Di-B68 or MYO1Di-B68-Na. Cell proliferation was measured by the MTT assay. Figure 54 compares the antisurvival effects of MYO1Di-B68 and MYO1Di-B68-Na on mouse-derived TNBC cells. 4T1 mouse TNBC cells were treated daily for 3 days with the vehicle (Con), MYO1Di-B68, or MYO1Di-B68-Na compounds. Cell proliferation was measured via MTT assay (left), and GFRs and MYO1D expression were confirmed by immunoblot analysis (right). Figure 55 is an experimental schematic diagram of a triple-negative breast cancer (TNBC) allograft mouse model including the treatment schedule of MYO1Di-B68-Na and cisplatin. 4T1 cells (5×10⁶ 5 ) was orthotopically injected into the fourth fat pad of BALB / c mice, and drug treatment was started 14 days after injection. Figure 56 shows the change in tumor growth (volume) of 4T1 / wild-type-tumor-mice after intraperitoneal injection (ip) of vehicle, cisplatin (5 mg / kg, once a week × 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week × 2 weeks). Figure 57 shows the tumor weight of 4T1 / wild-type-tumor-mice after intraperitoneal (IP) infusion of vehicle, cisplatin (5 mg / kg, once a week × 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week × 2 weeks). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group. *P<0.05; **P<0.01; ***P<0.001. Figure 58 shows the spleen weights of 4T1 / wild-type-tumor-mice after intraperitoneal (IP) infusion of vehicle, cisplatin (5 mg / kg, once a week for 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week for 2 weeks). Representative photographs of the spleen from each group are presented individually (left). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group. *P<0.05; **P<0.01; ***P<0.001. Figure 59 shows the change in body weight of 4T1 / wild-type-tumor-mice after intraperitoneal (IP) infusion of vehicle, cisplatin (5 mg / kg, once a week × 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week × 2 weeks). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group. *P<0.05; **P<0.01; ***P<0.001. Figure 60 shows individual tumor images of each group after intraperitoneal injection (IP) of vehicle, cisplatin (5 mg / kg, once a week × 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week × 2 weeks). Figure 61 shows images of lung metastases (left) and histograms of the number of lung metastatic nodules (right) for each group after intraperitoneal (IP) infusion of vehicle, cisplatin (5 mg / kg, once a week × 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week × 2 weeks) into 4T1 / wild-type-tumor-mice. Arrows indicate metastatic nodules. Figure 62 shows individual images of lung metastases after treatment with cisplatin or increasing concentrations of MYO1Di-B68-Na following intraperitoneal (IP) infusion of vehicle, cisplatin (5 mg / kg, once a week × 2 weeks), or MYO1Di-B68-Na (10, 20, 40 mg / kg, five times a week × 2 weeks) into 4T1 / wild-type-tumor-mice. Arrows indicate metastatic nodules. A histogram of the number of lung metastatic nodules between groups is presented on the right. The administration schedule for MYO1Di-B68-Na and cisplatin is the same as in Figure 14. Figure 63 is an experimental schematic of a TNBC allograft mouse model including a modified treatment schedule of MYO1Di-B68 and cisplatin. 4T1 cells (1×10⁵) were orthotopically injected into the fourth mammary gland of BALB / c mice, and drug treatment was started 9 days after injection. Figure 64 shows the change in tumor growth (volume) of 4T1 / wild-type-tumor-mice after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Figure 65 shows the tumor weight of 4T1 / wild-type-tumor-mice after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group (*P<0.05; **P<0.01). Figure 66 shows the spleen weight of 4T1 / wild-type-tumor-mice after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group (*P<0.05; **P<0.01). Figure 67 shows the number of 4T1 / wild-type-tumor-mice lung metastatic nodules after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group (*P<0.05; **P<0.01). Figure 68 shows the change in body weight of 4T1 / wild-type-tumor-mice after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Figure 69 shows individual photographs of tumors in each group after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Figure 70 shows individual images of lung metastases and histograms of the number of metastatic nodules between each group after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). Arrows indicate metastatic nodules. Figure 71 compares GFR expression in tumor tissue between the 40 mg / kg MYO1Di-B68-Na treatment group and the vehicle treatment group following intraperitoneal injection of the vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). The expression of EGFR, HER2, c-Met, VEGFR1, VEGFR2, MYO1D, and Ecm29 in tumor tissue was analyzed by immunoblotting. Quantification of each protein was measured by densitometry and expressed as an arbitrary score, presented as mean ± standard error (SEM), n=5. An asterisk (*) indicates a significant difference (**P<0.01). Figure 72 is an experimental schematic diagram of a TNBC allograft mouse model including a combined administration schedule of MYO1Di-B68 and cisplatin. 4T1 cells (1×10⁶ 5 ) was stereotactically injected into the fourth mammary fat pad of BALB / c mice, and drug administration began 15 days after injection. Figure 73 shows the changes in tumor growth (volume) of 4T1 / wild-type-tumor-mice after intraperitoneal infusion of vehicle (negative control), cisplatin alone (4 mg / kg, once a week × 3 weeks), and cisplatin (4 mg / kg, once a week × 3 weeks) + MYO1Di-B68-Na (40 mg / kg, daily × 21 days). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group (**P < 0.01; ***P < 0.001). Figure 74 shows the tumor weights of 4T1 / wild-type-tumor-mice after intraperitoneal infusion of vehicle (negative control), cisplatin alone (4 mg / kg, once a week × 3 weeks), and cisplatin (4 mg / kg, once a week × 3 weeks) + MYO1Di-B68-Na (40 mg / kg, daily × 21 days). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group (**P < 0.01; ***P < 0.001). Figure 75 shows the spleen weight of 4T1 / wild-type-tumor-mice after intraperitoneal infusion of vehicle (negative control), cisplatin alone (4 mg / kg, once a week × 3 weeks), and cisplatin (4 mg / kg, once a week × 3 weeks) + MYO1Di-B68-Na (40 mg / kg, daily × 21 days). Results are expressed as mean ± standard error (SEM). An asterisk (*) indicates a statistically significant difference compared to the vehicle treatment group (**P < 0.01; ***P < 0.001). Figure 76 shows the change in body weight of 4T1 / wild-type-tumor-mice after intraperitoneal infusion of vehicle (negative control), cisplatin alone (4 mg / kg, once a week × 3 weeks), and cisplatin (4 mg / kg, once a week × 3 weeks) + MYO1Di-B68-Na (40 mg / kg, daily × 21 days). Results are expressed as mean ± standard error (SEM). Figure 77 shows individual photographs of tumors in each group after intraperitoneal injection of vehicle, cisplatin (4 mg / kg, once a week for 3 weeks), or MYO1Di-B68-Na (20 or 40 mg / kg, daily for 21 days). The present invention will be described in more detail below. Unless otherwise defined, all technical terms used herein have the same meaning as generally understood by those skilled in the art to which the present invention pertains. Additionally, numerical values ​​described herein are deemed to include the meaning of "approximately" unless explicitly stated otherwise. All publications and other references mentioned herein are incorporated herein in their entirety by reference. The definition of each substituent used in this specification is described in detail. Unless otherwise specified, each substituent has the following definition. The definitions of residues used in this specification are described below. In addition, where no separate definition is provided, residues are used in the sense generally understood by those skilled in the art. The term "independently" as used herein means that when more than one substituent is selected from a number of possible substituents, these substituents may be identical or different from each other. As used herein, the terms “arbitrarily substituted” or “substituted” refer to replacing one or more hydrogen atoms with monovalent or divalent radicals. Suitable substituents include, for example, hydroxy, nitro, amino, imino, cyano, halo, thio, sulfonyl, thioamido, amido, imidino, oxo, oxamidino, methoxamidino, imidino, guanidino, sulfonamido, carboxyl, formyl, lower alkyl, halo lower alkyl, lower alkylamino, halo lower alkylamino, lower alkoxy, halo lower alkoxy, lower alkoxyalkyl, alkyl carbonyl, amino carbonyl, aryl carbonyl, aralkyl carbonyl, heteroaryl carbonyl, heteroaralkyl carbonyl, alkylthio, aminoalkyl, cyanoalkyl, aryl, heteroaryl, heterocyclil, cycloalkyl, etc. If the substituted substituent comprises a straight-chain group, the substitution may occur within the chain (e.g., 2-hydroxypropyl, 2-aminobutyl, etc.) or at the chain ends (e.g., 2-hydroxyethyl, 3-cyanopropyl, etc.). The substituted substituent may be a straight-chain, branched-chain, or cyclic arrangement of covalently bonded carbons or heteroatoms. It is understood that the above definition is not intended to include unacceptable substitution patterns (e.g., a methyl group substituted with five fluorogroups, or a halogen group substituted with another halogen atom). Such unacceptable substitution patterns are known to those skilled in the art. The terms “halo,” “halogen,” and “halide(s)” as used herein include fluoro, chloro, bromo, and iodo. As used herein, "alkyl" refers to an aliphatic hydrocarbon radical and includes both linear and branched hydrocarbon radicals. For example, C1-6 alkyl is an aliphatic hydrocarbon having 1 to 6 carbon atoms and may be methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, and 2-ethylbutyl. For example, alkyl means C1-6 alkyl, C1-5 alkyl, C1-4 alkyl, etc. As used herein, the term "haloalkyl" means an alkyl group substituted with one or more, for example, 1 to 3, or 1 to 4 halogen atoms, and said alkyl group is defined as above. "Halo" indicates F, Cl, Br, or I, and the term is used interchangeably with the term "halogen." For example, haloalkyl means fluoromethyl, difluoromethyl, chloromethyl, trifluoromethyl, or 2,2,2-trifluoroethyl. The term "alkoxy" as used herein refers to an -O-alkyl or alkyl-O-group, and said alkyl group is defined as above. For example, it may be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and t-butoxy. As used herein, the terms "hydroxy" or "hydroxyl" mean -OH, either alone or in combination with other terms. The term "amino" as used herein means -NH2. As used herein, the term "cycloalkyl" refers to a cyclic alkyl that can be substituted or unsubstituted, for example, C3- 20 Cycloalkyl represents a monovalent saturated hydrocarbon ring system having 3 to 20 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. Preferably, the cycloalkyl is C5-12 It can be a cycloalkyl or a C5-8 cycloalkyl. As used herein, the term "aryl" refers to a ring of 6 to 20 carbon atoms (C6-) derived by removing one hydrogen atom from a single carbon atom of a parent aromatic ring. 20 It refers to a monovalent aromatic hydrocarbon having ). The aryl may comprise a dicyclic radical containing an aromatic ring fused to a saturated or partially unsaturated ring. Exemplary aryl groups may include radicals derived from benzene (phenyl), substituted phenyl, biphenyl, naphthyl, toluyl, naphthalenyl, anthracenyl, indenyl, indanyl, etc. As a specific example, the aryl is C6- 12 Aryl, preferably C6- 10 It means Aril. As used herein, “heterocycle” refers to an aromatic, saturated or partially unsaturated mono-, bi-, or poly-ring system containing a specified number of ring atoms and comprising one or more heteroatoms selected from N, O, and S. Ring members, wherein the heterocyclic ring may be connected to the base molecule through ring atoms (which may be C or N). The bicyclic system may be connected via 1,1-fusion (spiro), 1,2-fusion (fused), or 1,2-fusion (bridgehead). As used herein, "heteroaryl" refers to a monovalent or divalent substituent derived from a monoheterocyclic or polyheterocyclic aromatic hydrocarbon containing one or more heteroatoms selected from N, O, and S, preferably 1 to 3 or 1 to 2 heteroatoms. Examples of heteroaryls include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and 1,2,4-oxazole; 3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl, indolyl, etc. Examples of bicyclic heteroaryls include, but are not limited to, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, quinolinyl, isoquinolinyl, propyridinyl, and similar groups thereof. Unless otherwise defined, the heteroaryl is a 4-12-membered heteroaryl, preferably a 4-10-membered heteroaryl, more preferably a 4-7-membered heteroaryl. As used herein, "heterocycloalkyl" refers to a monocyclic, noncyclic, tricyclic, or higher cyclic alkyl having 3 to 10 carbon ring members containing one or more heteroatoms selected from N, O, and S, for example, 1 to 4, 1 to 3, or 1 to 2 heteroatoms. Additionally, the heterocycle according to the present invention may also be a fused or cross-linked heterocycloalkyl. Examples of heterocycloalkyls may include azetidineyl, oxetanyl, tetrahydro, tetrahydrofuran, pyrrolidineyl, imidazolineyl, oxazolinyl, oxazolidineyl, piperidineyl, piperazineyl, tetrahydropyranyl, dihydropyranyl, tetrahydropyridineyl, dihydropyridineyl, dihydrothiopyranyl, tetrahydropyrimidineyl, tetrahydropyridazineyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydropyrazolopyridineyl, morpholineyl, indolineyl, azethiomorpholineyl, etc. The attachment of heterocycloalkyl substituents may occur through carbon atoms or heteroatoms. The heterocycloalkyl group may optionally be substituted with one or more suitable groups through one or more of the aforementioned groups. Unless otherwise defined, heterocycloalkyl refers to 4 to 12-membered heterocycloalkyl, preferably 4 to 10-membered heterocycloalkyl, more preferably 5 to 7-membered heterocycloalkyl. The above cyclic substituents (e.g., cycloalkyl, cycloalkenyl, aryl, heterocyclic, heteroaryl, heterocycloalkyl, etc.) may be unsubstituted or substituted. The term "solvent" refers to a complex of variable stoichiometry formed by a solute and a solvent. For the purposes of this disclosure, such a solvent may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. A solvent in which water is the solvent molecule is referred to as a hydrate. Hydrates include compositions containing stoichiometric amounts of water as well as compositions containing variable amounts of water. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in physical and / or chemical properties. Structural differences may occur in configuration (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With respect to stereoisomers, compounds in this specification may have one or more asymmetric carbon atoms and may exist as racemics, racemic mixtures, and as individual enantiomers or diastereomers. The term "stereoisomer" refers to a set of compounds that have the same atomic number and type and share the same bonding connectivity between these atoms, but differ in three-dimensional structure. The term "stereoisomer" refers to any member of this set of compounds. For example, stereoisomers can be enantiomers or diastereomers. The term "enantiomer" refers to a pair of stereoisomers that are mirror images of each other and cannot be superimposed. The term "enantiomer" refers to a single member of such a pair of stereoisomers. The term "racemy" refers to a 1:1 mixture of a pair of enantiomers. The term "diastereoisomer" refers to a superposition possible by rotation around a single bond.

[0045] It refers to a set of stereoisomers that cannot be formed. For example, compounds containing cis- and trans- double bonds on a dicyclic ring system, endo- and exo- substitutions, and multiple stereochemical centers with different relative stereoconfigurations are considered to be diastereoisomers. The term "diastereoisomer" refers to any member of this set of compounds. In some of the examples presented, the synthetic route may produce a single diastereoisomer or a mixture of diastereoisomers. The term "tautomer" or "tautomer form" refers to structural isomers of different energies that are interconvertible through a low energy barrier. Some non-limiting examples of proton tautomers (also known as protic tautomers) involve interconversion via proton transfer, such as keto-enol and imine-enamine isomerization. Valence tautomers involve interconversion by the rearrangement of some of the bonding electrons. The term "isotope variant" means that for any compound, at least one atom is replaced by another atom having the same number of atoms but a different atomic weight than that which is generally or mainly occurring in nature. When used in relation to a compound, the "effective amount" is an amount effective for treating or preventing a disease in a subject as described in this specification. compound To achieve the above objective, the present invention provides a compound of Formula 1, or an optical isomer thereof, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomeric isomer thereof, or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] In the above formula, A is a substituted or non-substituted C6-C 12It is an aryl, a substituted or unsubstituted 5-12 member heteroaryl, or a substituted or unsubstituted 7-20 member heterobicycle; Z is S or C; R1 and R2 are each independently H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C1-C6 alkylamine, substituted or unsubstituted C3-C 20 Cycloalkyl, substituted or unsubstituted C6-C 12 Aryl, substituted or unsubstituted 5-12-membered heteroaryl, substituted or unsubstituted 5-12-membered heterocycloalkyl, substituted or unsubstituted C9-C 20 It is a 7- to 15-membered heterobicycle of a bicycle, substituted or non-substituted, or, R1 and R2 form a 5-20-membered heterocycloalkyl group together with the bonded N, wherein the heterocycloalkyl group may be unsubstituted or substituted. As a specific mode of work, the above A is , , , or And, These are unsubstituted or halo, nitro, C1-C6 alkoxy, amino, mono- or di- C1-C6 alkyl amino, quaternary to 12-membered heterocycloalkyl, C6-C 12 Substituted with 1 to 5 substituents selected from the group consisting of allyl and 7 to 15 heterobicycles, and At this time, the above 4- to 12-membered heterocycloalkyl, C6-C 12 Allyl and 7- to 15-membered heterobicycles are unsubstituted or -CO(=O)R3, -OH, unsubstituted or halo-substituted C6-C 10It may be substituted with 1 to 3 substituents selected from the group consisting of aryl, C1-C6 alkyl, halo, and 5- to 7-membered heterocycloalkyl. As a specific mode of work, the above A may be selected from the elements represented by the structure below. In a specific embodiment, R1 and R2 are each independently H, C1-C5 alkyl, C2-C5 alkenyl, C6-C 10 Aryl, C1-C5 alkylamine, C5-C8 cycloalkyl, C6-C 10 Aryl, 5-10 member heteroaryl, 5-10 member heterocycloalkyl, C9-C 12 It is a bicycle or a 7- to 12-won heterobicycle, and At this time, the above C1-C5 alkyl, C2-C5 alkenyl, C6-C 10 Aryl, C1-C5 alkylamine, C5-C 12 Cycloalkyl, C6-C 10 Aryl, 5-10 member heteroaryl, 5-10 member heterocycloalkyl, C9-C 12 The bicycle or 7- to 12-won heterobicycle, Unsubstituted or halo, halo C1-C3 alkyl, C1-C3 alkoxy, C6-C 10 Aryloxy, unsubstituted or halo-substituted C6-C 10 Aril, C9-C 12 bicyclic, unsubstituted or oxo-substituted 5-7-membered heterocycloalkyl, amino, oxo, -C(=O)R'(where R1 is a C1-C6 alkoxy, C3-C8 cycloalkyl), -NH-C(=O)R”(where R” is an unsubstituted or C1-C3 alkyl-substituted C6-C 10 Aryl, unsubstituted or C6-C1-C3 alkyl-substituted C6-C1 10 It may be substituted with 1 to 3 substituents selected from the group consisting of aryl C1-C3 alkyl. As a specific embodiment, the above -NR1R2 may be selected from the following structure. In a specific embodiment, the compounds of Formula 1 according to the present invention may be one or more compounds selected from the group consisting of the following compounds 1) to 142), but are not limited thereto. 1) 5-(dimethylamino)-N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 2) N-(4-chloro-3-(trifluoromethyl)phenyl)-5-(dimethylamino)naphthalene-1-sulfonamide; 3) 5-(dimethylamino)-N-phenylnaphthalene-1-sulfonamide; 4) 5-(dimethylamino)-N-(3-methoxyphenyl)naphthalene-1-sulfonamide; 5) N-(2,3-dihydro-1H-indene-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide; 6) 5-(dimethylamino)-N-(3-phenoxyphenyl)naphthalene-1-sulfonamide; 7) N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(dimethylamino)naphthalene-1-sulfonamide; 8) 5-(dimethylamino)-N-(3-isopropoxyphenyl)naphthalene-1-sulfonamide; 9) N-(benzo[d][1,3]dioxol-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide; 10) 5-(dimethylamino)-N-(thiazole-2-yl)naphthalene-1-sulfonamide; 11) 5-(dimethylamino)-N-(quinoline-3-yl)naphthalene-1-sulfonamide; 12) 5-(dimethylamino)-N-(3-fluorobenzyl)naphthalene-1-sulfonamide; 13) N-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(dimethylamino)naphthalene-1-sulfonamide; 14) 5-(dimethylamino)-N-(4-fluorobenzyl)naphthalene-1-sulfonamide; 15) 5-(dimethylamino)-N-(3-(2-oxopyrrolidine-1-yl)propyl)naphthalene-1-sulfonamide; 16) 5-(dimethylamino)-N-(2-(pyrrolidine-1-yl)ethyl)naphthalene-1-sulfonamide; 17) 5-(dimethylamino)-N-(2-(piperidine-1-yl)ethyl)naphthalene-1-sulfonamide; 18) N-allyl-5-(dimethylamino)naphthalene-1-sulfonamide; 19) N-cyclohexyl-5-(dimethylamino)naphthalene-1-sulfonamide; 20) 5-(dimethylamino)-N-(tetrahydro-2H-pyran-4-yl)naphthalene-1-sulfonamide; 21) tert-butyl (2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-λ 2 - Azanecarboxylate; 22) tert-butyl 4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-carboxylate; 23) N,N-dimethyl-5-(piperazine-1-ylsulfonyl)naphthalene-1-amine; 24) N-(3-aminopropyl)-5-(dimethylamino)naphthalene-1-sulfonamide; 25) N-(3-((5-(dimethylamino)naphthalene)-1-sulfonamido)propyl)cyclobutanecarboxamide; 26) (4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-yl)(phenyl)methanone; 27) 1-(4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-yl)-2-phenylethane-1-one; 28) Cyclobutyl(4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-yl)methanone; 29) N-(2-aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide hydrochloride; 30) N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-4-methylbenzamide; 31) N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-2-(p-tolyl)acetamide; 32) 1-((5-bromothiophene-2-yl)sulfonyl)piperazine; 33) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(3-chlorophenyl)methanone; 34) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(3-(trifluoromethyl)phenyl)methanone; 35) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(4-nitrophenyl)methanone; 36) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(pyrazine-2-yl)methanone; 37) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(thiophene-2-yl)methanone; 38) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(1H-indole-3-yl)methanone; 39) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(5-nitro-1H-pyrazol-3-yl)methanone; 40) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(1H-indole-4-yl)methanone; 41) 5-Bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 42) 5-Bromo-N-(3,4-Dimethoxyphenyl)thiophene-2-sulfonamide; 43) 5-Bromo-N-(3-fluoro-2-methoxyphenyl)thiophene-2-sulfonamide; 44) 5-Bromo-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 45) 5-Bromo-N-(2,4-dimethylphenyl)thiophene-2-sulfonamide; 46) 5-Bromo-N-(3-fluoro-4-methoxyphenyl)thiophene-2-sulfonamide; 47) 5-Bromo-N-(4-morpholinophenyl)thiophene-2-sulfonamide; 48) 5-Bromo-N-(4-phenoxyphenyl)thiophene-2-sulfonamide; 49) 5-Bromo-N-(6-methoxypyridine-3-yl)thiophene-2-sulfonamide; 50) 5-Bromo-N-(2-methoxypyridine-3-yl)thiophene-2-sulfonamide; 51) N-(benzo[d][1,3]dioxol-5-yl)-5-bromothiophene-2-sulfonamide; 52) 5-Bromo-N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 53) 5-Bromo-N-(3-methylpyridine-2-yl)thiophene-2-sulfonamide; 54) 5-Bromo-N-(4-methylpyridine-2-yl)thiophene-2-sulfonamide; 55) 5-Bromo-N-(quinoline-3-yl)thiophene-2-sulfonamide; 56) 5-Bromo-N-(6-(trifluoromethyl)pyridine-3-yl)thiophene-2-sulfonamide; 57) 5-Bromo-N-(3-methoxyphenyl)thiophene-2-sulfonamide; 58) 5-Bromo-N-(2,3-Dihydro-1H-Indene-5-yl)thiophene-2-sulfonamide; 59) 5-Bromo-N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)thiophene-2-sulfonamide; 60) 5-Bromo-N-(3-isopropoxyphenyl)thiophene-2-sulfonamide; 61) 5-Bromo-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 62) 5-Bromo-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 63) N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 64) N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 65) N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 66) N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 67) N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 68) 5-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 69) 5-chloro-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 70) 5-chloro-N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 71) 5-chloro-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 72) 5-chloro-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 73) N-(2-fluoro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 74) N-(4-chloro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 75) 3,4-Dimethoxy-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide; 76) N-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 77) N-(2-fluoro-5-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 78) N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 79) N-(4-chloro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 80) N-(4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 81) N-(2-chloro-4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 82) N-(2-fluoro-5-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 83) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-phenylthiophene-2-sulfonamide; 84) 5-(2,4-difluorophenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 85) 5-([1,1'-biphenyl]-2-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 86) 5-(4-(tert-butyl)phenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 87) 5-(benzo[d][1,3]dioxol-4-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 88) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-morpholinothiophene-2-sulfonamide; 89) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperidine-1-yl)thiophene-2-sulfonamide; 90) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(pyrrolidin-1-yl)thiophene-2-sulfonamide; 91) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-phenylpiperazine-1-yl)thiophene-2-sulfonamide; 92) (S)-N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(3-hydroxypyrrolidine-1-yl)thiophene-2-sulfonamide; 93) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(piperidine-1-yl)piperazine-1-yl)thiophene-2-sulfonamide; 94) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(2-fluorophenyl)piperazine-1-yl)thiophene-2-sulfonamide; 95) tert-butyl 4-(5-(N-(2-fluoro-3-(trifluoromethyl)phenyl)sulfamoyl)thiophene-2-yl)piperazine-1-carboxylate; 96) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperazine-1-yl)thiophene-2-sulfonamide; 97) N-(2-fluoro-3-(trifluoromethyl)phenyl)pyridine-3-sulfonamide; 98) 2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 99) 2,4-difluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 100) 2-fluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 101) N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-methoxybenzenesulfonamide; 102) N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 103) 4-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 104) N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-nitrobenzenesulfonamide; 105) N-phenylthiophene-2-sulfonamide; *106) N-phenylpyridine-3-sulfonamide; 107) 3,4-Dimethoxy-N-phenylbenzenesulfonamide; 108) 2,3,4-trifluoro-N-phenylbenzenesulfonamide; 109) 2,4-difluoro-N-phenylbenzenesulfonamide; 110) 2-fluoro-N-phenylbenzenesulfonamide; 111) 4-methoxy-N-phenylbenzenesulfonamide; 112) N-phenylbenzenesulfonamide; 113) 4-chloro-N-phenylbenzenesulfonamide; 114) 4-nitro-N-phenylbenzenesulfonamide; 115) N-(benzo[d][1,3]dioxol-5-yl)-2,3,4-trifluorobenzenesulfonamide; 116) N-(benzo[d][1,3]dioxol-5-yl)-3,4,5-trifluorobenzenesulfonamide; 117) N-(benzo[d][1,3]dioxol-5-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide; 118) N-((3s,5s,7s)-adamantan-1-yl)-2,3,4-trifluorobenzenesulfonamide; 119) N-((3s,5s,7s)-adamantan-1-yl)-3,4,5-trifluorobenzenesulfonamide; 120) N-((3s,5s,7s)-adamantan-1-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide; 121) 1-(pyridine-2-yl)-4-((2,3,4-trifluorophenyl)sulfonyl)piperazine; 122) 1-(pyridine-2-yl)-4-((3,4,5-trifluorophenyl)sulfonyl)piperazine; 123) 1-((perfluorophenyl)sulfonyl)-4-(pyridine-2-yl)piperazine; 124) 2,3,4-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)benzenesulfonamide; 125) 3,4,5-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)benzenesulfonamide; 126) 2,3,4,5,6-pentafluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)benzenesulfonamide; 127) N-(2,6-dioxopiperidin-3-yl)-2,3,4-trifluorobenzenesulfonamide; 128) N-(2,6-dioxopiperidin-3-yl)-3,4,5-trifluorobenzenesulfonamide; 129) N-(2,6-dioxopiperidin-3-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide; 130) (S)-1'-((2,3,4-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine; 131) (S)-1'-((3,4,5-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine; 132) 2,3,4-trifluoro-N-(1H-indole-7-yl)benzenesulfonamide; 133) 3,4,5-trifluoro-N-(1H-indole-7-yl)benzenesulfonamide; 134) 2,3,4,5,6-pentafluoro-N-(1H-indole-7-yl)benzenesulfonamide; 135) 2,3,4-trifluoro-N-(1H-indole-6-yl)benzenesulfonamide; 136) 3,4,5-trifluoro-N-(1H-indole-6-yl)benzenesulfonamide; 137) 2,3,4,5,6-pentafluoro-N-(1H-indole-6-yl)benzenesulfonamide; 138) N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxosoidolindolin-5-yl)-2,3,4-trifluorobenzenesulfonamide; 139) N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxosoidolindolin-5-yl)-3,4,5-trifluorobenzenesulfonamide; 140) 2,3,4,5,6-pentafluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 141) 2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzamide; and 142) (S)-1'-((perfluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine; In a specific embodiment, the compound of chemical formula 1 of the present invention may be one or more compounds selected from the above compounds 2, 14, 17, 18, 21, 30, 37, 39, 41, 42, 44 to 51, 62, 63, 67 to 71, 80, 84, 85, 89 to 93, 96, 98, 103, 110, 111, 117 to 121, 125, 128 to 130, 132, 135 to 138, 140, or 142. In a specific embodiment, the compound of Formula 1 of the present invention may be one or more compounds selected from the above compounds 14, 17, 18, 21, 30, 39, 41, 42, 44, 46, 48, 49, 50, 62, 68 to 71, 80, 84, 90, 92, 96, 98, 103, 111, 117, 118, 120, 129, 130, 132, 135 to 137, or 140. In a specific embodiment, the compound of Formula 1 of the present invention may be one or more compounds selected from the compounds 44, 68, 96, 98, 117, or 137, but is not necessarily limited thereto. Unless otherwise specified, the formulas or names given in the specification and claims herein encompass tautomers and all stereochemical, optical, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.) and their racemates, as well as mixtures of distinct enantiomers in different proportions, mixtures of diastereomers, or any of the above forms of mixtures in which isomers and enantiomers are present, and pharmaceutically acceptable salts thereof and salts including solvates thereof, such as solvates and hydrates of free compounds or solvates and hydrates of salts of said compounds. In one embodiment, the compound of the present invention may exist in the form of a pharmaceutically acceptable salt. As the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. The term "pharmaceutically acceptable salt" in the present invention refers to any organic or inorganic addition salt of said compound at a concentration having an effective action that is relatively non-toxic and harmless to the patient, such that side effects caused by said salt do not impair the beneficial efficacy of the compound according to the present invention. Acid addition salts are prepared by conventional methods, for example, by dissolving a compound in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone, or acetonitrile. An equal molar amount of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water may be heated, and then the mixture may be dried by evaporation or the precipitated salt may be filtered by suction. At this time, organic acids and inorganic acids may be used as free acids. Inorganic acids may include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc., and organic acids may include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, hydroiodic acid, etc., but are not limited to these. In addition, pharmaceutically acceptable metal salts can be prepared using a base. Alkali metal salts or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium, or calcium salts as the metal salts, but is not limited to these. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate). Pharmaceutically acceptable salts of the compounds of the present invention comprise, unless otherwise indicated, salts of acidic or basic groups that may be present in the compounds described in Formula 1. For example, pharmaceutically acceptable salts may include sodium, calcium, and potassium salts of hydroxyl groups, and other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, and may be prepared through methods for preparing salts known in the art. In a specific embodiment, the pharmaceutically acceptable salt of the compounds of the present invention may be a hydrochloride salt. As for the salt of the compound described in Formula 1 of the present invention, any salt of the compound described in Formula 1 that is pharmaceutically acceptable and exhibits pharmacological activity equivalent to that of the compound of Formula 1 may be used without limitation. Furthermore, the compound described in Formula 1 according to the present invention comprises, without limitation, its pharmaceutically acceptable salts as well as solvates, such as possible hydrates, that can be prepared therefrom, and all possible stereoisomers. All stereoisomers of the present invention, including enantiomer forms and diastereomer forms (e.g., those that may exist due to asymmetric carbons in various substituents), are included within the scope of the present invention. Individual stereoisomers of the compounds of the present invention may, for example, have substantially no other isomers (e.g., as pure or substantially pure optical isomers having specific activity), or, for example, as racemics or mixed with all other or other selected stereoisomers. The chiral center of the compounds of the present invention may have an S or R structure as defined by the IUPAC 1974 recommendations. Racemic forms may be analyzed by physical methods such as separation by chiral column chromatography, separation of diastereomer derivatives, crystallization, or fractional shape crystallization. Individual optical isomers can be obtained from a racemic mixture by any suitable method including crystallization following salt formation with an optically active acid, but not limited to this. Solvents and stereoisomers of the compound of Chemical Formula 1 above can be prepared from the compound using methods known in the art. Furthermore, the compound of Formula 1 according to the present invention may be prepared in a crystalline or amorphous form, and if prepared in a crystalline form, it may be optionally hydrated or solvated. The present invention may include not only the stoichiometric hydrate of the compound described in Formula 1 but also compounds containing various amounts of water. The solvates of the compound of Formula 1 according to the present invention include both stoichiometric solvates and non-stoichiometric solvates. The manufacturing method of the present invention may use commercially available compounds as reactants for the above reaction formulas, or synthesize them by performing one or more reactions known in the art as they are or with appropriate modifications. For example, synthesis may be performed by carrying out one or more reactions in a series of sequences, taking into account the presence, type, and / or location of reactive functional groups and / or heteroelements included in the skeletal structure, but is not limited thereto. The compound of Formula 1 according to the present invention can be prepared by the following exemplary method, and a specific example is the reaction scheme described in the examples below. The compound of the present invention is a MYO1D inhibitor, that is, a compound that inhibits the activity of MYO1D. The compound of the present invention has the activity of inhibiting the activity of MYO1D and thereby degrading wild-type and mutant GFRs, so it is useful for preventing, improving, or treating diseases such as cancer in which GFR is overexpressed, diseases or disorders caused by the overexpression of GFR, or degenerative brain diseases caused by the inhibition of MYO1D activity. In addition, due to the above activity, the compound of the present invention is useful for treating cancer cells that have developed resistance to anticancer agents that inhibit the activity of tyrosine kinase receptors, such as tyrosine kinase inhibitors (TKIs) or monoclonal antibodies (mAbs). In one embodiment, the compound of the present invention binds to Ecm29 to recruit the MYO1D molecular motor to the E3 ligase / 26S proteasome complex, thereby degrading MYO1D. Since MYO1D plays a role in supporting growth factor receptors (GFRs) such as EGFR, HER2, c-Met, VEGFR1, and VEGFR2 that are fixed to the plasma membrane, the degradation of MYO1D leads to the defixation and degradation of these GFRs, thereby blocking the generation of GFR-induced carcinogenic signals. Accordingly, the compound of the present invention acts like a Molecular Glue Degrader (MGD) to first target and degrade MYO1D, and consequently secondarily degrades wild-type and mutant GFRs immobilized on the plasma membrane; therefore, it is useful for preventing, improving, or treating diseases such as cancer with GFR overexpression or diseases or disorders caused by GFR overexpression, as well as for preventing, improving, or treating cancer by replacing or combining it with anticancer agents targeting wild-type and mutant GFRs. Furthermore, as described above, the compound of the present invention is useful for preventing, improving, or treating neurodegenerative diseases through its activity of inhibiting MYO1D. In one embodiment, the compound of the present invention reduces the survival and motility of H1975 / OR cells that have acquired resistance to osimertinib, one of the third-generation EGFR-TKIs developed to address the T790M mutation in NSCLC patients, so the compound of the present invention is very useful for inhibiting the growth and invasion of lung cancer cells expressing ErbB mutations that show resistance to conventional anti-ErbB drugs. In one embodiment, the compound of the present invention, when administered in combination with cisplatin, further enhances the tumor progression inhibitory effect compared to administration of cisplatin alone, thereby more effectively inhibiting TNBC tumorigenicity in vivo; thus, it is very useful for inhibiting the growth and invasion of cancer cells when used in combination with conventional anticancer agents such as anti-PD-1 immune checkpoint inhibitors. Pharmaceutical compositions and medicinal uses Accordingly, the compounds of the present invention, their optical isomers, their stereoisomers, their solvates, their isotopic variants, their tautomers, or their pharmaceutically acceptable salts may be suitable for preventing, improving, or treating various diseases, including cancers caused by cells overexpressing GFR, due to the inhibition of MYO1D activity and the resulting degradation activity of GFR and mutant GFR, due to their biological properties. Accordingly, in another aspect, the present invention relates to a pharmaceutical composition for preventing, improving, or treating diseases such as cancer with GFR overexpression, diseases or disorders caused by GFR overexpression, or degenerative brain diseases, comprising the compound of Formula 1, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomeric isomer, or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier thereof. Cancers that can be prevented, improved, or treated by the compounds of the present invention include pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, oropharyngeal tonsil cancer, oropharyngeal hypopharyngeal cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell tumor, male breast cancer, brain tumor, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphoblastic leukemia, retinoblastoma, choroidal melanoma, diffuse large B-cell lymphoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, rhinosinus cancer, non-small cell lung cancer, non-Hodgkin lymphoma, tongue cancer, and genital cord stromal tumor. Astrocytoma, Small cell lung cancer, Pediatric brain tumor, Pediatric lymphoma, Pediatric leukemia, Small intestine cancer, Meningioma, Esophageal cancer, Glioma, Neuroblastoma, Renal pelvis cancer, Kidney cancer, Heart cancer, Duodenal cancer, Malignant bone tumor, Malignant lymphoma, Malignant soft tissue tumor, Malignant mesothelioma, Malignant melanoma, Eye tumor, Vulvar cancer, Ureteral cancer, Urethral cancer, Cancer of unknown primary site, Gastric lymphoma, Gastric cancer, Gastric carcinoid tumor, Gastrointestinal stromal tumor, Wilms tumor, Breast cancer, Triple-negative breast cancer (TNBC), Sarcoma, Penile cancer, Gestational trophoblastic disease, Cervical cancer, Endometrial cancer, Uterine sarcoma, Prostate cancer, Metastatic bone tumor, Metastatic brain tumor, Mediastinal cancer, Rectal neuroendocrine tumor, Rectal cancer, Vaginal cancer, Spinal cord tumor, Acoustic neuroma, Pancreatic cancer, Salivary gland cancer, Kaposi sarcoma, Paget's disease, It may include, but is not limited to, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, thymic cancer, etc. All the aforementioned cancers characterized by specific locations or organs within the body refer to both primary tumors and metastatic tumors derived therefrom. All the aforementioned cancers can be further distinguished by their histopathological classification. Diseases or disorders caused by GFR overexpression that can be prevented, improved, or treated by the compound of the present invention may include, but are not limited to, fibrotic diseases such as pulmonary fibrosis, hepatic fibrosis, and renal fibrosis; retinal vascular diseases such as wet macular degeneration, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion; psoriasis; rheumatoid arthritis; stroke; hemangiomas such as infantile hemangioma and telangiectasia; glomerular diseases such as proteinuria and renal failure; placenta previa; eclampsia; arteriovenous malformations. In addition, diseases or disorders that can be prevented, improved, or treated by the compound of the present invention may include degenerative brain diseases such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Huntington's disease. According to recent studies, α-syn PFF (α-Synuclein preformed fibrils) in peripheral blood pass through the blood-brain barrier (BBB), causing α-synuclein to be deposited in brain tissue, which leads to the development of Parkinson's disease; it has been studied that tunneling nanotuves (TNT) and MYO1D are involved in the process of α-syn PFF passing through the BBB (Qingrui et al. 2023). Therefore, since the compound of the present invention inhibits MYO1D activity, it inhibits the passage of α-syn PFF through the BBB, thereby inhibiting the deposition of α-synuclein in brain tissue, which can prevent, improve, or treat neurological diseases such as Parkinson's disease. The terms “individual” or “patient,” used interchangeably in this specification, refer to any animal including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, or primates, and most preferably humans. The term "therapeutic effective dose" refers to the amount of an active compound or pharmaceutical agent sought by a researcher, veterinarian, physician, or other clinician to induce a biological or medical response in a tissue, system, animal, individual, or human. The terms “treating,” “improving,” “treatment,” or “improvement” refer to one or more of (1) suppressing a disease; for example, suppressing a disease, condition, or disorder in an individual who experiences or exhibits a pathology or symptom of a disease, condition, or disorder (i.e., preventing further occurrence of the pathology and / or symptom); and (2) improving a disease; for example, improving a disease, condition, or disorder in an individual who experiences or exhibits a pathology or symptom of a disease, condition, or disorder (i.e., reversing the pathology and / or symptom), for example, reducing the severity of the disease. In one embodiment, treating or treatment includes preventing or reducing the risk of the disease occurring; for example, preventing or reducing the risk of the disease, condition, or disorder occurring in an individual who may have a predisposition to the disease, condition, or disorder but has not yet experienced or exhibited a pathology or symptom of the disease. In a specific embodiment, the pharmaceutical composition according to the present invention may further comprise, together with the compound of Formula 1, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomeric isomer, or its pharmaceutically acceptable salt and its pharmaceutically acceptable carrier, an additional anticancer agent, a GFR agent, or a MYO1D inhibitor as an active ingredient. The above-mentioned cancer treatments may be used without restriction as long as they are related to the treatment of cancer. Specific examples thereof are the same as the agents listed in the combination therapy below. The above-mentioned GFR therapeutic agents may be used without restriction as long as they are related to GFR treatment, such as EGFR (Epidermal Growth Factor receptor), HER2 (Human Epidermal Growth Factor Receptor 2), VEGFR (Vascular Endothelial Growth Factor Receptor), PDGFR (Platelet-Derived Growth Factor Receptor), FGFR (Fibroblast Growth Factor Receptor), and IGF1R (Insulin-like Growth Factor 1 Receptor). Specific examples of these are the same as the agents listed in the combination therapy below. The aforementioned treatments for degenerative brain diseases or disorders, such as Parkinson's disease, may be used without restriction if they are related to the treatment of degenerative brain diseases. Specific examples thereof are the same as the agents listed in the combination therapy below. In a specific embodiment, the compound of Formula 1 according to the present invention, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomeric isomer, or its pharmaceutically acceptable salt, and pharmaceutical compositions comprising these may be used in conjunction with non-drug therapies for the prevention, improvement, and treatment of cancer, diseases caused by GFR overexpression, or degenerative brain diseases. For example, in combination with radiation therapy and / or surgery and / or other compounds, they may be used for the prevention, short-term, or long-term treatment of the aforementioned diseases. The pharmaceutical composition of the present invention may be administered to mammals such as rats, mice, livestock, and humans by various routes. In the present invention, the routes of administration of the pharmaceutical composition are not limited to these but include oral, intravenous, intramuscular, intra-arterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, or rectal. In addition, oral and parenteral administration are preferred methods of administering the pharmaceutical composition. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intradural, intralesional, and intracranial injection or infusion techniques. The pharmaceutical composition according to the present invention may further comprise one or more pharmaceutically acceptable carriers, one or more excipients and / or diluents. Non-limiting examples of pharmaceutically suitable carriers include solids and / or liquids, e.g., ethanol, glycerol, water, etc. The amount of carrier in the therapeutic composition may be in the range of about 5 to about 99 weight percent based on the total weight of the therapeutic composition or therapeutic combination. Non-limiting examples of suitable pharmaceutically acceptable excipients and diluents include non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, wetting agents, extenders, antioxidants, lubricants, flavoring agents, thickeners, coloring agents, surfactants, emulsifiers, turbidizers, etc. Examples of such excipients and diluents include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, and it is obvious to a person skilled in the art that all other pharmaceutically acceptable carriers, excipients, and diluents may be used. The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as tablets, powders, granules, pills, capsules, suspensions, emulsions, liquids, emulsions, syrups, external preparations, suppositories, or sterile injectable solutions, each according to conventional methods. The pharmaceutical composition according to the present invention may be in the form of a sterile injectable formulation as a sterile injectable aqueous or oily suspension. This suspension may be formulated according to techniques known in the art using a suitable dispersant or wetting agent (e.g., Tween 80) and a suspending agent. The sterile injectable formulation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent (e.g., a solution in 1,3-butanediol). Acceptable vehicles and solvents include mannitol, water, Ringer's solution, or isotonic sodium chloride solution. Additionally, sterile nonvolatile oils are typically used as solvents or suspension media. For this purpose, any nonvolatile oil with low irritation, including synthetic mono or diglycerides, may be used. Fatty acids such as oleic acid and its glyceride derivatives are useful in injectable preparations, as are pharmaceutically acceptable natural oils (e.g., olive oil or castor oil), especially their polyoxyethylated forms. The pharmaceutical composition according to the present invention may be administered orally in any orally acceptable dose, including but not limited to these, capsules, tablets, aqueous suspensions, and solutions. The pharmaceutical compositions of the present invention may also be administered in the form of suppositories for rectal administration. These compositions may be prepared by mixing the compounds of the present invention with suitable non-irritating excipients that are solid at room temperature but liquid at rectal temperature. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycol. Oral administration of the pharmaceutical composition according to the present invention is particularly useful when the intended treatment involves a site or organ that is easily accessible by topical application. When applied topically to the skin, the pharmaceutical composition should be formulated as a suitable ointment containing an active ingredient suspended or dissolved in a carrier. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid paraffin, white petroleum jelly, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes, and water. Alternatively, the pharmaceutical composition may be formulated as a suitable lotion or cream containing an active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water. The pharmaceutical composition of the present invention may also be applied topically to the lower intestinal tract by a rectal suppository or by a suitable enema. A locally applied transdermal patch is also included in the present invention. The pharmaceutical composition of the present invention may be administered by nasal aerosol or inhalation. Such composition may be prepared according to techniques well known in the field of pharmaceuticals and may be prepared as a solution in saline using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons and / or other solubilizing agents or dispersing agents known in the art. The novel compound described above is contained in the pharmaceutical composition of the present invention in a therapeutically effective amount or a prophylactically effective amount. The preferred dosage of the compound according to the present invention varies depending on the patient's condition and body weight, the severity of the disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, the compound of Formula 1 of the present invention may be administered in an amount of 0.0001 to 1000 mg / kg, preferably 0.01 to 500 mg / kg, divided into one to several doses per day. In the composition of the present invention, the compound of Formula 1 may be incorporated in an amount of 0.0001 to 50% by weight relative to the total weight of the composition. In another aspect, the present invention relates to a method for preventing, improving, or treating cancer, cancer, diseases caused by the overexpression of GFR, or degenerative brain diseases, comprising the compound of Formula 1, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomeric isomer, or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier thereof. At this time, the compound of Formula 1 of the present invention, its optical isomer, its stereoisomer, its solvate, its isotopic variant, its tautomer, or its pharmaceutically acceptable salt is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" in the present invention means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause adverse effects. The effective dose level may be determined based on factors including the patient's health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without adverse effects, taking all of the above factors into consideration, and this can be easily determined by a person skilled in the art. For example, since the dosage may be increased or decreased depending on the route of administration, severity of the disease, gender, body weight, age, etc., the above dosage does not limit the scope of the present invention in any way. The preferred dosage of the compound of the present invention varies depending on the patient's condition and weight, the severity of the disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art. Combination therapy The treatments defined herein may be applied as monotherapy or may involve conventional surgery, radiation therapy, or chemotherapy in addition to the compounds of the present disclosure. Accordingly, the compounds of the present invention may also be used in combination with existing therapeutic agents for cancer treatment. In addition to the compounds disclosed herein, conventional surgery, radiation therapy, chemotherapy, or immunotherapy may be used for cancer treatment. These treatment methods may be administered simultaneously, sequentially, or separately with the compounds disclosed herein and may include one or more of the following categories of antitumor agents: (i) antiproliferative / antineoplastic drugs used in medical oncology, such as alkylating agents (e.g., cis-platin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolomide, and nitrosourea), and combinations thereof; Antimetabolites (e.g., gemcitabine, antifolates, fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); Antitumor antibiotics (e.g., anthracycs, e.g., adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin); antimitotic agents (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, and taxoids such as taxol and taxotere, and polokinase inhibitors);Topoisomerase inhibitors (e.g., epipodophillotoxin such as etoposide and teniposide, amsacrine, topotecan, and camptothecin); (ii) cytostatic agents, e.g., antiestrogens (e.g., tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene, and iodoxyfene), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or LHRH agonists (e.g., goserelin, leuprorelin, and buserelin), progestogens (e.g., megestrol acetate), aromatase inhibitors inhibitor)(e.g., anastrozole, letrozole, vorazole, and exemestane), and 5α-reductase inhibitors, e.g., finasteride; (iii) anti-invasion agents [e.g., c-Src kinase family inhibitors such as 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazine-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazolin [AZD0530 (saracatinib)], N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazine-1-yl]-2-methylpyrimidine-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS354825) and bosutinib (SKI-606), marimastat, urokinase plasminogen activator receptor function inhibitors, or antibodies against heparanase]; (iv) Growth factor function inhibitors: for example, these inhibitors include growth factor antibodies and growth factor receptor antibodies (e.g., anti-ErbB2 antibody trastuzumab [Herceptin], anti-EGFR antibody panitumumab and anti-ErbB1 antibody cetuximab [Erbitux, C225]); These inhibitors are also tyrosine kinase inhibitors, e.g., inhibitors of the epidermal growth factor family (e.g., EGFR-family tyrosine kinase inhibitors, e.g., N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)-quinazolin-4-amine (gefitinib, ZD 1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), ErbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; Inhibitors of the platelet-derived growth factor family, such as imatinib and / or nilotinib (AMN107); serine / threonine kinase inhibitors (e.g., Ras / Raf signaling inhibitors, e.g., farnesyl transferase inhibitors, e.g., sorafenib (BAY 43-9006), tipifarnib (Rl 15777), and lonafarnib (SCH66336)), inhibitors of cell signaling via MEK and / or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; Includes aurora kinase inhibitors (e.g., AZD1152, PH739358, VX680, MLN8054, R763, MP235, MP529, VX-528, and AX39459) and cyclin-dependent kinase inhibitors, e.g., CDK2 and / or CDK4 inhibitors; (v) anti-angiogenic agents that inhibit the effects of vascular endothelial growth factor [e.g., anti-human vascular endothelial growth factor antibody bevacizumab (Avastin) and VEGF receptor tyrosine kinase inhibitors such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SUI1248), axitinib (AG-013736), pazopanib (GW 786034) and 4-(4-fluoro-2-methylindole-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazolin (AZD2171) and compounds acting by other mechanisms (e.g., linomaid, integrin ανβ3 function inhibitors and angiostatin)]; (vi) Vascular damaging agents such as combretastatin A4; (vii) Endothelin receptor antagonists, e.g., zibotentan (ZD4054) or atrasentan; (viii) Antisense therapy, e.g., ISIS 2503, anti-ras antisense, and therapies for the targets listed above; (ix) gene therapy approaches including, for example, approaches to replace abnormal genes such as abnormal p53 or abnormal BRCA1 or BRCA2; GDEPT (gene-directed enzyme pro-drug therapy) approaches such as using cytosine deaminase, thymidine kinase, or bacterial nitroreductase enzyme; and approaches to increase a patient's resistance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and (x) Immunotherapy approaches including in vitro and in vivo approaches to increase the immunogenicity of patient tumor cells, such as, for example, transformation using cytokines such as interleukin 2, interleukin 4, or granulocyte-macrophage colony-stimulating factor; approaches to reduce T cell non-response; approaches using transformed immune cells such as cytokine-transformed dendritic cells; approaches using cytokine-transformed tumor cell lines; approaches using anti-ideotype antibodies; approaches to reduce the function of immunosuppressive cells such as regulatory T cells, myeloid-derived suppressor cells, or dendritic cells expressing IDO (indoleamine 2,3-deoxygenase); and approaches using cancer vaccines composed of proteins or peptides derived from tumor-associated antigens such as NY-ESO-1, MAGE-3, WTI, or Her2 / neu. The compounds of the present invention may also be used in combination with existing therapeutic agents for the treatment of diseases or disorders associated with GFR overexpression. In addition to the compounds disclosed herein, conventional surgery, radiation therapy, chemotherapy, or immunotherapy may be used for the treatment of diseases or disorders associated with GFR overexpression. These treatment methods may be administered simultaneously, sequentially, or separately from the compounds disclosed herein, and examples thereof include, but are not limited to, the (iv) growth factor function inhibitors and (v) anti-angiogenic agents that inhibit the effects of vascular endothelial growth factor described above. The compounds of the present invention may also be used in combination with existing therapeutic agents for the treatment of degenerative brain diseases such as Parkinson's disease. In addition to the compounds disclosed herein, conventional surgery, radiation therapy, chemotherapy, or immunotherapy may be used for the treatment of degenerative brain diseases. These treatment methods may be administered simultaneously, sequentially, or separately from the compounds disclosed herein and may include one or more of the following therapeutic agents: dopamine supplements such as carbidopa / levodopa; dopamine agonists such as pyramipexol, ropinirol, rotigotine, and apomorphine; MAO-B inhibitors such as selegiline, rasagiline, and safinamide; COMP inhibitors such as entacapone and tolcapone; anticholinergics such as trihexyphenidyl and benztropine; NMDA antagonists such as amantadine and memantine; AChE inhibitors such as donepezil, rivastigmine, and galantamine; riluzole, edaravone, tetrabenazine, and deutetrabenazine. Examples The structure and effects of the present invention will be explained in more detail below through examples. These examples are solely for the purpose of illustrating the present invention, and the scope of the present invention is not limited by these examples. Preparation of compounds Examples 1-31: Preparation of compounds 1 to 31 (MYO1Di-A001 to MYO1Di-A031) according to the present invention Compounds 1 to 31 of the present invention (MYO1Di-A001 to MYO1Di-A031) were synthesized according to the following reaction scheme 1. [Reaction Equation 1] Specifically, 5-(dimethylamino)naphthalene-1-sulfonyl chloride (1 equivalent) was dissolved in pyridine (3 mL per 1 mmol of starting material), and piperidine (1 equivalent) dissolved in pyridine was slowly added to the reaction mixture in an ice bath. The mixture was stirred at 90°C for 1 hour under a nitrogen atmosphere. After the reaction was complete, the resulting solution was extracted with ethyl acetate, the organic layer was washed with 1 N hydrochloric acid and brine, and then dried with anhydrous sodium sulfate (Na2SO4). The solution was then concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (ethyl acetate / n-hexane = 20 / 100) to obtain compound 1 (MYO1Di-A001). Compounds 2 to 31 (MYO1Di-A002 to MYO1Di-A031) were prepared in the same manner. Compound 1: 5-(dimethylamino)-N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide, MYO1Di-A001) 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.53 (d, J = 8.7 Hz, 1H), 8.26 (d, J = 8.7 Hz, 1H), 8.22 (d, J = 7.3 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.57 (t, J) = 8.2 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.19 (q, J = 7.2 Hz, 2H), 7.09 (t, J = 7.5 Hz, 2H), 2.85 (s, 6H) MS (ESI+, m / z): 413[M+H] Compound 2: N-(4-chloro-3-(trifluoromethyl)phenyl)-5-(dimethylamino)naphthalene-1-sulfonamide (N-(4-chloro-3-(trifluoromethyl)phenyl)-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A002) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.54 (d, J = 8.2 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.48 (t, J) = 8.0 Hz, 1H), 7.18-7.26 (m, 3H), 7.10 (dd, J = 8.7, 2.7 Hz, 1H), 2.87 (s, 6H) MS (ESI+, m / z): 429 [M+H] Compound 3: 5-(dimethylamino)-N-phenylnaphthalene-1-sulfonamide (5-(dimethylamino)-N-phenylnaphthalene-1-sulfonamide, MYO1Di-A003) 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.49 (d, J = 8.7 Hz, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.16 (d, J = 7.3 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.42 (t, J) = 8.0 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.12 (t, J = 7.3 Hz, 2H), 7.01 (t, J = 8.0 Hz, 1H), 6.92 (d, J = 7.3 Hz, 2H), 6.86 (s, 1H), 2.87 (t, J = 1.1 Hz, 6H) MS (ESI+, m / z): 327 [M+H] Compound 4: 5-(dimethylamino)-N-(3-methoxyphenyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(3-methoxyphenyl)naphthalene-1-sulfonamide, MYO1Di-A004) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.50 (d, J = 8.7 Hz, 1H), 8.34 (t, J = 4.3 Hz, 1H), 8.20 (d, J = 7.3 Hz, 1H), 7.57 (t, J = 8.2 Hz, 1H), 7.44 (dd, J = 8.2, 7.3 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.00 (t, J = 8.2 Hz, 1H), 6.55 (d, J = 10.1 Hz, 2H), 6.47 (d, J = 6.9 Hz, 1H), 3.64 (d, J = 1.8 Hz, 3H), 2.87 (s, 6H) MS (ESI+, m / z): 357 [M+H] Compound 5: N-(2,3-dihydro-1H-inden-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide (N-(2,3-dihydro-1H-inden-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A005) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.49 (d, J = 8.7 Hz, 1H), 8.35 (d, J = 8.2 Hz, 1H), 8.14 (dd, J = 7.3, 0.9 Hz, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.42 (dd, J = 8.2, 7.3 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 6.93 (d, J = 7.8 Hz, 1H), 6.82 (s, 1H), 6.60 (dd, J = 8.0, 2.1 Hz, 1H), 2.88 (s, 6H), 2.74 (q, J = 7.9 Hz, 4H), 1.93-2.01 (m, 2H) MS (ESI+, m / z): 367 [M+H] Compound 6: 5-(dimethylamino)-N-(3-phenoxyphenyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(3-phenoxyphenyl)naphthalene-1-sulfonamide, MYO1Di-A006) 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.50 (d, J = 8.5 Hz, 0H), 8.30 (d, J = 8.7 Hz, 0H), 8.15 (d, J = 7.3 Hz, 0H), 7.53 (t, J = 8.2 Hz, 0H), 7.41 (t, J) = 8.0 Hz, 0H), 7.26 (t, J = 7.3 Hz, 0H), 7.15 (d, J = 7.8 Hz, 0H), 7.05-7.11 (m, 0H), 6.78 (d, J = 7.8 Hz, 0H), 6.68 (d, J = 8.2 Hz, 0H), 6.61 (d, J = 8.2 Hz, 0H), 6.57 (d, J = 2.3 Hz, 0H), 2.86 (s, 1H) MS (ESI+, m / z): 419 [M+H] Compound 7: N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(dimethylamino)naphthalene-1-sulfonamide (N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A007) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.50 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.11 (d, J = 7.3 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.42 (t, J) = 8.0 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 6.57 (d, J = 8.7 Hz, 2H), 6.48 (d, J = 2.7 Hz, 1H), 6.32 (dd, J = 8.7, 2.7 Hz, 1H), 4.13 (s, 4H), 2.88 (s, 6H) MS (ESI+, m / z): 385 [M+H] Compound 8: 5-(dimethylamino)-N-(3-isopropoxyphenyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(3-isopropoxyphenyl)naphthalene-1-sulfonamide, MYO1Di-A008) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.49 (t, J = 9.4 Hz, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.14-8.22 (m, 1H), 7.49-7.57 (m, 1H), 7.41 (dd, J = 8.5, 7.5 Hz, 1H), 7.16 (d, J = 6.9 Hz, 1H), 6.96 (t, J = 8.0 Hz, 1H), 6.41-6.55 (m, 3H), 4.27-4.33 (m, 1H), 2.85 (s, 6H), 1.17 (s, 3H), 1.15 (s, 3H) MS (ESI+, m / z): 385 [M+H] Compound 9: N-(benzo[d][1,3]dioxol-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide (N-(benzo[d][1,3]dioxol-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A009) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.50 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.08 (d, J = 7.3 Hz, 1H), 7.58 (t, J = 8.2 Hz, 1H), 7.41 (t, J) = 8.0 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 6.47-6.53 (m, 3H), 6.22 (dd, J = 8.2, 1.8 Hz, 1H), 5.85 (s, 2H), 2.88 (s, 6H) MS (ESI+, m / z): 371 [M+H] Compound 10: 5-(dimethylamino)-N-(thiazol-2-yl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(thiazol-2-yl)naphthalene-1-sulfonamide, MYO1Di-A010) 1 H-NMR (400 MHz, DMSO-D6) δ 8.35 (dd, J = 13.3, 8.7 Hz, 2H), 8.14 (d, J = 7.3 Hz, 1H), 7.54 (dt, J = 18.1, 8.0 Hz, 2H), 7.17-7.19 (m, 2H), 6.76 (d, J = 4.6 Hz, 1H), 2.77 (s, 6H) MS (ESI+, m / z): 334 [M+H] Compound 11: 5-(dimethylamino)-N-(quinolin-3-yl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(quinolin-3-yl)naphthalene-1-sulfonamide, MYO1Di-A011) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.48 (d, J = 8.7 Hz, 1H), 8.36-8.38 (m, 2H), 8.19 (dd, J = 7.4, 1.5 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 2.3 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.60 (td, J = 8.2, 6.3 Hz, 2H), 7.49 (t, J = 7.5 Hz, 1H), 7.39 (dd, J = 8.3, 7.2 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 2.86 (s, 6H) MS (ESI+, m / z): 378 [M+H] Compound 12: 5-(dimethylamino)-N-(3-fluorobenzyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(3-fluorobenzyl)naphthalene-1-sulfonamide, MYO1Di-A012) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.53 (d, J = 8.2 Hz, 1H), 8.26 (t, J = 8.0 Hz, 2H), 7.57 (t, J = 8.2 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.19 (d, J) = 7.8 Hz, 1H), 7.11 (dd, J = 14.0, 8.0 Hz, 1H), 6.81-6.86 (m, 2H), 6.74 (d, J = 9.1 Hz, 1H), 4.07 (d, J = 6.4 Hz, 2H), 2.90 (s, 6H) MS (ESI+, m / z): 359 [M+H] Compound 13: N-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(dimethylamino)naphthalene-1-sulfonamide (N-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A013) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.54 (d, J = 8.2 Hz, 1H), 8.24-8.27 (m, 2H), 7.53 (qd, J = 8.9, 7.5 Hz, 2H), 7.19 (d, J = 7.8 Hz, 1H), 6.57 (d, J = 7.8 Hz, 1H), 6.48-6.52 (m, 2H), 5.87 (s, 2H), 3.97 (d, J = 5.9 Hz, 2H), 2.90 (s, 6H) MS (ESI+, m / z): 385 [M+H] Compound 14: 5-(dimethylamino)-N-(4-fluorobenzyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(4-fluorobenzyl)naphthalene-1-sulfonamide, MYO1Di-A014) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.53 (d, J = 8.7 Hz, 0H), 8.24-8.26 (m, 0H), 7.53 (dt, J = 21.3, 8.1 Hz, 0H), 7.19 (d, J = 7.8 Hz, 0H), 6.99-7.04 (m, 0H), 6.82 (t, J = 8.7 Hz, 0H), 4.05 (d, J = 6.4 Hz, 0H), 2.90 (s, 1H) MS (ESI+, m / z): 359 [M+H] Compound 15: 5-(dimethylamino)-N-(3-(2-oxopyrrolidin-1-yl)propyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(3-(2-oxopyrrolidin-1-yl)propyl)naphthalene-1-sulfonamide, MYO1Di-A015) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.51 (d, J = 8.7 Hz, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.22 (d, J = 7.3 Hz, 1H), 7.59 (t, J = 8.0 Hz, 1H), 7.50 (t, J) = 7.8 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 3.26 (q, J = 6.9 Hz, 4H), 2.88-2.92 (m, 8H), 2.33 (t, J = 8.2 Hz, 2H), 1.93-2.01 (m, 2H), 1.57 (t, J = 5.9 Hz, 2H) MS (ESI+, m / z): 376 [M+H] Compound 16: 5-(dimethylamino)-N-(2-(pyrrolidin-1-yl)ethyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(2-(pyrrolidin-1-yl)ethyl)naphthalene-1-sulfonamide, MYO1Di-A016) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.53 (d, J = 8.7 Hz, 1H), 8.25-8.31 (m, 2H), 7.51-7.58 (m, 2H), 7.18 (d, J = 7.3 Hz, 1H), 2.88 (s, 6H), 2.86 (d, J = 5.9 Hz, 2H), 2.36 (t, J = 5.7 Hz, 2H), 2.05 (d, J = 3.7 Hz, 4H), 1.48-1.51 (m, 4H) MS (ESI+, m / z): 348 [M+H] Compound 17: 5-(dimethylamino)-N-(2-(piperidin-1-yl)ethyl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(2-(piperidin-1-yl)ethyl)naphthalene-1-sulfonamide, MYO1Di-A017) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.53 (d, J = 8.7 Hz, 1H), 8.29 (dd, J = 28.6, 8.0 Hz, 2H), 7.55 (td, J = 15.8, 7.8 Hz, 2H), 7.18 (d, J = 7.8 Hz, 1H), 2.88 (s, 6H), 2.86 (d, J = 6.4 Hz, 2H), 2.13 (t, J = 5.7 Hz, 2H), 1.93 (s, 4H), 1.27 (d, J = 7.3 Hz, 6H) MS (ESI+, m / z): 362 [M+H] Compound 18: N-allyl-5-(dimethylamino)naphthalene-1-sulfonamide (N-allyl-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A018) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.54 (d, J = 8.7 Hz, 1H), 8.26 (dd, J = 11.7, 8.0 Hz, 2H), 7.54 (dt, J = 18.0, 8.0 Hz, 2H), 7.18 (d, J = 7.3 Hz, 1H), 5.57-5.65 (m, 1H), 5.08 (d, J = 16.9 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 3.52 (t, J = 5.9 Hz, 2H), 2.88 (s, 6H) MS (ESI+, m / z): 291 [M+H] Compound 19: N-cyclohexyl-5-(dimethylamino)naphthalene-1-sulfonamide (MYO1Di-A019) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.61 (t, J = 2.1 Hz, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.25 (t, J = 8.0 Hz, 2H), 7.49-7.56 (m, 2H), 7.16 (d, J = 7.8 Hz, 1H), 3.11 (q, J = 3.5 Hz, 1H), 2.88 (s, 6H), 1.42-1.65 (m, 5H), 1.01-1.18 (m, 5H) MS (ESI+, m / z): 333 [M+H] Compound 20: 5-(dimethylamino)-N-(tetrahydro-2H-pyran-4-yl)naphthalene-1-sulfonamide (5-(dimethylamino)-N-(tetrahydro-2H-pyran-4-yl)naphthalene-1-sulfonamide, MYO1Di-A020) 1 H-NMR (400 MHz, DMSO-D6) δ 8.44 (d, J = 8.7 Hz, 1H), 8.29 (d, J = 8.7 Hz, 1H), 8.14 (d, J = 7.3 Hz, 1H), 8.03 (d, J = 7.8 Hz, 1H), 7.59 (dd, J = 18.8, 8.2 Hz, 2H), 7.24 (d, J = 7.3 Hz, 1H), 3.64 (d, J = 11.4 Hz, 2H), 3.13 (t, J = 10.3 Hz, 3H), 2.82 (s, 6H), 1.22-1.41 (m, 4H) MS (ESI+, m / z): 335 [M+H] Compound 21: tert-butyl (2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-λ 2 -Azanecarboxylate (tert-butyl (2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-λ 2 -azanecarboxylate, MYO1Di-A021) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.54 (d, J = 8.2 Hz, 1H), 8.22-8.28 (m, 2H), 7.49-7.58 (m, 2H), 7.18 (d, J = 7.3 Hz, 1H), 3.15 (t, J = 5.3 Hz, 2H), 3.00 (q, J = 5.6 Hz, 2H), 2.88 (s, 6H), 1.38 (s, 9H) MS (ESI+, m / z): 393 [M+H] Compound 22: tert-butyl 4-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazine-1-carboxylate (MYO1Di-A022) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.57 (d, J = 8.2 Hz, 1H), 8.39 (d, J = 8.7 Hz, 1H), 8.20 (d, J = 6.4 Hz, 1H), 7.52-7.56 (m, 2H), 7.19 (d, J = 7.3 Hz, 1H), 3.44 (t, J = 5.0 Hz, 4H), 3.14 (t, J = 5.0 Hz, 4H), 2.89 (s, 6H), 1.39 (s, 9H) MS (ESI+, m / z): 420 [M+H] Compound 23: N,N-dimethyl-5-(piperazin-1-ylsulfonyl)naphthalen-1-amine (N,N-dimethyl-5-(piperazin-1-ylsulfonyl)naphthalen-1-amine, MYO1Di-A023) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.56 (d, J = 8.2 Hz, 1H), 8.43 (d, J = 8.7 Hz, 1H), 8.19 (d, J = 7.3 Hz, 1H), 7.51-7.55 (m, 2H), 7.18 (d, J = 7.8 Hz, 1H), 3.15 (t, J = 5.0 Hz, 4H), 2.88 (s, 6H), 2.86 (d, J = 4.6 Hz, 4H) MS (ESI+, m / z): 320 [M+H] Compound 24: N-(3-aminopropyl)-5-(dimethylamino)naphthalene-1-sulfonamide (N-(3-aminopropyl)-5-(dimethylamino)naphthalene-1-sulfonamide, MYO1Di-A024) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.53 (d, J = 8.7 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.25 (d, J = 5.9 Hz, 1H), 7.53 (dd, J = 17.8, 8.2 Hz, 2H), 7.18 (d, J = 7.3 Hz, 1H), 3.01 (t, J = 6.2 Hz, 2H), 2.89 (s, 6H), 2.70 (t, J = 5.9 Hz, 2H), 1.46-1.52 (m, 2H) MS (ESI+, m / z): 308 [M+H] Compound 25: N-(3-((5-(dimethylamino)naphthalene)-1-sulfonamido)propyl)cyclobutanecarboxamide (MYO1Di-A025) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.52 (d, J = 8.7 Hz, 1H), 8.34 (d, J = 8.7 Hz, 1H), 8.21-8.22 (m, 1H), 7.60 (dd, J = 8.7, 7.8 Hz, 1H), 7.51 (dd, J = 8.5, 7.5 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 3.26 (q, J = 6.3 Hz, 2H), 2.89 (dd, J = 12.8, 5.0 Hz, 9H), 2.04-2.15 (m, 4H), 1.80-1.92 (m, 2H), 1.55 (t, J = 5.9 Hz, 2H) MS (ESI+, m / z): 390 [M+H] Compound 26: (4-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazin-1-yl)(phenyl)methanone ((4-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazin-1-yl)(phenyl)methanone, MYO1Di-A026) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.59 (d, J = 8.2 Hz, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.20 (d, J = 7.3 Hz, 1H), 7.54 (t, J = 8.0 Hz, 2H), 7.35-7.41 (m, 3H), 7.30 (d, J = 6.4 Hz, 2H), 7.19 (d, J = 7.3 Hz, 1H), 3.26-3.81 (m, 8H), 2.90 (s, 6H) MS (ESI+, m / z): 424 [M+H] Compound 27: 1-(4-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazin-1-yl)-2-phenylethan-1-one (1-(4-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazin-1-yl)-2-phenylethan-1-one, MYO1Di-A027) 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.58 (d, J = 8.7 Hz, 1H), 8.30 (d, J = 9.1 Hz, 1H), 8.15 (dd, J = 7.5, 1.1 Hz, 1H), 7.50-7.54 (m, 2H), 7.17-7.24 (m, 4H), 7.11-7.13 (m, 2H), 3.65-3.67 (m, 4H), 3.44 (t, J = 5.0 Hz, 2H), 3.14 (t, J = 5.0 Hz, 2H), 2.95 (t, J = 5.0 Hz, 2H), 2.90 (s, 6H) MS (ESI+, m / z): 438 [M+H] Compound 28: Cyclobutyl(4-((5-(dimethylamino)naphthalen-1-yl)sulfonyl)piperazin-1-yl)methanone (MYO1Di-A028) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.58 (d, J = 8.2 Hz, 1H), 8.36 (d, J = 8.7 Hz, 1H), 8.20 (d, J = 7.3 Hz, 1H), 7.54 (t, J = 7.8 Hz, 2H), 7.19 (d, J) = 7.3 Hz, 1H), 3.63 (d, J = 10.1 Hz, 2H), 3.37 (d, J = 10.1 Hz, 2H), 3.14 (d, J = 5.0 Hz, 5H), 2.89 (s, 6H), 2.25 (s, 2H), 2.08 (s, 2H), 1.99-1.76 (2H) MS (ESI+, m / z): 402 [M+H] Compound 29: N-(2-aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide hydrochloride (N-(2-aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide hydrochloride, MYO1Di-A029) 1 H-NMR (400 MHz, DMSO-D6) δ 8.74 (d, J = 8.7 Hz, 1H), 8.46-8.51 (m, 2H), 8.19 (d, J = 6.9 Hz, 1H), 8.11 (s, 2H), 7.74 (q, J = 8.0 Hz, 2H), 7.68 (s, 1H), 2.98-3.04 (m, 8H), 2.80 (q, J = 6.1 Hz, 2H) MS (ESI+, m / z): 330 [M+H] Compound 30: N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-4-methylbenzamide (N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-4-methylbenzamide, MYO1Di-A030) 1 H-NMR (400 MHz, DMSO-D6) δ 8.43 (d, J = 8.7 Hz, 1H), 8.26-8.31 (m, 2H), 8.06-8.11 (m, 2H), 7.55-7.64 (m, 4H), 7.21 (dd, J = 7.3, 5.5 Hz, 3H), 3.24 (q, J = 6.3 Hz, 2H), 2.91 (q, J = 6.4 Hz, 2H), 2.80 (s, 6H), 2.31 (s, 3H) MS (ESI+, m / z): 412 [M+H] Compound 31: N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-2-(p-tolyl)acetamide (N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-2-(p-tolyl)acetamide, MYO1Di-A031) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.54 (d, J = 8.2 Hz, 1H), 8.24 (d, J = 8.7 Hz, 1H), 8.18 (dd, J = 7.3, 0.9 Hz, 1H), 7.57 (dd, J = 8.7, 7.8 Hz, 1H), 7.50 (dd, J = 8.7, 7.3 Hz, 1H), 7.18 (d, J = 6.9 Hz, 1H), 7.08 (d, J = 7.8 Hz, 2H), 6.94 (d, J = 7.8 Hz, 2H), 3.33 (s, 2H), 3.21 (q, J = 5.6 Hz, 2H), 2.95 (q, J = 5.6 Hz, 2H), 2.88 (s, 6H), 2.31 (s, 3H) MS (ESI+, m / z): 426 [M+H] Example 32: Preparation of Compound 32 (MYO1Di-B002) according to the present invention Compound 32 (MYO1Di-B002) of the present invention was synthesized according to the following reaction scheme 2. [Reaction Equation 2] Specifically, 5-bromothiophene-2-sulfonyl chloride (1 equivalent) was dissolved in pyridine (3 mL per 1 mmol of starting material), and piperidine (1 equivalent) dissolved in pyridine was slowly added to the reaction mixture in an ice bath. The mixture was stirred overnight at room temperature under a nitrogen atmosphere. After the reaction was complete, the resulting solution was extracted with ethyl acetate, the organic layer was washed with 1N hydrochloric acid and brine, and then dried with anhydrous sodium sulfate (Na2SO4). The solution was then concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (ethyl acetate / n-hexane = 20 / 100) to obtain compound 32 (MYO1Di-B002). Compound 32: 1-((5-bromothiophen-2-yl)sulfonyl)piperazine (1-((5-bromothiophen-2-yl)sulfonyl)piperazine, MYO1Di-B002) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.28 (d, J = 3.8 Hz, 1H), 7.12 (d, J = 3.8 Hz, 1H), 3.05-2.94 (m, 8H), 2.57 (t, J = 4.5 Hz, 1H) MS (ESI+, m / z): 312[M+H] Examples 33-37: Preparation of compounds 33 to 37 (MYO1Di-B003 to MYO1Di-B007) according to the present invention Compounds 33 to 37 (MYO1Di-B003 to MYO1Di-B007) of the present invention were synthesized according to the following reaction scheme 3. [Reaction Equation 3] Specifically, 1-((5-bromothiophene-2-yl)sulfonyl)piperazine (1 equivalent) was dissolved in DCM (3 mL per 1 mmol of starting material), and 3-chlorobenzoyl chloride (1 equivalent) was added to the reaction mixture. The mixture was stirred at room temperature for 6 hours under a nitrogen atmosphere. After the reaction was complete, the resulting solution was extracted with DCM, the organic layer was washed with water and brine, and then dried with anhydrous sodium sulfate (Na2SO4). The solution was then concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (ethyl acetate / n-hexane = 20 / 100) to obtain compound 33 (MYO1Di-B003). Additionally, compounds 34 to 37 (MYO1Di-B004 to MYO1Di-B007) were prepared and obtained by the same method. Compound 33: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(3-chlorophenyl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(3-chlorophenyl)methanone, MYO1Di-B003) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.42 (dt, J = 8.1, 0.9 Hz, 1H), 7.36-7.34 (m, 2H), 7.29 (d, J = 4.1 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 7.15 (d, J = 4.1 Hz, 1H), 3.87-3.58 (m, 4H), 3.16 (m, 4H) MS (ESI+, m / z): 451[M+H] Compound 34: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(3-(trifluoromethyl)phenyl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(3-(trifluoromethyl)phenyl)methanone, MYO1Di-B004) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.73-7.71 (m, 1H), 7.66 (s, 1H), 7.58-7.54 (m, 2H), 7.30 (d, J = 3.8 Hz, 1H), 7.16 (d, J = 3.8 Hz, 1H), 3.91-3.59 (m, 4H), 3.21-3.12 (m, 4H) MS (ESI+, m / z): 484[M+H] Compound 35: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(4-nitrophenyl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(4-nitrophenyl)methanone, MYO1Di-B005) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 8.29 (dt, J = 8.8, 2.1 Hz, 2H), 7.55 (dt, J = 8.8, 2.1 Hz, 2H), 7.31 (d, J = 4.1 Hz, 1H), 7.16 (d, J = 4.1 Hz, 1H), 3.93-3.51 (m, 4H), 3.22-3.05 (m, 4H) MS (ESI+, m / z): 461[M+H] Compound 36: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(pyrazin-2-yl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(pyrazin-2-yl)methanone, MYO1Di-B006) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 8.98 (d, J = 1.4 Hz, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.53 (q, J = 1.4 Hz, 1H), 7.31 (d, J = 3.8 Hz, 1H), 7.15 (d, J) = 3.8 Hz, 1H), 3.90 (dt, J = 59.6, 4.8 Hz, 4H), 3.20 (dt, J = 37.0, 4.9 Hz, 4H) MS (ESI+, m / z): 418[M+H] Compound 37: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(thiophene-2-yl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(thiophen-2-yl)methanone, MYO1Di-B007) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.47 (dd, J = 5.2, 1.0 Hz, 1H), 7.29-7.27 (m, 2H), 7.14 (d, J = 4.1 Hz, 1H), 7.05 (dd, J = 4.7, 3.9 Hz, 1H), 3.88 (t, J = 5.2 Hz, 4H), 3.12 (t, J = 5.2 Hz, 4H) MS (ESI+, m / z): 422[M+H] Examples 38-40: Preparation of compounds 38 to 40 (MYO1Di-B008 to MYO1Di-B010) according to the present invention Compounds 38 to 40 of the present invention (MYO1Di-B008 to MYO1Di-B010) were synthesized according to the following reaction scheme 4. [Reaction Equation 4] Specifically, 1-((5-bromothiophene-2-yl)sulfonyl)piperazine (1 equivalent) was dissolved in THF (3 mL per 1 mmol of starting material), and HBTU (1 equivalent), DIEA (1 equivalent), and 1H-indole-3-carboxylic acid (1 equivalent) were added to the reaction mixture. The mixture was stirred at room temperature for 3 hours under a nitrogen atmosphere. After the reaction was complete, the resulting solution was extracted with DCM, the organic layer was washed with water and brine, and then dried with anhydrous sodium sulfate (Na2SO4). The solution was then concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (ethyl acetate / n-hexane = 40 / 100) to obtain compound 38 (MYO1Di-B008). In addition, compounds 39 to 40 (MYO1Di-B009 to MYO1Di-B010) were also obtained by preparing them in the same way. Compound 38: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(1H-indole-3-yl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(1H-indol-3-yl)methanone, MYO1Di-B008) 1 H-NMR (600 MHz, DMSO-D6) δ 11.60 (s, 1H), 7.70 (d, J = 2.8 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 3.8 Hz, 1H), 7.47 (d, J = 4.1 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.15-7.12 (m, 1H), 7.09-7.06 (m, 1H), 3.74 (t, J = 5.0 Hz, 4H), 3.05-3.02 (m, 4H) MS (ESI+, m / z): 455[M+H] Compound 39: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(5-nitro-1H-pyrazol-3-yl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(5-nitro-1H-pyrazol-3-yl)methanone, MYO1Di-B009) 1 H-NMR (600 MHz, DMSO-D6) δ 7.51 (d, J = 4.1 Hz, 1H), 7.46 (d, J = 4.1 Hz, 1H), 7.37 (s, 1H), 3.75 (m, 4H), 3.08 (d, J = 4.8 Hz, 4H), 2.67 (s, 1H) MS (ESI-, m / z): 451[M+H] Compound 40: (4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(1H-indole-4-yl)methanone ((4-((5-bromothiophen-2-yl)sulfonyl)piperazin-1-yl)(1H-indol-4-yl)methanone, MYO1Di-B010) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 8.62 (s, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.28 (t, J = 3.6 Hz, 1H), 7.21 (t, J = 2.9 Hz, 1H), 7.19-7.14 (m, 2H), 7.10-7.09 (m, 1H), 6.42 (t, J = 2.1 Hz, 1H), 4.00-3.54 (m, 4H), 3.17 (m, 4H) MS (ESI+, m / z): 455[M+H] Examples 41-82: Preparation of compounds 41 to 82 (MYO1Di-B011 to MYO1Di-B052) according to the present invention Compounds 41 to 82 (MYO1Di-B011 to MYO1Di-B052) of the present invention were synthesized according to the following reaction scheme 5. [Reaction Equation 5] Specifically, 5-bromothiophene-2-sulfonyl chloride (1 equivalent) was dissolved in pyridine (3 mL per 1 mmol of starting material), and 4-chloro-3-(trifluoromethyl)aniline (1 equivalent) dissolved in pyridine was slowly added to the reaction mixture in an ice bath. The mixture was stirred overnight at room temperature under a nitrogen atmosphere. After the reaction was complete, the resulting solution was extracted with ethyl acetate, the organic layer was washed with 1 N hydrochloric acid and brine, and then dried with anhydrous sodium sulfate (Na₂SO₄). The solution was then concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (ethyl acetate / n-hexane = 20 / 100) to obtain compound 41 (MYO1Di-B011). In addition, compounds 42 to 82 (MYO1Di-B012 to MYO1Di-B052) were also obtained by preparing them in the same way. Compound 41: 5-bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-bromo-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B011) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.47-7.43 (m, 2H), 7.32-7.29 (m, 2H), 7.03 (d, J = 3.7 Hz, 1H), 6.91 (s, 1H) MS (ESI-, m / z): 419[MH] Compound 42: 5-bromo-N-(3,4-dimethoxyphenyl)thiophene-2-sulfonamide (5-bromo-N-(3,4-dimethoxyphenyl)thiophene-2-sulfonamide, MYO1Di-B012) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.17 (d, J = 4.1 Hz, 1H), 6.98 (d, J = 4.1 Hz, 1H), 6.76-6.74 (m, 2H), 6.58 (dd, J = 8.5, 2.5 Hz, 1H), 3.86 (s, 3H), 3.84 (d, J = 3.7 Hz, 3H) MS (ESI-, m / z): 377[MH] Compound 43: 5-bromo-N-(3-fluoro-2-methoxyphenyl)thiophene-2-sulfonamide (5-bromo-N-(3-fluoro-2-methoxyphenyl)thiophene-2-sulfonamide, MYO1Di-B013) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.37 (d, J = 8.2 Hz, 1H), 7.28 (d, J = 4.1 Hz, 1H), 7.19 (s, 1H), 7.01-6.96 (m, 2H), 6.87 (m, 1H), 3.81 (d, J = 2.3 Hz, 3H) MS (ESI-, m / z): 365[MH] Compound 44: 5-bromo-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-bromo-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B014) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.84 (t, J = 7.8 Hz, 1H), 7.42 (t, J = 7.1 Hz, 1H), 7.32-7.27 (m, 2H), 7.04-7.03 (m, 1H), 6.96 (s, 1H) MS (ESI-, m / z): 403[MH] Compound 45: 5-bromo-N-(2,4-dimethylphenyl)thiophene-2-sulfonamide (5-bromo-N-(2,4-dimethylphenyl)thiophene-2-sulfonamide, MYO1Di-B015) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.18-7.15 (m, 2H), 6.98 (t, J = 3.7 Hz, 3H), 6.27 (s, 1H), 2.29 (s, 3H), 2.06 (s, 3H) MS (ESI-, m / z): 345[MH] Compound 46: 5-bromo-N-(3-fluoro-4-methoxyphenyl)thiophene-2-sulfonamide (5-bromo-N-(3-fluoro-4-methoxyphenyl)thiophene-2-sulfonamide, MYO1Di-B016) 1 H-NMR (400 MHz, DMSO-D6) δ 10.41 (s, 1H), 7.30 (dq, J = 13.0, 1.8 Hz, 2H), 7.10 (t, J = 9.1 Hz, 1H), 6.95 (dd, J = 12.6, 2.5 Hz, 1H), 6.88-6.85 (m, 1H), 3.77 (s, 3H) MS (ESI-, m / z): 365[MH] Compound 47: 5-bromo-N-(4-morpholinophenyl)thiophene-2-sulfonamide (MYO1Di-B017) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.17 (q, J = 3.2 Hz, 1H), 7.05 (d, J = 8.7 Hz, 2H), 6.98 (d, J = 3.7 Hz, 1H), 6.93 (d, J = 13.3 Hz, 1H), 6.48 (s, 1H), 3.87 (m, 4H), 3.17 (t, J = 4.6 Hz, 4H) MS (ESI-, m / z): 404[M+H] Compound 48: 5-bromo-N-(4-phenoxyphenyl)thiophene-2-sulfonamide (5-bromo-N-(4-phenoxyphenyl)thiophene-2-sulfonamide, MYO1Di-B018) 1 H-NMR (400 MHz, DMSO-D6) δ 10.63 (s, 1H), 7.42-7.38 (m, 2H), 7.32-7.28 (m, 3H), 7.18-7.14 (m, 1H), 6.97-6.89 (m, 3H), 6.76 (dq, J = 8.2, 1.1 Hz, 1H), 6.71 (t, J = 2.3 Hz, 1H) MS (ESI-, m / z): 411 [M+H] Compound 49: 5-bromo-N-(6-methoxypyridin-3-yl)thiophene-2-sulfonamide (MYO1Di-B019) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.84 (d, J = 2.7 Hz, 1H), 7.52-7.49 (m, 1H), 7.18 (q, J = 1.8 Hz, 1H), 7.02-7.00 (m, 1H), 6.73 (d, J = 8.7 Hz, 1H), 6.51 (s, 1H), 3.92 (s, 3H) MS (ESI-, m / z): 348 [MH] Compound 50: 5-bromo-N-(2-methoxypyridin-3-yl)thiophene-2-sulfonamide (MYO1Di-B020) 1 H-NMR (400 MHz, DMSO-D6) δ 10.16 (s, 1H), 8.00 (q, J = 2.3 Hz, 1H), 7.60 (dd, J = 7.8, 1.8 Hz, 1H), 7.29 (dd, J = 6.3, 4.2 Hz, 2H), 6.99 (dd, J = 7.8, 5.0 Hz, 1H), 3.67 (s, 3H) MS (ESI-, m / z): 348 [MH] Compound 51: N-(benzo[d][1,3]dioxol-5-yl)-5-bromothiophene-2-sulfonamide (N-(benzo[d][1,3]dioxol-5-yl)-5-bromothiophene-2-sulfonamide, MYO1Di-B021) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.19 (d, J = 4.1 Hz, 1H), 7.00 (d, J = 4.1 Hz, 1H), 6.72-6.69 (m, 2H), 6.50 (dd, J = 8.2, 2.3 Hz, 1H), 6.37 (s, 1H), 5.99 (d, J = 5.9 Hz, 2H) MS (ESI-, m / z): 361 [MH] Compound 52: 5-bromo-N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-bromo-N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B022) 1 H-NMR (400 MHz, DMSO-D6) δ 11.15 (s, 1H), 7.67 (d, J = 8.7 Hz, 2H), 7.50-7.49 (m, 1H), 7.34-7.31 (m, 3H) MS (ESI-, m / z): 385 [MH] Compound 53: 5-bromo-N-(3-methylpyridin-2-yl)thiophene-2-sulfonamide (5-bromo-N-(3-methylpyridin-2-yl)thiophene-2-sulfonamide, MYO1Di-B023) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.55-7.47 (m, 2H), 7.37 (d, J = 4.1 Hz, 1H), 6.97 (d, J = 3.7 Hz, 1H), 6.64 (t, J = 6.6 Hz, 1H), 2.23 (s, 3H) MS (ESI+, m / z): 334 [M+H] Compound 54: 5-bromo-N-(4-methylpyridin-2-yl)thiophene-2-sulfonamide (MYO1Di-B024) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.10 (d, J = 6.4 Hz, 1H), 7.41 (m, 2H), 7.01 (d, J = 3.7 Hz, 1H), 6.74 (d, J = 6.4 Hz, 1H), 2.42 (s, 3H) MS (ESI+, m / z): 334 [M+H] Compound 55: 5-bromo-N-(quinolin-3-yl)thiophene-2-sulfonamide (MYO1Di-B025) 1 H-NMR (400 MHz, DMSO-D6) δ 7.88 (d, J = 2.7 Hz, 1H), 7.43 (d, J = 2.3 Hz, 1H), 7.18 (dd, J = 21.7, 8.5 Hz, 2H), 7.00-6.96 (m, 1H), 6.87 (t, J = 7.5 Hz, 1H), 6.55 (d, J = 4.1 Hz, 1H), 6.31 (d, J = 4.1 Hz, 1H) MS (ESI+, m / z): 370 [M+H] Compound 56: 5-bromo-N-(6-(trifluoromethyl)pyridin-3-yl)thiophene-2-sulfonamide (MYO1Di-B026) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.43 (d, J = 2.1 Hz, 1H), 7.82 (dd, J = 8.7, 2.1 Hz, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.41 (s, 1H), 7.37 (d, J = 4.1 Hz, 1H), 7.05 (d, J = 4.1 Hz, 1H) MS (ESI-, m / z): 386 [MH] Compound 57: 5-bromo-N-(3-methoxyphenyl)thiophene-2-sulfonamide (5-bromo-N-(3-methoxyphenyl)thiophene-2-sulfonamide, MYO1Di-B027) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.25 (d, J = 1.1 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 6.97 (d, J = 4.1 Hz, 1H), 6.74-6.70 (m, 3H), 6.67 (dd, J = 8.0, 1.1 Hz, 1H), 3.77 (s, 3H) MS (ESI-, m / z): 347 [MH] Compound 58: 5-bromo-N-(2,3-dihydro-1H-inden-5-yl)thiophene-2-sulfonamide (5-bromo-N-(2,3-dihydro-1H-inden-5-yl)thiophene-2-sulfonamide, MYO1Di-B028) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.20 (d, J = 4.1 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 7.02 (s, 1H), 6.97 (d, J = 4.1 Hz, 1H), 6.83 (dd, J = 8.2, 2.1 Hz, 1H), 6.52 (s, 1H), 2.86 (td, J = 7.4, 3.0 Hz, 4H), 2.11-2.03 (m, 2H) MS (ESI-, m / z): 357 [MH] Compound 59: 5-bromo-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)thiophene-2-sulfonamide (MYO1Di-B029) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.20 (d, J = 3.7 Hz, 1H), 6.99 (d, J = 3.7 Hz, 1H), 6.77 (d, J = 8.7 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 6.57 (dd, J = 8.7, 2.5 Hz, 1H), 6.34 (s, 1H), 4.24 (s, 4H) MS (ESI-, m / z): 375 [MH] Compound 60: 5-bromo-N-(3-isopropoxyphenyl)thiophene-2-sulfonamide (MYO1Di-B030) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.25 (d, J = 3.7 Hz, 1H), 7.17 (t, J = 8.5 Hz, 1H), 6.98 (d, J = 3.7 Hz, 1H), 6.72-6.70 (m, 2H), 6.63 (dt, J = 7.8, 0.9 Hz, 1H), 6.57 (s, 1H), 4.50 (t, J = 6.2 Hz, 1H), 1.32 (s, 3H), 1.30 (s, 3H) MS (ESI-, m / z): 377 [M+H] Compound 61: 5-bromo-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-bromo-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B031) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.80 (d, J = 8.2 Hz, 1H), 7.62 (s, 1H), 7.54 (d, J = 8.7 Hz, 1H), 7.36-7.34 (m, 1H), 7.03 (d, J = 3.7 Hz, 1H) MS (ESI-, m / z): 419 [MH] Compound 62: 5-bromo-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-bromo-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B032) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.92 (d, J = 6.9 Hz, 1H), 7.44-7.41 (m, 1H), 7.32 (d, J = 4 Hz, 1H), 7.18 (t, J = 9.1 Hz, 1H), 7.02 (d, J = 4 Hz, 1H), 6.95 (s, 1H) MS (ESI-, m / z): 403 [MH] Compound 63: N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B033) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.87 (t, J = 7.8 Hz, 1H), 7.60 (dd, J = 5.0, 0.9 Hz, 1H), 7.55 (d, J = 3.7 Hz, 1H), 7.38 (t, J = 7.3 Hz, 1H), 7.24 (m, 1H), 7.06-7.03 (m, 1H), 6.95 (s, 1H) MS (ESI-, m / z): 324 [MH] Compound 64: N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B034) 1 H-NMR (400 MHz, DMSO-D6) δ 10.99 (s, 1H), 7.95 (d, J = 5.0 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 7.61 (q, J = 1.7 Hz, 1H), 7.53 (d, J = 2.7 Hz, 1H), 7.42 (dd, J = 8.7, 2.7 Hz, 1H), 7.14 (dd, J = 5.0, 4.1 Hz, 1H) MS (ESI-, m / z): 340 [MH] Compound 65: N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B035) 1 H-NMR (400 MHz, DMSO-D6) δ 11.01 (s, 1H), 7.93 (d, J = 4.8 Hz, 1H), 7.64 (m,, 3H), 7.33 (d, J = 8.2 Hz, 2H), 7.13 (t, J = 4.3 Hz, 1H) MS (ESI-, m / z): 306 [MH] Compound 66: N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B036) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.83 (d, J = 8.7 Hz, 1H), 7.62-7.58 (m, 3H), 7.53 (d, J = 8.7 Hz, 1H), 7.27 (s, 1H), 7.06 (dd, J = 5.0, 4.1 Hz, 1H) MS (ESI-, m / z): 340 [MH] Compound 67: N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B037) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.94 (dd, J = 7.3, 2.3 Hz, 1H), 7.58 (qd, J = 4.4, 1.4 Hz, 2H), 7.37 (t, J = 2.5 Hz, 1H), 7.12 (t, J = 9.1 Hz, 1H), 7.04 (dd, J = 5.0, 3.7 Hz, 1H), 6.92 (s, 1H) MS (ESI-, m / z): 324 [MH] Compound 68: 5-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B038) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.84 (t, J = 7.8 Hz, 1H), 7.42 (t, J = 7.1 Hz, 1H), 7.35 (d, J = 4.1 Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 6.91 (s, 1H), 6.89 (d, J = 4.1 Hz, 1H) MS (ESI-, m / z): 358 [MH] Compound 69: 5-chloro-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-chloro-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B039) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.46 (d, J = 8.7 Hz, 1H), 7.43 (d, J = 2.7 Hz, 1H), 7.33 (d, J = 3.7 Hz, 1H), 7.31 (dd, J = 8.7, 2.3 Hz, 1H), 6.89 (d, J = 4.1 Hz, 1H), 6.76 (s, 1H) MS (ESI-, m / z): 374[MH] Compound 70: 5-chloro-N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-chloro-N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B040) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.58 (d, J = 8.7 Hz, 2H), 7.36 (dd, J = 4.1, 0.9 Hz, 1H), 7.24 (s, 1H), 6.88 (dd, J = 4.1, 0.9 Hz, 2H) MS (ESI-, m / z): 340 [MH] Compound 71: 5-chloro-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-chloro-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B041) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.80 (d, J = 8.7 Hz, 1H), 7.62 (s, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.39 (td, J = 2.6, 1.4 Hz, 1H), 6.90-6.89 (m, 1H) MS (ESI-, m / z): 374 [MH] Compound 72: 5-chloro-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-chloro-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B042) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.92 (d, J = 5.5 Hz, 1H), 7.45-7.41 (m, 1H), 7.36 (d, J = 4.1 Hz, 1H), 7.18 (t, J = 9.1 Hz, 1H), 6.90 (s, 1H), 6.88 (d, J = 3.7 Hz, 1H) MS (ESI-, m / z): 358 [MH] Compound 73: N-(2-fluoro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide, MYO1Di-B043) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.82 (t, J = 7.8 Hz, 1H), 7.40-7.37 (m, 1H), 7.33 (d, J = 7.3 Hz, 1H), 7.23-7.20 (m, 2H), 6.86 (d, J = 8.7 Hz, 1H), 6.83 (s, 1H), 3.91 (s, 3H), 3.84 (s, 3H) MS (ESI-, m / z): 378 [MH] Compound 74: N-(4-chloro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide (N-(4-chloro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide, MYO1Di-B044) 1 H-NMR (400 MHz, DMSO-D6) δ 10.64 (s, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.48 (d, J = 2.7 Hz, 1H), 7.35-7.30 (m, 2H), 7.22 (d, J = 1.8 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 3.74 (d, J = 12.8 Hz, 6H) MS (ESI-, m / z): 394 [MH] Compound 75: 3,4-dimethoxy-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide (3,4-dimethoxy-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B045) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.50 (d, J = 8.2 Hz, 2H), 7.46 (dd, J = 8.7, 2.3 Hz, 1H), 7.24 (d, J = 2.3 Hz, 1H), 7.19 (d, J = 8.2 Hz, 2H), 7.12 (s, 1H), 6.88 (d, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.82 (s, 3H) MS (ESI-, m / z): 360 [MH] Compound 76: N-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide (N-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide, MYO1Di-B046) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.77 (d, J = 8.7 Hz, 1H), 7.55 (d, J = 1.8 Hz, 1H), 7.49-7.44 (m, 2H), 7.21 (d, J = 2.3 Hz, 1H), 7.17 (s, 1H), 6.87 (d, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.84 (s, 3H) MS (ESI-, m / z): 394 [MH] Compound 77: N-(2-fluoro-5-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide (N-(2-fluoro-5-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide, MYO1Di-B047) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.92 (d, J = 6.9 Hz, 1H), 7.44 (td, J = 5.6, 2.7 Hz, 1H), 7.34-7.32 (m, 1H), 7.21 (t, J = 1.1 Hz, 1H), 7.09 (t, J = 9.1 Hz, 1H), 6.94 (s, 1H), 6.87 (dd, J = 8.7, 1.4 Hz, 1H), 3.90 (t, J = 1.5 Hz, 3H), 3.82 (d, J = 1.4 Hz, 3H) MS (ESI-, m / z): 378 [MH] Compound 78: N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide, MYO1Di-B048) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.62 (d, J = 8.2 Hz, 1H), 8.24 (dt, J = 7.5, 1.5 Hz, 1H), 8.08 (d, J = 8.2 Hz, 1H), 7.95-7.93 (m, 1H), 7.71-7.66 (m, 2H), 7.64-7.60 (m, 1H), 7.49 (td, J = 7.8, 1.8 Hz, 1H), 7.23 (t, J = 7.3 Hz, 1H), 7.12 (t, J = 8.0 Hz, 1H) MS (ESI-, m / z): 368 [MH] Compound 79: N-(4-chloro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide (N-(4-chloro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide, MYO1Di-B049) 1 H-NMR (400 MHz, DMSO-D6) δ 11.28 (s, 1H), 8.65 (d, J = 8.7 Hz, 1H), 8.25 (d, J = 7.5 Hz, 2H), 8.09 (d, J = 7.8 Hz, 1H), 7.76-7.73 (m, 1H), 7.69-7.63 (m, 2H), 7.51 (d, J = 8.7 Hz, 1H), 7.41 (d, J = 2.7 Hz, 1H), 7.28 (dd, J = 8.8, 2.6 Hz, 1H) MS (ESI-, m / z): 384 [MH] Compound 80: N-(4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide (N-(4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide, MYO1Di-B050) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.69 (d, J = 8.2 Hz, 1H), 8.28 (dt, J = 7.3, 1.4 Hz, 1H), 8.06 (q, J = 4.1 Hz, 1H), 7.93 (q, J = 3.8 Hz, 1H), 7.68-7.49 (m, 4H), 7.38 (dd, J = 8.7, 2.3 Hz, 2H), 7.09 (d, J = 8.7 Hz, 2H) MS (ESI-, m / z): 350 [MH] Compound 81: N-(2-chloro-4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide (N-(2-chloro-4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide, MYO1Di-B051) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.64 (d, J = 8.7 Hz, 1H), 8.30 (dd, J = 7.3, 1.4 Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.73-7.69 (m, 1H), 7.67 (d, J = 8.7 Hz, 1H), 7.64-7.60 (m, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.48 (s, 1H), 7.43 (s, 1H), 7.40-7.38 (m, 1H) MS (ESI-, m / z): 384 [MH] Compound 82: N-(2-fluoro-5-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide (N-(2-fluoro-5-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide, MYO1Di-B052) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 8.64 (d, J = 8.7 Hz, 1H), 8.27 (dd, J = 7.3, 1.4 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.73-7.80 (1H), 7.70 (s, 1H), 7.62 (s, 1H), 7.51 (t, J = 7.8 Hz, 1H), 7.20-7.25 (1H), 7.03-7.14 (1H), 6.96 (s, 1H) MS (ESI-, m / z): 368 [MH] Examples 83-87: Preparation of compounds 83 to 87 (MYO1Di-B053 to MYO1Di-B057) according to the present invention Compounds 83 to 87 (MYO1Di-B053 to MYO1Di-B057) of the present invention were synthesized according to the following reaction scheme 6. [Reaction Equation 6] Specifically, 5-bromo-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (1 equivalent), a suitable voronic acid (1.2 equivalents), and tetrakis(triphenylphosphine)palladium (0) (0.2 equivalents) were dissolved in toluene, and a 2 M aqueous solution of Na2CO3 (5 equivalents) was added to the reaction mixture. The mixture was stirred at 100°C for 3 hours. After the reaction was complete, the reaction mixture was cooled to room temperature and diluted with ethyl acetate. It was then washed with water and brine, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 20 / 100) to obtain compound 83 (MYO1Di-B053). In addition, compounds 84 to 87 (MYO1Di-B054 to MYO1Di-B057) were also obtained by preparing them in the same way. Compound 83: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-phenylthiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-phenylthiophene-2-sulfonamide, MYO1Di-B053) 1 H-NMR (400 MHz, DMSO-D6) δ 10.81 (s, 1H), 7.70-7.60 (m, 4H), 7.56 (d, J = 3.7 Hz, 1H), 7.53 (d, J = 3.7 Hz, 1H), 7.47-7.38 (m, 4H) MS (ESI-, m / z): 400 [MH] Compound 84: 5-(2,4-difluorophenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-(2,4-difluorophenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B054) 1 H-NMR (400 MHz, DMSO-D6) δ 10.82 (s, 1H), 7.89 (td, J = 8.9, 6.4 Hz, 1H), 7.61 (q, J = 7.6 Hz, 2H), 7.57 (d, J = 4.1 Hz, 1H), 7.54 (dd, J = 3.9, 1.1 Hz, 1H), 7.47-7.41 (m, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.23-7.18 (m, 1H) MS (ESI-, m / z): 436 [MH] Compound 85: 5-([1,1'-biphenyl]-2-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-([1,1'-biphenyl]-2-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B055) 1 H-NMR (400 MHz, DMSO-D6) δ 10.68 (s, 1H), 7.64 (t, J = 6.9 Hz, 1H), 7.56-7.47 (m, 4H), 7.39-7.34 (m, 3H), 7.29 (q, J = 5.9 Hz, 3H), 7.16 (dd, J = 7.5, 2.1 Hz, 2H), 6.87 (d, J = 3.7 Hz, 1H) MS (ESI-, m / z): 476 [MH] Compound 86: 5-(4-(tert-butyl)phenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-(4-(tert-butyl)phenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B056) 1H-NMR (400 MHz, DMSO-D6) δ 10.77 (s, 1H), 7.67-7.58 (m, 4H), 7.52-7.45 (m, 4H), 7.39 (t, J = 8.0 Hz, 1H), 1.27 (s, 9H) MS (ESI-, m / z): 456 [MH] Compound 87: 5-(benzo[d][1,3]dioxol-4-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (5-(benzo[d][1,3]dioxol-4-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide, MYO1Di-B057) 1 H-NMR (400 MHz, DMSO-D6) δ 10.77 (s, 1H), 7.67-7.60 (m, 2H), 7.49 (d, J = 4.1 Hz, 1H), 7.43 (d, J = 4.1 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.31 (d, J = 1.8 Hz, 1H), 7.16 (dd, J = 8.2, 1.8 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.08 (s, 2H) MS (ESI-, m / z): 444 [MH] Examples 88-95: Preparation of compounds 88 to 95 (MYO1Di-B058 to MYO1Di-B065) according to the present invention Compounds 88 to 95 of the present invention (MYO1Di-B058 to MYO1Di-B065) were synthesized according to the following reaction scheme 7. [Reaction Equation 7] Specifically, 5-bromo-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide (1 equivalent), a suitable secondary amine (1.2 equivalents), cesium carbonate (2.15 equivalents), and copper(I) bromide (0.2 equivalents) were dissolved in DMSO. The mixture was stirred at 100°C for 16 hours. After the reaction was complete, the reaction mixture was cooled to room temperature and diluted with DCM. It was then washed with 1N hydrochloric acid and brine, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 50 / 100) to obtain compound 88 (MYO1Di-B058). Additionally, compounds 89 to 95 (MYO1Di-B059 to MYO1Di-B065) were prepared and obtained by the same method. Compound 88: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-morpholinothiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-morpholinothiophene-2-sulfonamide, MYO1Di-B058) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.82 (t, J = 7.5 Hz, 1H), 7.35-7.30 (m, 2H), 7.21 (t, J = 8.0 Hz, 1H), 7.04 (s, 1H), 5.94 (d, J = 4.1 Hz, 1H), 3.84-3.79 (m, 4H), 3.16 (t, J = 5.0 Hz, 4H) MS (ESI-, m / z): 409 [MH] Compound 89: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperidin-1-yl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperidin-1-yl)thiophene-2-sulfonamide, MYO1Di-B059) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.83 (t, J = 7.5 Hz, 1H), 7.34-7.29 (m, 2H), 7.21 (t, J = 8.0 Hz, 1H), 6.82 (s, 1H), 5.89 (d, J = 4.6 Hz, 1H), 3.18 (t, J = 5.5 Hz, 4H), 1.71-1.66 (m, 4H), 1.60 (dd, J = 10.7, 6.2 Hz, 2H) MS (ESI-, m / z): 407 [MH] Compound 90: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(pyrrolidin-1-yl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(pyrrolidin-1-yl)thiophene-2-sulfonamide, MYO1Di-B060) 1 H-NMR (400 MHz, CHLOROFORM-D) δ 7.82 (d, J = 7.3 Hz, 1H), 7.31-7.28 (m, 2H), 7.21 (d, J = 8.7 Hz, 1H), 6.82 (s, 1H), 5.59 (d, J = 4.1 Hz, 1H), 3.26 (t, J = 6.6 Hz, 4H), 2.07-2.04 (m, 4H) MS (ESI-, m / z): 393 [MH] Compound 91: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-phenylpiperazin-1-yl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-phenylpiperazin-1-yl)thiophene-2-sulfonamide, MYO1Di-B061) 1H-NMR (400 MHz, DMSO-D6) δ 10.43 (s, 1H), 7.66 (t, J = 7.3 Hz, 1H), 7.58 (t, J = 7.1 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.30-7.24 (m, 3H), 7.01 (d, J = 8.2 Hz, 2H), 6.84 (t, J = 7.3 Hz, 1H), 6.24 (d, J = 4.1 Hz, 1H), 3.32 (s, 4H), 3.28 (d, J = 5.9 Hz, 4H) MS (ESI-, m / z): 484 [MH] Compound 92: (S)-N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(3-hydroxypyrrolidin-1-yl)thiophene-2-sulfonamide ((S)-N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(3-hydroxypyrrolidin-1-yl)thiophene-2-sulfonamide, MYO1Di-B062) 1 H-NMR (400 MHz, DMSO-D6) δ 10.23 (s, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.49 (t, J = 7.1 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.20 (d, J = 4.1 Hz, 1H), 5.69 (d, J = 4.6 Hz, 1H), 5.06 (d, J = 3.0 Hz, 1H), 4.36 (s, 1H), 3.35 (dd, J = 10.3, 4.3 Hz, 1H), 3.26 (s, 1H), 3.22-3.18 (m, 1H), 3.01-2.95 (m, 1H), 2.04-2.01 (m, 1H), 1.89 (s, 1H) MS (ESI-, m / z): 409 [MH] Compound 93: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(piperidin-1-yl)piperazin-1-yl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(piperidin-1-yl)piperazin-1-yl)thiophene-2-sulfonamid, MYO1Di-B063) 1 H-NMR (400 MHz, DMSO-D6) δ 7.57 (q, J = 4.0 Hz, 1H), 7.26 (d, J = 16.0 Hz, 1H), 7.21 (q, J = 4.3 Hz, 1H), 7.13-7.10 (m, 1H), 6.05 (d, J = 4.1 Hz, 1H), 3.58-3.51 (m, 2H), 2.88-2.82 (m, 2H), 2.74 (s, 4H), 1.88 (d, J = 13.7 Hz, 2H), 1.58 (s, 6H), 1.44 (d, J = 5.0 Hz, 2H) MS (ESI+, m / z): 491 [MH] Compound 94: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(2-fluorophenyl)piperazin-1-yl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(2-fluorophenyl)piperazin-1-yl)thiophene-2-sulfonamide, MYO1Di-B064) 1H-NMR (400 MHz, DMSO-D6) δ 10.39 (s, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.55 (t, J = 6.9 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.27 (d, J = 4.6 Hz, 1H), 7.18-6.99 (m, 4H), 6.20 (d, J = 4.6 Hz, 1H), 3.33 (d, J = 4.1 Hz, 4H), 3.12 (t, J = 4.8 Hz, 4H) MS (ESI-, m / z): 502 [MH] Compound 95: tert-butyl 4-(5-(N-(2-fluoro-3-(trifluoromethyl)phenyl)sulfamoyl)thiophen-2-yl)piperazine-1-carboxylate (tert-butyl 4-(5-(N-(2-fluoro-3-(trifluoromethyl)phenyl)sulfamoyl)thiophen-2-yl)piperazine-1-carboxylate, MYO1Di-B065) 1 H-NMR (400 MHz, DMSO-D6) δ 10.38 (s, 1H), 7.61 (t, J = 7.8 Hz, 1H), 7.53 (s, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.24 (d, J = 4.1 Hz, 1H), 6.15 (d, J = 4.1 Hz, 1H), 3.42 (t, J = 4.8 Hz, 4H), 3.14 (t, J = 5.0 Hz, 4H), 1.40 (s, 9H) MS (ESI-, m / z): 508 [MH] Example 96: Preparation of Compound 96 (MYO1Di-B066) According to the Present Invention Compound 96 (MYO1Di-B066) of the present invention was synthesized according to the following reaction scheme 8. [Reaction Equation 8] Specifically, tert-butyl 4-(5-(N-(2-fluoro-3-(trifluoromethyl)phenyl)sulfonyl)thiophene-2-yl)piperazine-1-carboxylate (MYO1DI-B065) was dissolved in methanol and TFA was added. The mixture was stirred at room temperature for 2 hours and then distilled under reduced pressure to obtain compound 96 (MYO1Di-B066). Compound 96: N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperazin-1-yl)thiophene-2-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperazin-1-yl)thiophene-2-sulfonamide, MYO1Di-B066) 1 H-NMR (400 MHz, DMSO-D6) δ 10.47 (s, 1H), 8.87 (s, 1H), 7.60 (dt, J = 25.3, 7.3 Hz, 2H), 7.36 (t, J = 8.0 Hz, 1H), 7.28 (d, J = 4.1 Hz, 1H), 6.25 (d, J = 4.6 Hz, 1H), 3.36 (t, J = 5.0 Hz, 4H), 3.23 (s, 4H) MS (ESI-, m / z): 408 [MH] Examples 97-104: Preparation of compounds 97 to 104 (MYO1Di-B067 to MYO1Di-B074) according to the present invention Compounds 97 to 104 of the present invention (MYO1Di-B067 to MYO1Di-B074) were synthesized according to the following reaction scheme 9. [Reaction Equation 9] Specifically, 2-fluoro-3-(trifluoromethyl)aniline (38.7 μL, 0.3 mmol) was dissolved in pyridine, and pyridine-3-sulfonyl chloride (40.1 μL, 0.33 mmol) dissolved in pyridine was slowly added to the reaction mixture. The mixture was stirred overnight at room temperature under a nitrogen atmosphere. After the reaction was complete, the resulting solution was extracted with ethyl acetate, the organic layer was washed with 1N hydrochloric acid and brine, and then dried with anhydrous sodium sulfate (Na2SO4). The solution was then concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (n-hexane / ethyl acetate = 1 / 5) to obtain compound 97 (MYO1Di-B067) (white solid, yield 57.3%). Compounds 98 to 104 (MYO1Di-B068 to MYO1Di-B074) were also obtained by preparing them in the same way. Compound 97: N-(2-fluoro-3-(trifluoromethyl)phenyl)pyridine-3-sulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)pyridine-3-sulfonamide, MYO1Di-B067) 1 H-NMR (600 MHz, DMSO-D6) δ 10.80 (s, 1H), 8.86-8.83 (m, 2H), 8.10 (dt, J = 8.1, 2.0 Hz, 1H), 7.63-7.59 (m, 3H), 7.38 (t, J = 8.1 Hz, 1H) MS (ESI-, m / z): 319[MH] Compound 98: 2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide (2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B068) 1H-NMR (600 MHz, DMSO-D6) δ 11.07 (s, 1H), 7.62 (dt, J = 28.7, 6.8 Hz, 3H), 7.48 (q, J = 8.5 Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H) MS (ESI-, m / z): 372[MH] Compound 99: 2,4-difluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide (2,4-difluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B069) 1 H-NMR (600 MHz, DMSO-D6) δ 10.88 (s, 1H), 7.78 (td, J = 8.6, 6.2 Hz, 1H), 7.62-7.56 (m, 3H), 7.36 (t, J = 8.1 Hz, 1H), 7.24 (td, J = 8.5, 2.2 Hz, 1H) MS (ESI-, m / z): 354[MH] Compound 100: 2-fluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide (2-fluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B070) 1 H-NMR (600 MHz, DMSO-D6) δ 10.83 (s, 1H), 7.74-7.71 (m, 2H), 7.60-7.58 (m, 2H), 7.47-7.44 (m, 1H), 7.37-7.33 (m, 2H) MS (ESI-, m / z): 336[MH] Compound 101: N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-methoxybenzenesulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-methoxybenzenesulfonamide, MYO1Di-B071) 1 H-NMR (600 MHz, DMSO-D6) δ 10.38 (s, 1H), 7.66-7.64 (m, 2H), 7.54 (td, J = 14.5, 7.1 Hz, 2H), 7.32 (t, J = 8.1 Hz, 1H), 7.08-7.06 (m, 2H), 3.80 (s, 3H) MS (ESI-, m / z): 348[MH] Compound 102: N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B072) 1 H-NMR (600 MHz, DMSO-D6) δ 10.55 (s, 1H), 7.73-7.71 (m, 2H), 7.67-7.64 (m, 1H), 7.58-7.54 (m, 4H), 7.34 (t, J = 8.1 Hz, 1H) MS (ESI-, m / z): 318[MH] Compound 103: 4-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide (4-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B073) 1H-NMR (600 MHz, DMSO-D6) δ 10.64 (s, 1H), 7.72 (dt, J = 8.8, 2.2 Hz, 2H), 7.66 (dt, J = 9.1, 2.3 Hz, 2H), 7.59-7.55 (m, 2H), 7.36 (t, J = 8.1 Hz, 1H) MS (ESI-, m / z): 352[MH] Compound 104: N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-nitrobenzenesulfonamide (N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-nitrobenzenesulfonamide, MYO1Di-B074) 1 H-NMR (600 MHz, DMSO-D6) δ 10.88 (s, 1H), 8.50 (dd, J = 8.3, 2.1 Hz, 1H), 8.43 (t, J = 1.9 Hz, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.88 (t, J = 8.1 Hz, 1H), 7.62-7.57 (m, 2H), 7.36 (t, J = 8.1 Hz, 1H) MS (ESI-, m / z): 363[MH] Examples 105-114: Preparation of compounds 105 to 114 (MYO1Di-B075 to MYO1Di-B084) according to the present invention Compounds 105 to 114 of the present invention (MYO1Di-B075 to MYO1Di-B084) were synthesized according to the following reaction scheme 10. [Reaction Equation 10] Specifically, aniline (50 mg, 0.537 mmol), 3,4-dimethoxybenzenesulfonyl chloride (140 mg, 0.591 mmol), and triethylamine were dissolved in DCM. The mixture was stirred overnight at room temperature under a nitrogen atmosphere. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (n-hexane / ethyl acetate = 1 / 5) to obtain compound 107 (MYO1Di-B077) (white solid, yield 57%). Compounds 105 (MYO1Di-B075), 106 (MYO1Di-B076), and 108 to 114 (MYO1Di-B078 to MYO1Di-B084) were also prepared and obtained by the same method. Compound 105: N-phenylthiophene-2-sulfonamide (MYO1Di-B075) 1 H-NMR (600 MHz, DMSO-D6) δ 10.38 (s, 1H), 7.88-7.87 (m, 1H), 7.51 (dd, J = 3.6, 1.2 Hz, 1H), 7.27-7.24 (m, 2H), 7.13-7.05 (m, 4H) MS (ESI-, m / z): 238[MH] Compound 106: N-phenylpyridine-3-sulfonamide (MYO1Di-B076) 1H-NMR (600 MHz, DMSO-D6) δ 10.45 (s, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.76 (dd, J = 4.8, 1.4 Hz, 1H), 8.09 (dt, J = 8.0, 2.0 Hz, 1H), 7.58 (dd, J = 7.9, 4.8 Hz, 1H), 7.26-7.23 (m, 2H), 7.09-7.05 (m, 3H) MS (ESI-, m / z): 233[MH] Compound 107: 3,4-dimethoxy-N-phenylbenzenesulfonamide (3,4-dimethoxy-N-phenylbenzenesulfonamide, MYO1Di-B077) 1 H-NMR (600 MHz, DMSO-D6) δ 10.04 (s, 1H), 7.29 (dd, J = 8.4, 2.2 Hz, 1H), 7.22-7.20 (m, 3H), 7.08 (dd, J = 8.6, 1.0 Hz, 2H), 7.02 (dd, J = 11.2, 7.7 Hz, 2H), 3.77 (s, 3H), 3.72 (s, 3H) MS (ESI-, m / z): 292[MH] Compound 108: 2,3,4-trifluoro-N-phenylbenzenesulfonamide (2,3,4-trifluoro-N-phenylbenzenesulfonamide, MYO1Di-B078) 1 H-NMR (600 MHz, DMSO-D6) δ 10.79 (s, 1H), 7.69-7.65 (m, 1H), 7.49-7.45 (m, 1H), 7.27-7.24 (m, 2H), 7.10-7.06 (m, 3H) MS (ESI-, m / z): 286[MH] Compound 109: 2,4-difluoro-N-phenylbenzenesulfonamide (2,4-difluoro-N-phenylbenzenesulfonamide, MYO1Di-B079) 1 H-NMR (600 MHz, DMSO-D6) δ 10.61 (s, 1H), 7.87 (td, J = 8.7, 6.4 Hz, 1H), 7.52-7.48 (m, 1H), 7.24-7.21 (m, 3H), 7.08 (d, J = 7.6 Hz, 2H), 7.02 (t, J = 7.4 Hz, 1H) MS (ESI-, m / z): 268[MH] Compound 110: 2-fluoro-N-phenylbenzenesulfonamide (2-fluoro-N-phenylbenzenesulfonamide, MYO1Di-B080) 1 H-NMR (600 MHz, DMSO-D6) δ 10.57 (s, 1H), 7.81 (td, J = 7.6, 1.7 Hz, 1H), 7.68-7.64 (m, 1H), 7.40-7.37 (m, 1H), 7.33 (td, J = 7.6, 1.0) Hz, 1H), 7.22-7.19 (m, 2H), 7.09-7.07 (m, 2H), 7.01-6.99 (m, 1H) MS (ESI-, m / z): 250[MH] Compound 111: 4-methoxy-N-phenylbenzenesulfonamide (MYO1Di-B081) 1H-NMR (600 MHz, DMSO-D6) δ 10.10 (s, 1H), 7.67 (dt, J = 9.6, 2.6 Hz, 2H), 7.20 (td, J = 7.0, 1.6 Hz, 2H), 7.07-7.03 (m, 4H), 7.01-6.98 (m, 1H), 3.77 (s, 3H) MS (ESI-, m / z): 262[MH] Compound 112: N-phenylbenzenesulfonamide (MYO1Di-B082) 1 H-NMR (600 MHz, DMSO-D6) δ 7.74-7.72 (m, 2H), 7.58 (t, J = 7.2 Hz, 1H), 7.52 (t, J = 7.6 Hz, 2H), 7.20 (t, J = 7.9 Hz, 2H), 7.06-7.05 (m, 2H), 7.00 (t, J = 7.2 Hz, 1H) MS (ESI-, m / z): 232[MH] Compound 113: 4-chloro-N-phenylbenzenesulfonamide (MYO1Di-B083) 1 H-NMR (600 MHz, DMSO-D6) δ 7.73-7.71 (m, 2H), 7.61-7.59 (m, 2H), 7.22 (td, J = 7.0, 1.6 Hz, 2H), 7.06-7.02 (m, 3H) MS (ESI-, m / z): 266[MH] Compound 114: 4-nitro-N-phenylbenzenesulfonamide (MYO1Di-B084) 1H-NMR (600 MHz, DMSO-D6) δ 10.53 (s, 1H), 8.47 (t, J = 1.9 Hz, 1H), 8.43 (dq, J = 8.3, 1.0 Hz, 1H), 8.11 (dt, J = 8.0, 1.2 Hz, 1H), 7.84 (t, J = 8.1 Hz, 1H), 7.25 (td, J = 7.0, 1.6 Hz, 2H), 7.10-7.06 (m, 3H) MS (ESI-, m / z): 277[MH] Example 115: Preparation of Compound 115 (MYO1Di-B085) According to the Present Invention Compound 115 (MYO1Di-B085) of the present invention was synthesized according to the following reaction scheme 11. [Reaction Equation 11] Specifically, benzo[d][1,3]dioxol-5-amine (137 mg, 1 mmol) and pyridine were dissolved in DCM (3 mL), and 2,3,4-trifluorobenzenesulfonyl chloride (148 μL, 1.05 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 10 / 100) to obtain compound 115 (MYO1Di-B085). Compound 115: N-(benzo[d][1,3]dioxol-5-yl)-2,3,4-trifluorobenzenesulfonamide (N-(benzo[d][1,3]dioxol-5-yl)-2,3,4-trifluorobenzenesulfonamide, MYO1Di-B085) 1H-NMR (600 MHz, CHLOROFORM-D) δ 7.58-7.54 (m, 1H), 7.06-7.01 (m, 1H), 6.91 (s, 1H), 6.71 (d, J = 2.2 Hz, 1H), 6.64 (d, J = 8.3 Hz, 1H), 6.52 (dd, J = 8.3, 2.1 Hz, 1H), 5.93 (s, 2H) MS (ESI-, m / z): 330[MH] Example 116: Preparation of Compound 116 (MYO1Di-B086) According to the Present Invention Compound 116 (MYO1Di-B086) of the present invention was synthesized according to the following reaction scheme 12. [Reaction Equation 12] Specifically, benzo[d][1,3]dioxol-5-amine (137 mg, 1 mmol) and pyridine were dissolved in DCM (3 mL), and 3,4,5-trifluorobenzenesulfonyl chloride (148 μL, 1.05 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 10 / 100) to obtain compound 116 (MYO1Di-B086). Compound 116: N-(benzo[d][1,3]dioxol-5-yl)-3,4,5-trifluorobenzenesulfonamide (N-(benzo[d][1,3]dioxol-5-yl)-3,4,5-trifluorobenzenesulfonamide, MYO1Di-B086) 1H-NMR (600 MHz, CHLOROFORM-D) δ 7.42 (t, J = 6.2 Hz, 2H), 7.05 (s, 1H), 6.68-6.66 (m, 2H), 6.47 (dd, J = 8.3, 2.1 Hz, 1H), 5.96 (s, 2H) MS (ESI-, m / z): 330[MH] Example 117: Preparation of the compound (MYO1Di-B087) according to the present invention Compound 117 (MYO1Di-B087) of the present invention was synthesized according to the following reaction scheme 13. [Reaction Equation 13] Specifically, benzo[d][1,3]dioxol-5-amine (137 mg, 1 mmol) and pyridine were dissolved in DCM (3 mL), and 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (148 μL, 1.05 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 10 / 100) to obtain compound 117 (MYO1Di-B087). Compound 117: N-(benzo[d][1,3]dioxol-5-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide (N-(benzo[d][1,3]dioxol-5-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide, MYO1Di-B087) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.17 (s, 1H), 6.76 (d, J = 2.4 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.58 (dd, J = 8.3, 2.1 Hz, 1H), 5.96 (s, 2H) MS (ESI-, m / z): 366[MH] Example 118: Preparation of Compound 118 (MYO1Di-B088) According to the Present Invention Compound 118 (MYO1Di-B088) of the present invention was synthesized according to the following reaction scheme 14. [Reaction Equation 14] Specifically, 1-aminoadamantan (60.5 mg, 0.4 mmol) and pyridine were dissolved in DCM (2 mL), and 2,3,4-trifluorobenzenesulfonyl chloride (59.4 μL, 0.4 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 5 / 100) to obtain compound 118 (MYO1Di-B088). Compound 118: N-((3s,5s,7s)-adamantan-1-yl)-2,3,4-trifluorobenzenesulfonamide (N-((3s,5s,7s)-adamantan-1-yl)-2,3,4-trifluorobenzenesulfonamide, MYO1Di-B088) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.71-7.67 (m, 1H), 7.11-7.06 (m, 1H), 4.87 (s, 1H), 2.03 (d, J = 9.6 Hz, 3H), 1.79 (d, J = 2.8 Hz, 6H), 1.62-1.55 (m, 6H) MS (ESI-, m / z): 344[MH] Example 119: Preparation of Compound 119 (MYO1Di-B089) According to the Present Invention Compound 119 (MYO1Di-B089) of the present invention was synthesized according to the following reaction scheme 15. [Reaction Equation 15] Specifically, 1-aminoadamantan (60.5 mg, 0.4 mmol) and pyridine were dissolved in DCM (2 mL), and 3,4,5-trifluorobenzenesulfonyl chloride (59.4 μL, 0.4 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 5 / 100) to obtain compound 119 (MYO1Di-B089). Compound 119: N-((3s,5s,7s)-adamantan-1-yl)-3,4,5-trifluorobenzenesulfonamide (N-((3s,5s,7s)-adamantan-1-yl)-3,4,5-trifluorobenzenesulfonamide, MYO1Di-B089) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.57 (t, J = 6.4 Hz, 2H), 5.04 (s, 1H), 2.03 (s, 3H), 1.79 (d, J = 2.8 Hz, 6H), 1.63-1.56 (m, 6H) MS (ESI-, m / z): 344[MH] Example 120: Preparation of Compound 120 (MYO1Di-B090) According to the Present Invention Compound 120 (MYO1Di-B090) of the present invention was synthesized according to the following reaction scheme 16. [Reaction Equation 16] Specifically, 1-aminoadamantan (60.5 mg, 0.4 mmol) and pyridine were dissolved in DCM (2 mL), and 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (59.4 μL, 0.4 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / n-hexane = 5 / 100) to obtain compound 120 (MYO1Di-B090). Compound 120: N-((3s,5s,7s)-adamantan-1-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide (N-((3s,5s,7s)-adamantan-1-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide, MYO1Di-B090) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 5.13 (s, 1H), 2.07 (s, 3H), 1.87 (d, J = 2.8 Hz, 6H), 1.63 (q, J = 12.4 Hz, 6H) MS (ESI-, m / z): 380[MH] Example 121: Preparation of Compound 121 (MYO1Di-B091) According to the Present Invention Compound 121 (MYO1Di-B091) of the present invention was synthesized according to the following reaction scheme 17. [Reaction Equation 17] Specifically, 1-(pyridine-2-yl)piperazine (76 μL, 0.5 mmol) and pyridine were dissolved in DCM (3 mL), and then 2,3,4-trifluorobenzenesulfonyl chloride (70.3 μL, 0.5 mmol) dissolved in DCM was slowly added to the reaction mixture. The mixture was stirred at room temperature for 3 hours. After the reaction was complete, the resulting solution was filtered, and the filter cake was washed with DCM. The solvent was removed from the filtrate by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / enhexane = 10 / 100) to obtain compound 121 (MYO1Di-B091). Compound 121: 1-(pyridin-2-yl)-4-((2,3,4-trifluorophenyl)sulfonyl)piperazine (1-(pyridin-2-yl)-4-((2,3,4-trifluorophenyl)sulfonyl)piperazine, MYO1Di-B091) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 8.15 (dd, J = 5.0, 1.2 Hz, 1H), 7.64-7.60 (m, 1H), 7.51-7.48 (m, 1H), 7.13-7.09 (m, 1H), 6.67-6.63 (m, 2H), 3.67 (t, J = 4.8 Hz, 4H), 3.30 (t, J = 4.8 Hz, 4H) MS (ESI+, m / z): 358[M+H] Example 122: Preparation of Compound 122 (MYO1Di-B092) According to the Present Invention Compound 122 (MYO1Di-B092) of the present invention was synthesized according to the following reaction scheme 18. [Reaction Equation 18] Specifically, 1-(pyridine-2-yl)piperazine (76 μL, 0.5 mmol) and pyridine were dissolved in DCM (3 mL), and then 3,4,5-trifluorobenzenesulfonyl chloride (70.3 μL, 0.5 mmol) dissolved in DCM was slowly added to the reaction mixture. The mixture was stirred at room temperature for 3 hours. After the reaction was complete, the resulting solution was filtered, and the filter cake was washed with DCM. The solvent was removed from the filtrate by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / enhexane = 10 / 100) to obtain compound 122 (MYO1Di-B092). Compound 122: 1-(pyridin-2-yl)-4-((3,4,5-trifluorophenyl)sulfonyl)piperazine (1-(pyridin-2-yl)-4-((3,4,5-trifluorophenyl)sulfonyl)piperazine, MYO1Di-B092) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 8.15-8.14 (m, 1H), 7.50-7.47 (m, 1H), 7.43 (t, J = 6.2 Hz, 2H), 6.66 (dd, J = 6.7, 5.0 Hz, 1H), 6.61 (d, J = 8.6 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.15 (t, J = 4.8 Hz, 4H) MS (ESI+, m / z): 358[M+H] Example 123: Preparation of Compound 123 (MYO1Di-B093) According to the Present Invention Compound 123 (MYO1Di-B093) of the present invention was synthesized according to the following reaction scheme 19. [Reaction Equation 19] Specifically, 1-(pyridine-2-yl)piperazine (76 μL, 0.5 mmol) and pyridine were dissolved in DCM (3 mL), and then 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (70.3 μL, 0.5 mmol) dissolved in DCM was slowly added to the reaction mixture. The mixture was stirred at room temperature for 3 hours. After the reaction was complete, the resulting solution was filtered, and the filter cake was washed with DCM. The solvent was removed from the filtrate by distillation under reduced pressure. The resulting residue was purified by column chromatography (ethyl acetate / enhexane = 10 / 100) to obtain compound 123 (MYO1Di-B093). Compound 123: 1-((perfluorophenyl)sulfonyl)-4-(pyridin-2-yl)piperazine (1-((perfluorophenyl)sulfonyl)-4-(pyridin-2-yl)piperazine (MYO1Di-B093) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 8.16 (dd, J = 4.8, 1.0 Hz, 1H), 7.52-7.49 (m, 1H), 6.68 (dd, J = 7.1, 5.0 Hz, 1H), 6.65 (d, J = 8.3 Hz, 1H), 3.70 (t, J = 4.8 Hz, 4H), 3.37 (t, J = 4.8 Hz, 4H) MS (ESI+, m / z): 394[M+H] Example 124: Preparation of Compound 124 (MYO1Di-B094) According to the Present Invention Compound 124 (MYO1Di-B094) of the present invention was synthesized according to the following reaction scheme 20. [Reaction Equation 20] Specifically, 5-amino-1,3-dihydro-2H-benzo[d]imidazole-2-one (74.6 mg, 0.5 mmol) was dissolved in pyridine, and 2,3,4-trifluorobenzenesulfonyl chloride (77.3 μL, 0.55 mmol) was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, THF and EA were added to the reaction mixture, and the organic layer was washed three times with 1N hydrochloric acid solution followed by washing with saline solution. Subsequently, the organic layer was separated, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was ground with dichloromethane to obtain compound 124 (MYO1Di-B094). Compound 124: 2,3,4-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide (2,3,4-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide, MYO1Di-B094) 1 H-NMR (600 MHz, DMSO-D6) δ 10.55 (d, J = 16.5 Hz, 2H), 10.41 (s, 1H), 7.55-7.52 (m, 1H), 7.43 (q, J = 8.1 Hz, 1H), 6.78 (t, J = 4.1 Hz, 1H), 6.72 (d, J = 1.7 Hz, 1H), 6.65 (dd, J = 8.3, 2.1 Hz, 1H) MS (ESI-, m / z): 342[MH] Example 125: Preparation of Compound 125 (MYO1Di-B095) According to the Present Invention Compound 125 (MYO1Di-B095) of the present invention was synthesized according to the following reaction scheme 21. [Reaction Equation 21] Specifically, 5-amino-1,3-dihydro-2H-benzo[d]imidazole-2-one (74.6 mg, 0.5 mmol) was dissolved in pyridine, and 3,4,5-trifluorobenzenesulfonyl chloride (77.3 μL, 0.55 mmol) was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, THF and EA were added to the reaction mixture, and the organic layer was washed three times with 1N hydrochloric acid solution followed by washing with saline solution. Subsequently, the organic layer was separated, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was ground with dichloromethane to obtain compound 125 (MYO1Di-B095). Compound 125: 3,4,5-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide (3,4,5-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide, MYO1Di-B095) 1 H-NMR (600 MHz, DMSO-D6) δ 10.56 (d, J = 23.4 Hz, 2H), 10.10 (s, 1H), 7.58 (t, J = 6.5 Hz, 2H), 6.79 (d, J = 8.3 Hz, 1H), 6.69 (d, J = 2.1 Hz, 1H), 6.62 (dd, J = 8.3, 2.1 Hz, 1H) MS (ESI-, m / z): 342[MH] Example 126: Preparation of Compound 126 (MYO1Di-B096) According to the Present Invention Compound 126 (MYO1Di-B096) of the present invention was synthesized according to the following reaction scheme 22. [Reaction Equation 22] Specifically, 5-amino-1,3-dihydro-2H-benzo[d]imidazole-2-one (74.6 mg, 0.5 mmol) was dissolved in pyridine, and 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (77.3 μL, 0.55 mmol) was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, THF and EA were added to the reaction mixture, and the organic layer was washed three times with 1N hydrochloric acid solution followed by washing with saline solution. Subsequently, the organic layer was separated, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was ground with dichloromethane to obtain compound 126 (MYO1Di-B096). Compound 126: 2,3,4,5,6-pentafluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide (2,3,4,5,6-pentafluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide, MYO1Di-B096) 1 H-NMR (600 MHz, DMSO-D6) δ 10.90 (s, 1H), 10.59 (d, J = 11.0 Hz, 2H), 6.83-6.78 (m, 2H), 6.70 (dd, J = 8.3, 2.1 Hz, 1H) MS (ESI-, m / z): 378[MH] Example 127: Preparation of Compound 127 (MYO1Di-B097) According to the Present Invention Compound 127 (MYO1Di-B097) of the present invention was synthesized according to the following reaction scheme 23. [Reaction Equation 23] Specifically, 3-aminopiperidine-2,6-dione hydrochloride (99 mg, 0.6 mmol) was dissolved in DCM, and triethylamine (251 μL, 1.8 mmol) was added to the reaction solution. Subsequently, 2,3,4-trifluorobenzenesulfonyl chloride (85 μL, 0.6 mmol) was slowly added to the reaction mixture over an ice bath. The mixture was moved to room temperature and stirred for 16 hours. After the reaction was complete, the resulting solution was filtered, and the filter cake was washed with DCM. The solvent was removed from the filtrate by distillation under reduced pressure. The resulting residue was purified by column chromatography (methanol / dichloromethane = 3 / 100) to obtain compound 127 (MYO1Di-B097). Compound 127: N-(2,6-dioxopiperidin-3-yl)-2,3,4-trifluorobenzenesulfonamide (N-(2,6-dioxopiperidin-3-yl)-2,3,4-trifluorobenzenesulfonamide, MYO1Di-B097) 1 H-NMR (600 MHz, DMSO-D6) δ 10.77 (s, 1H), 8.70 (d, J = 9.0 Hz, 1H), 7.67 (t, J = 6.5 Hz, 1H), 7.45 (q, J = 8.3 Hz, 1H), 4.29-4.25 (m, 1H), 2.75-2.69 (m, 1H), 2.49-2.46 (m, 1H), 1.98-1.91 (m, 2H) MS (ESI-, m / z): 321[MH] Example 128: Preparation of Compound 128 (MYO1Di-B098) According to the Present Invention Compound 128 (MYO1Di-B098) of the present invention was synthesized according to the following reaction scheme 24. [Reaction Equation 24] Specifically, 3-aminopiperidine-2,6-dione hydrochloride (99 mg, 0.6 mmol) was dissolved in DCM, and triethylamine (251 μL, 1.8 mmol) was added to the reaction solution. Subsequently, 3,4,5-trifluorobenzenesulfonyl chloride (85 μL, 0.6 mmol) was slowly added to the reaction mixture over an ice bath. The mixture was moved to room temperature and stirred for 16 hours. After the reaction was complete, the resulting solution was filtered, and the filter cake was washed with DCM. The solvent was removed from the filtrate by distillation under reduced pressure. The resulting residue was purified by column chromatography (methanol / dichloromethane = 3 / 100) to obtain compound 128 (MYO1Di-B098). Compound 128: N-(2,6-dioxopiperidin-3-yl)-3,4,5-trifluorobenzenesulfonamide (N-(2,6-dioxopiperidin-3-yl)-3,4,5-trifluorobenzenesulfonamide, MYO1Di-B098) 1 H-NMR (600 MHz, DMSO-D6) δ 10.80 (s, 1H), 8.51 (d, J = 8.6 Hz, 1H), 7.77 (t, J = 6.7 Hz, 2H), 4.36-4.32 (m, 1H), 2.69-2.63 (m, 1H), 2.48 (dt, J = 17.4, 3.4 Hz, 1H), 1.95-1.85 (m, 2H) MS (ESI-, m / z): 321[MH] Example 129: Preparation of Compound 129 (MYO1Di-B099) According to the Present Invention Compound 129 (MYO1Di-B099) of the present invention was synthesized according to the following reaction scheme 25. [Reaction Equation 25] Specifically, 3-aminopiperidine-2,6-dione hydrochloride (99 mg, 0.6 mmol) was dissolved in DCM, and triethylamine (251 μL, 1.8 mmol) was added to the reaction solution. Subsequently, 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (85 μL, 0.6 mmol) was slowly added to the reaction mixture over an ice bath. The mixture was moved to room temperature and stirred for 16 hours. After the reaction was complete, the resulting solution was filtered, and the filter cake was washed with DCM. The solvent was removed from the filtrate by distillation under reduced pressure. The resulting residue was purified by column chromatography (methanol / dichloromethane = 3 / 100) to obtain compound 129 (MYO1Di-B099). Compound 129: N-(2,6-dioxopiperidin-3-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide (N-(2,6-dioxopiperidin-3-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide, MYO1Di-B099) 1 H-NMR (600 MHz, METHANOL-D4) δ 4.41 (dd, J = 12.7, 5.5 Hz, 1H), 2.77 (ddd, J = 18.2, 12.8, 5.1 Hz, 1H), 2.65 (ddd, J = 17.7, 4.6, 2.9 Hz, 1H), 2.22 (tt, J = 7.9, 2.6 Hz, 1H), 2.09-2.04 (m, 1H) MS (ESI-, m / z): 357[MH] Example 130: Preparation of Compound 130 (MYO1Di-B100) According to the Present Invention Compound 130 (MYO1Di-B100) of the present invention was synthesized according to the following reaction scheme 26. [Reaction Equation 26] Specifically, (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine hydrochloride (192.6 mg, 0.7 mmol) was dissolved in DMF (15 mL), and DIPEA (366 μL, 2.1 mmol) was added to the reaction solution. Subsequently, 2,3,4-trifluorobenzenesulfonyl chloride (98.4 μL, 0.7 mmol) was slowly added to the reaction mixture over an ice bath. The mixture was moved to room temperature and stirred for 16 hours. After the reaction was complete, the resulting solution was stopped with saline and water, and extracted with ethyl acetate and THF. The organic layer was then washed with saline and dried with anhydrous sodium sulfate. The solution was then evaporated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (methanol / dichloromethane = 3 / 100) to obtain compound 130 (MYO1Di-B100). Compound 130: (S)-1'-((2,3,4-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine ((S)-1'-((2,3,4-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine, MYO1Di-B100) 1 H-NMR (600 MHz, CHLOROFORM-D) δ 7.64-7.60 (m, 1H), 7.29 (d, J = 6.9 Hz, 1H), 7.20-7.09 (m, 4H), 3.93 (s, 1H), 3.70-3.64 (m, 2H), 2.88-2.82 (m, 3H), 2.56 (d, J = 15.8 Hz, 1H), 1.88-1.78 (m, 2H), 1.59-1.55 (m, 1H), 1.38-1.34 (m, 1H) MS (ESI+, m / z): 397[M+H] Example 131: Preparation of Compound 131 (MYO1Di-B101) According to the Present Invention Compound 131 (MYO1Di-B101) of the present invention was synthesized according to the following reaction scheme 27. [Reaction Equation 27] Specifically, (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine hydrochloride (192.6 mg, 0.7 mmol) was dissolved in DMF (15 mL), and DIPEA (366 μL, 2.1 mmol) was added to the reaction solution. Subsequently, 3,4,5-trifluorobenzenesulfonyl chloride (98.4 μL, 0.7 mmol) was slowly added to the reaction mixture over an ice bath. The mixture was moved to room temperature and stirred for 16 hours. After the reaction was complete, the resulting solution was stopped with saline and water, and extracted with ethyl acetate and THF. The organic layer was then washed with saline and dried with anhydrous sodium sulfate. The solution was then evaporated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (methanol / dichloromethane = 3 / 100) to obtain compound 131 (MYO1Di-B101). Compound 131: (S)-1'-((3,4,5-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine ((S)-1'-((3,4,5-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine, MYO1Di-B101) 1H-NMR (600 MHz, DMSO-D6) δ 7.75 (t, J = 6.5 Hz, 2H), 7.27 (d, J = 6.9 Hz, 1H), 7.14-7.07 (m, 3H), 3.80 (s, 1H), 3.52-3.46 (m, 2H), 2.78 (d, J = 15.8 Hz, 1H), 2.58 (dtd, J = 32.8, 11.7, 2.5 Hz, 2H), 2.40 (d, J = 15.5 Hz, 1H), 1.80-1.67 (m, 2H), 1.50 (d, J = 13.1 Hz, 1H), 1.11 (d, J = 13.4 Hz, 1H) MS (ESI+, m / z): 397[M+H] Example 132: Preparation of Compound 132 (MYO1Di-B102) According to the Present Invention Compound 132 (MYO1Di-B102) of the present invention was synthesized according to the following reaction scheme 28. [Reaction Equation 28] Specifically, 1H-indole-7-amine (79.3 mg, 0.6 mmol) and pyridine (71.6 μL, 0.9 mmol) were dissolved in DCM (6 mL), and 2,3,4-trifluorobenzenesulfonyl chloride (84.4 μL, 0.6 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, and the organic layer was washed three times with 1 N hydrochloric acid followed by washing with saline solution. It was then dried with anhydrous sodium sulfate. The solution was evaporated under reduced pressure to obtain the residue, which was purified by column chromatography (ethyl acetate / enhexane = 9 / 100) to obtain compound 132 (MYO1Di-B102). Compound 132: 2,3,4-trifluoro-N-(1H-indol-7-yl)benzenesulfonamide (2,3,4-trifluoro-N-(1H-indol-7-yl)benzenesulfonamide, MYO1Di-B102) H-NMR (600 MHz, DMSO-D6) δ 10.82 (s, 1H), 10.45 (s, 1H), 7.58 (q, J = 6.7 Hz, 1H), 7.41-7.33 (m, 3H), 6.84 (t, J = 7.7 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1H), 6.43 (t, J = 2.2 Hz, 1H) MS (ESI-, m / z): 325[MH] Example 133: Preparation of Compound 133 (MYO1Di-B103) According to the Present Invention Compound 133 (MYO1Di-B103) of the present invention was synthesized according to the following reaction scheme 29. [Reaction Equation 29] Specifically, 1H-indole-7-amine (79.3 mg, 0.6 mmol) and pyridine (71.6 μL, 0.9 mmol) were dissolved in DCM (6 mL), and 3,4,5-trifluorobenzenesulfonyl chloride (84.4 μL, 0.6 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, and the organic layer was washed three times with 1 N hydrochloric acid and then washed with saline solution. It was then dried with anhydrous sodium sulfate. The solution was evaporated under reduced pressure to obtain the residue, which was purified by column chromatography (ethyl acetate / enhexane = 9 / 100) to obtain compound 133 (MYO1Di-B103). Compound 133: 3,4,5-trifluoro-N-(1H-indol-7-yl)benzenesulfonamide (3,4,5-trifluoro-N-(1H-indol-7-yl)benzenesulfonamide, MYO1Di-B103) 1 H-NMR (600 MHz, DMSO-D6) δ 10.81 (s, 1H), 10.11 (s, 1H), 7.62 (t, J = 6.5 Hz, 2H), 7.38 (d, J = 7.6 Hz, 1H), 7.31 (t, J = 2.9 Hz, 1H), 6.86 (t, J = 7.7 Hz, 1H), 6.71 (dd, J = 7.6, 0.7 Hz, 1H), 6.42 (q, J = 1.7 Hz, 1H) MS (ESI-, m / z): 325[MH] Example 134: Preparation of Compound 134 (MYO1Di-B104) According to the Present Invention Compound 134 (MYO1Di-B104) of the present invention was synthesized according to the following reaction scheme 30. [Reaction Equation 30] Specifically, 1H-indole-7-amine (79.3 mg, 0.6 mmol) and pyridine (71.6 μL, 0.9 mmol) were dissolved in DCM (6 mL), and 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (84.4 μL, 0.6 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, and the organic layer was washed three times with 1 N hydrochloric acid followed by washing with saline solution. It was then dried with anhydrous sodium sulfate. The solution was evaporated under reduced pressure to obtain the residue, which was purified by column chromatography (ethyl acetate / enhexane = 9 / 100) to obtain compound 134 (MYO1Di-B104). Compound 134: 2,3,4,5,6-pentafluoro-N-(1H-indol-7-yl)benzenesulfonamide (2,3,4,5,6-pentafluoro-N-(1H-indol-7-yl)benzenesulfonamide, MYO1Di-B104) 1 H-NMR (600 MHz, DMSO-D6) δ 10.89 (d, J = 11.4 Hz, 2H), 7.43 (d, J = 7.9 Hz, 1H), 7.34 (t, J = 2.8 Hz, 1H), 6.89 (t, J = 7.7 Hz, 1H), 6.79-6.78 (m, 1H), 6.45 (q, J = 1.7 Hz, 1H) MS (ESI-, m / z): 361[MH] Example 135: Preparation of Compound 135 (MYO1Di-B105) According to the Present Invention Compound 135 (MYO1Di-B105) of the present invention was synthesized according to the following reaction scheme 31. [Reaction Equation 31] Specifically, 1H-indole-6-amine (79.3 mg, 0.6 mmol) and pyridine (71.6 μL, 0.9 mmol) were dissolved in DCM (6 mL), and 2,3,4-trifluorobenzenesulfonyl chloride (84.4 μL, 0.6 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, the organic layer was washed three times with 1 N hydrochloric acid, washed with saline solution, and dried with anhydrous sodium sulfate. The resulting residue was filtered through DCM, and the solid was collected separately. The filtrate dissolved in DCM was purified by column chromatography (ethyl acetate / enhexane = 10 / 100) and combined with the solid not dissolved in DCM to obtain compound 135 (MYO1Di-B105). Compound 135: 2,3,4-trifluoro-N-(1H-indol-6-yl)benzenesulfonamide (2,3,4-trifluoro-N-(1H-indol-6-yl)benzenesulfonamide, MYO1Di-B105) 1 H-NMR (600 MHz, DMSO-D6) δ 11.02 (s, 1H), 10.49 (s, 1H), 7.57 (d, J = 6.2 Hz, 1H), 7.41-7.38 (m, 2H), 7.27 (t, J = 2.8 Hz, 1H), 7.20 (s, 1H), 6.78 (dd, J = 8.4, 1.9 Hz, 1H), 6.33 (s, 1H) MS (ESI-, m / z): 325[MH] Example 136: Preparation of Compound 136 (MYO1Di-B106) According to the Present Invention Compound 136 (MYO1Di-B106) of the present invention was synthesized according to the following reaction scheme 32. [Reaction Equation 32] Specifically, 1H-indole-6-amine (79.3 mg, 0.6 mmol) and pyridine (71.6 μL, 0.9 mmol) were dissolved in DCM (6 mL), and 3,4,5-trifluorobenzenesulfonyl chloride (84.4 μL, 0.6 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, the organic layer was washed three times with 1 N hydrochloric acid, washed with saline solution, and dried with anhydrous sodium sulfate. The resulting residue was filtered through DCM, and the solid was collected separately. The filtrate dissolved in DCM was purified by column chromatography (ethyl acetate / enhexane = 10 / 100) and combined with the solid not dissolved in DCM to obtain compound 136 (MYO1Di-B106). Compound 136: 3,4,5-trifluoro-N-(1H-indol-6-yl)benzenesulfonamide (3,4,5-trifluoro-N-(1H-indol-6-yl)benzenesulfonamide, MYO1Di-B106) 1 H-NMR (600 MHz, DMSO-D6) δ 11.03 (s, 1H), 10.19 (s, 1H), 7.61 (t, J = 6.5 Hz, 2H), 7.40 (d, J = 8.6 Hz, 1H), 7.27 (t, J = 2.6 Hz, 1H), 7.20 (s, 1H), 6.76 (dd, J = 8.4, 1.9 Hz, 1H), 6.33 (t, J = 2.1 Hz, 1H) MS (ESI-, m / z): 325[MH] Example 137: Preparation of Compound 137 (MYO1Di-B107) According to the Present Invention Compound 137 (MYO1Di-B107) of the present invention was synthesized according to the following reaction scheme 33. [Reaction Equation 33] Specifically, 1H-indole-6-amine (79.3 mg, 0.6 mmol) and pyridine (71.6 μL, 0.9 mmol) were dissolved in DCM (6 mL), and 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (84.4 μL, 0.6 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, the organic layer was washed three times with 1 N hydrochloric acid, washed with saline solution, and dried with anhydrous sodium sulfate. The resulting residue was filtered through DCM, and the solid was collected separately. The filtrate dissolved in DCM was purified by column chromatography (ethyl acetate / enhexane = 10 / 100) and combined with the solid not dissolved in DCM to obtain compound 137 (MYO1Di-B107). Compound 137: 2,3,4,5,6-pentafluoro-N-(1H-indol-6-yl)benzenesulfonamide (2,3,4,5,6-pentafluoro-N-(1H-indol-6-yl)benzenesulfonamide, MYO1Di-B107) 1 H-NMR (600 MHz, DMSO-D6) δ 11.08 (s, 1H), 10.96 (s, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.30-7.27 (m, 2H), 6.81 (dd, J = 8.4, 1.9 Hz, 1H), 6.35-6.34 (m, 1H) MS (ESI-, m / z): 361[MH] Example 138: Preparation of Compound 138 (MYO1Di-B108) According to the Present Invention Compound 138 (MYO1Di-B108) of the present invention was synthesized according to the following reaction scheme 34. [Reaction Equation 34] Specifically, 5-amino-2-(2,6-dioxopiperidine-3-yl)isoindolin-1,3-dione (82 mg, 0.3 mmol) was dissolved in pyridine (2 mL), and 2,3,4-trifluorobenzenesulfonyl chloride (105 μL, 0.75 mmol) was added to the reaction solution. The reaction mixture was stirred at 40°C for 24 hours. After the reaction was complete, THF and EA were added to the reaction mixture, and the organic layer was washed three times with a 1 N hydrochloric acid solution followed by washing with saline solution. Subsequently, the organic layer was separated, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was triturated with methanol to obtain compound 138 (MYO1Di-B108) (pale yellow solid, 90 mg, 0.192 mmol, yield: 64%). Compound 138: N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,3,4-trifluorobenzenesulfonamide (N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,3,4-trifluorobenzenesulfonamide, MYO1Di-B108) 1 H-NMR (600 MHz, DMSO-D6) δ 11.82 (s, 1H), 11.09 (s, 1H), 7.85-7.81 (m, 2H), 7.55-7.51 (m, 3H), 5.09 (dd, J = 12.9, 5.3 Hz, 1H), 2.89-2.83 (m, 1H), 2.59-2.56 (m, 1H), 2.52-2.45 (m, 1H), 2.03-1.99 (m, 1H) MS (ESI-, m / z): 466[MH] Example 139: Preparation of Compound 139 (MYO1Di-B109) According to the Present Invention Compound 139 (MYO1Di-B109) of the present invention was synthesized according to the following reaction scheme 35. [Reaction Equation 35] Specifically, 5-amino-2-(2,6-dioxopiperidine-3-yl)isoindolin-1,3-dione (82 mg, 0.3 mmol) was dissolved in pyridine (2 mL), and 3,4,5-trifluorobenzenesulfonyl chloride (105 μL, 0.75 mmol) was added to the reaction solution. The reaction mixture was stirred at 40°C for 24 hours. After the reaction was complete, THF and EA were added to the reaction mixture, and the organic layer was washed three times with a 1 N hydrochloric acid solution followed by washing with saline solution. Subsequently, the organic layer was separated, dried with anhydrous sodium sulfate, filtered, and distilled under reduced pressure. The resulting residue was triturated with methanol to obtain compound 139 (MYO1Di-B109). Compound 139: N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,4,5-trifluorobenzenesulfonamide (N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3,4,5-trifluorobenzenesulfonamide, MYO1Di-B109) 1 H-NMR (600 MHz, DMSO-D6) δ 11.43 (s, 1H), 11.09 (s, 1H), 7.85-7.83 (m, 3H), 7.56 (dd, J = 7.1, 1.9 Hz, 2H), 5.10 (dd, J = 12.9, 5.3 Hz, 1H), 2.89-2.83 (m, 1H), 2.58 (dd, J = 14.5, 3.1 Hz, 1H), 2.52-2.47 (m, 1H), 2.03-2.00 (m, 1H) MS (ESI-, m / z): 466[MH] Example 140: Preparation of Compound 140 (MYO1Di-B110) According to the Present Invention Compound 140 (MYO1Di-B110) of the present invention was synthesized according to the following reaction scheme 36. [Reaction Equation 36] Specifically, 2-fluoro-3-(trifluoromethyl)aniline (130 μL, 1.0 mmol) and pyridine (113 μL, 1.4 mmol) were dissolved in DCM (6 mL), and 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (160 μL, 1.0 mmol) dissolved in DCM was slowly added to the reaction mixture in an ice bath. The mixture was moved to room temperature and stirred for 3 hours. After the reaction was complete, the resulting solution was extracted with DCM, and the organic layer was washed three times with 1 N hydrochloric acid followed by washing with saline solution. It was then dried with anhydrous sodium sulfate. The solution was evaporated under reduced pressure to obtain the residue, which was purified by column chromatography (ethyl acetate / enhexane = 9 / 100) to obtain compound 140 (MYO1Di-B110). Compound 140: 2,3,4,5,6-pentafluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide (2,3,4,5,6-pentafluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide, MYO1Di-B110) 1 H-NMR (600 MHz, CDCl3) δ 7.81-7.84 (m, 1H), 7.52 (s, 1H), 7.44 (t, J = 7.2 Hz, 1H), 7.27 (t, J = 8.1 Hz, 1H) MS (ESI-, m / z): 408[MH] Example 141: Preparation of Compound 141 (MYO1Di-B111) According to the Present Invention Compound 141 (MYO1Di-B111) of the present invention was synthesized according to the following reaction scheme 37. [Reaction Equation 37] Specifically, 2-fluoro-3-(trifluoromethyl)aniline (258 μL, 2.0 mmol), 2,3,4-(trifluorobenzoyl chloride) (254 μL, 2.0 mmol), and triethylamine (281 μL, 2.0 mmol) were dissolved in DCM (10 mL). The mixture was stirred at room temperature for 3 hours. After the reaction was complete, the resulting solution was extracted with EA, the organic layer was washed three times with water, and then washed with saline solution. Subsequently, it was dried with anhydrous sodium sulfate. The solution was evaporated under reduced pressure to obtain the residue, which was purified by column chromatography (ethyl acetate / enhexane = 9 / 100) to obtain compound 141 (MYO1Di-B111). Compound 141: 2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzamide (2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzamide, MYO1Di-B111) 1 H-NMR (600 MHz, CDCl3) δ 8.67 (t, J = 7.2 Hz, 1H), 8.61 (d, J = 13.8 Hz, 1H), 7.93-7.97 (m, 1H), 7.37-7.40 (m, 1H), 7.29 (t, J = 8.3 Hz, 1H), 7.15-7.19 (m, 1H) MS (ESI-, m / z): 336[MH] Example 142: Preparation of Compound 142 (MYO1Di-B112) According to the Present Invention Compound 142 (MYO1Di-B112) of the present invention was synthesized according to the following reaction scheme 38. [Reaction Equation 38] Specifically, (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine hydrochloride (83 mg, 0.3 mmol) was dissolved in DMF (15 mL), and DIPEA (157 μL, 0.9 mmol) was added to the reaction solution. Subsequently, 2,3,4,5,6-pentafluorobenzenesulfonyl chloride (45 μL, 0.3 mmol) was slowly added to the reaction mixture over an ice bath. The mixture was moved to room temperature and stirred for 16 hours. After the reaction was complete, the resulting solution was stopped with saline and water, and extracted with ethyl acetate and THF. The organic layer was then washed with saline and dried with anhydrous sodium sulfate. The solution was then evaporated under reduced pressure to obtain the residue. The obtained residue was purified by column chromatography (methanol / dichloromethane = 5 / 100) to obtain compound 142 (MYO1Di-B112). Compound 142: (S)-1'-((perfluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine ((S)-1'-((perfluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine, MYO1Di-B112) 1 H-NMR (600 MHz, CDCl3) δ 7.36-7.37 (m, 1H), 7.21-7.24 (m, 2H), 7.15-7.20 (m, 1H), 4.00 (s, 1H), 3.70 (t, J = 11.4 Hz, 2H), 2.92-3.00 (m, 3H), 2.62 (d, J = 15.8 Hz, 1H), 1.79-1.87 (m, 2H), 1.57-1.60 (m, 1H), 1.43 (d, J = 13.8 Hz, 1H) MS (ESI-, m / z): 433[M+H] The compound described above, prepared in the above example, was evaluated as follows. Experimental Example 1: Cell culture, preparation of reagents, and statistical processing Cell lines were purchased from the Korean Cell Line Bank (KCLB, Seoul, South Korea) and periodically tested for Mycoplasma contamination. CT-26-WT-iRFP-Neo cells were purchased from Imanis Life Sciences (Rochester). Cells were cultured in RPMI-1640 or DMEM medium supplemented with 10% FBS (GenDEPOT), penicillin (100 units / mL), and streptomycin (100 μg / mL, Corning) at 37°C under humid conditions containing 5% CO2. Cells were passaged before reaching confluence. Cycloheximide (Sigma) was treated at the concentrations indicated in the experiment. Non-small cell lung cancer (NSCLC) cell lines (A549, PC9, PC9 / GR, H1975, H1781) were obtained from the American Type Culture Collection (ATCC), and H1975 / OR and U87-MG glioblastoma cell lines were provided by Dr. Jin-Kyung Noh (Asan Medical Center) and Dr. Ho-Shin Kwak (National Cancer Center, Goyang), respectively. These cells were also cultured in RPMI-1640 medium or DMEM medium supplemented with 10% FBS (GenDEPOT), penicillin (100 units / mL), and streptomycin (100 μg / mL, Corning) at 37°C in a 5% CO2 environment. The antibodies were used as follows: Antibodies against EGFR, c-Met, MYO1D, total ERK, Ubiquitin (Santa Cruz Biotech); ErbB2, GAPDH, AKT, p-AKT, p-ERK, p-p38, p38, p-stat-3, stat-3 (Cell Signaling Technology); Myc (MBL); and HA, Actin (Sigma) were used in combination with appropriate secondary antibodies (MBL). Gefitinib, afatinib, and osimertinib were purchased from Selleck Chemicals. Antibodies against the following proteins were obtained from their respective suppliers: GFP (Santa Cruz Biotechnology); Ecm29 (GeneTex); Myc, GAPDH, His, c-Jun (Cell Signaling Technology); V5 (MBL); HA, Actin (Sigma); KITENIN (Atlas); His (Abcam). Secondary antibodies were purchased from Thermo Fisher Scientific. For transient transfection analyses, 293T cells and various cancer cells were transfected with various plasmids, harvested 48 hours after transfection, and immunoblot analysis was performed. In most experiments using stabilized cell lines, mixed polyclonal cells were used to exclude the effects of clonal variation. Meanwhile, the statistical significance of the experimental results described in this specification was evaluated using Tukey HSD post-hoc tests or Student's t-tests after ANOVA. All statistical tests were performed as two-sided tests, and a P value < 0.05 was considered statistically significant. Statistical analysis was performed using PASW Statistics 20 (SPSS, IBM Company, Chicago, IL). Experimental Example 2: Experimental Method 2-1. Protein-Protein Interaction Analysis System Using NanoBiT The NanoBiT (NanoLuc Binary Technology) expression vector is NanoLuc ® It contains a luciferase (Promega, LgBiT, or SmBiT) subunit and a flexible linker (GSSGGGGSGGGGSSG) sequence. Using standard molecular biology techniques, eight expression plasmids (EGFR-LgBiT-N, EGFR-SmBiT-N, EGFR-LgBiT-C, EGFR-SmBiT-C, MYO1D-LgBiT-N, MYO1D-SmBiT-N, MYO1D-LgBiT-C, MYO1D-SmBiT-C) were constructed by fusing a NanoLuc luciferase subunit (LgBiT or SmBiT) to the human tail homology domain of MYO1D or the human kinase domain of EGFR using a flexible linker and inserting a unique restriction site (Xho I / Nhe I). Sequence verification was completed for all vectors. Eight combinations (EGFR-LgBiT-N / MYO1D-SmBiT-C, EGFR-LgBiT-N / MYO1D-SmBiT-N, EGFR-LgBiT-C / MYO1D-SmBiT-C, EGFR-LgBiT-C / MYO1D-SmBiT-N, EGFR-SmBiT-C / MYO1D-SmBiT-N, EGFR-SmBiT-C / MYO1D-LgBiT-N, EGFR-SmBiT-C / MYO1D-LgBiT-C, EGFR-SmBiT-N / MYO1D-LgBiT-N, EGFR-SmBiT-N / MYO1D-LgBiT-N, EGFR-SmBiT-N / MYO1D-LgBiT-C) were designed to construct an optimal NanoBiT analysis system for searching for compounds that inhibit MYO1D-EGFR interactions through library screening. The protein-protein interaction (PPI) activity of each combination was evaluated by transient transfection of HEK293T cells, and 5 × 10⁶ cells were placed in poly-D-lysine-coated 96-well plates. 4 Cells were inoculated into wells and cultured overnight. Analysis was performed using the Nano-Glo Live Cell reagent (Promega), and luminescence was measured using an Envision plate reader (Perkin Elmer). 2-2. Compound Library Screening Using NanoBiT Analysis HEK293 cells were co-transfected with the MYO1D-LgBiT-N and EGFR-SmBiT-C plasmid combination using the FuGENE transformation reagent (Promega). After incubation at 37°C for 6 hours following transformation, the medium was replaced with fresh medium and re-inoculated into 96-well white plates. Subsequently, compounds prepared from the compound library were added to the cells at various concentrations, and the cells were incubated at 37°C for 12 hours. Finally, the Nano-Glo Live Cell Assay reagent (Promega) was added to measure luminescence, and data were collected using an Envision plate reader (Perkin Elmer). 2-3. Western Blot and Immunoprecipitation Proteins were extracted from CRC, NSCLC, TNBC, and glioblastoma cells using RIPA (radioimmunoprecipitation assay) buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS), and protease and phosphatase inhibitors (Thermo Fisher Scientific) were added. The lysate was reacted on ice for 30 minutes, centrifuged at 13,000 × g for 15 minutes at 4°C, and the supernatant was collected. Protein concentration was quantified using the BCA assay (Thermo Fisher Scientific). Proteins (20–30 μg) were separated by 8–12% SDS-PAGE and transferred to a PVDF membrane (Millipore) using a semi-dry transfer instrument (Bio-Rad). The membrane was blocked with 5% skim milk or 5% BSA for 1 hour, followed by overnight incubation with the primary antibody at 4°C. After washing with TBST, the sample was incubated with an HRP-conjugated secondary antibody (Cell Signaling Technology) for 1 hour, and the signal was detected using an iBright FL1500 imaging system (Thermo Fisher Scientific) with ECL reagent (Thermo Fisher Scientific). Band intensity was quantified using ImageJ software (NIH), and GAPDH or β-actin was used as a loading control. For immunoprecipitation, 500–1000 μg of total protein and 1–2 μg of target protein-specific antibody were incubated overnight at 4°C. The next day, 20–30 μL of Protein A / G agarose beads (Thermo Fisher Scientific or Pierce) were added and incubated for 2–4 hours, followed by three washes to remove non-specific binding. Finally, the beads were suspended in 2× SDS sample buffer and heated at 95°C for 5 minutes to elute the protein, after which SDS-PAGE and Western blot were performed. 2-4. Plasmids, RNA Interference, and Transformation V5-tagged KITENIN, His-tagged Ecm29 mutants (including deletion and point mutations), and bacterial expression version plasmids were constructed via PCR, and the GFP-tagged Ecm29 plasmid was obtained from VectorBuilder (USA). The nucleotide sequences of all plasmids were verified. The siRNA for gene silencing was purchased from Santa Cruz Biotechnology and consisted of a mixture of multiple sequences to eliminate sequence specificity variability. For siRNA interference experiments, human MYO1D-specific siRNA was purchased from Invitrogen, and the sequences are as follows: si-MYO1D (#1): 5'-GCGCCUUAUGUAUAACAGUUCAAAU-3' (Sequence No. 1), si-MYO1D (#2): 5'-CCCUUACAAGUUGUUGAACAUCUAU-3' (Sequence No. 2) Nonspecific scrambled siRNA (si-scr) was All Stars Negative Control siRNA (Qiagen). siRNA duplexes were transformed according to the Lipofectamine™ RNAiMAX protocol and used for RT-PCR, Western blot, and invasion analysis after 48 hours of treatment for maximum knockdown. Typical knockdown efficiency was 70–80% based on Q-PCR results of the target RNA after si-RNA transformation. 2-5. Cell Invasion Analysis Cell invasion was measured using a Transwell migration apparatus. Briefly, cells pretreated with siRNA (48 hours), gefitinib, afatinib, and osimertinib were inoculated into the top of a 24-well invasion chamber (Costar). DMEM medium containing fibronectin (10 μg / mL, Calbiochem) and 1% FBS was added to the bottom chamber. Cell migration was induced by incubation at 37°C for 16 hours. Cells remaining on the top filter were removed with a cotton swab, and after drying the filter, the migrated cells were counted in four random areas measuring 0.5 mm × 0.5 mm. Results were expressed as the mean ± standard error (SEM) of cell counts from three independent experiments. 2-6. Clonogenic Survival Assay Clonal viability analyses were performed on Caco2, Caco2 / MYO1D, and Caco2 / EGFR-C797S cell lines treated with TKI inhibitors, si-MYO1D RNA, or MYO1Di-B014. Cultured cells were grown for 14 days, fixed with an acetic acid-methanol (1:3 V / V) solution, and stained with 0.25% crystal violet in 80% methanol. Cells were placed in 6-well plates at a density of 1 × 10⁶ 3 Cells were inoculated into wells and cultured in a humid 37°C incubator containing 5% CO2. After 24 hours of attachment, TKIs (tyrosine kinase inhibitors), si-MYO1D (siRNA targeting MYO1D), and MYO1Di-B014 were administered according to experimental conditions. Subsequently, the cells were cultured for 14 days to induce colony formation. After culture, the colonies were fixed with 4% paraformaldehyde at room temperature for 10 minutes, followed by staining with 0.25% crystal violet solution for 30 minutes. After staining, residual dye was removed by washing with distilled water, and the plates were dried for analysis. 2-7. Cell Viability Assay Cell viability was measured using the EZ-Cytox Cell Viability Assay kit (Daeil Lab Service Co., Korea), based on the MTT assay. Briefly, cells were placed in a 96-well plate at a rate of 5 × 10⁶ 3 Cells were inoculated into wells and cultured. After 24, 48, or 72 hours, the medium was removed, 10 μL of EZ-Cytox reagent was added to each well, and the cells were incubated for another hour at 37°C. Subsequently, cell viability was evaluated by measuring absorbance at 450 nm using an ELISA microplate reader. 2-8. Protein Expression and Purification Using the full length of Ecm29 (1-1846) as a template, the following five Ecm29 variants were constructed by PCR cloning: ΔC (1-881), ΔN (881-1846), Cut-1 (1-307), Cut-2 (308-648), and Cut-3 (649-881). Each clone was restricted with EcoRI (5') and XhoI (3') and then cloned into the pcDNA3.4 vector. They were cultured at 37°C in medium containing ampicillin (100 μg / mL). Cell density OD 600When the level reached 0.6–0.8, 1 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) was added to induce protein expression, and the cells were cultured overnight at 25°C. Cells were harvested and lysed by sonication with lysis buffer (25 mM Tris, pH 7.5; 500 mM NaCl; 5 mM imidazole), and the supernatant was obtained by centrifuging at 15,000 × g for 30 minutes at 4°C. The supernatant was loaded onto pre-equilibrated Ni-NTA affinity resin (Qiagen), washed with washing buffer (25 mM Tris, pH 7.5; 500 mM NaCl; 20 mM imidazole), and the protein was eluted with elution buffer (25 mM Tris, pH 7.5; 500 mM NaCl; 200 mM imidazole). The eluted protein was reacted with thrombin (HTI) overnight at 4°C to remove the His-tag. Subsequently, it was further purified by size exclusion chromatography (SEC; HiLoad 16 / 60 Superdex 200 pg; GE Healthcare) and fractionated with column buffer (50 mM Tris, pH 7.5; 150 mM NaCl). The fraction corresponding to the target molecular weight was collected, dialyzed with column buffer overnight, and then used for isothermal titration calorimetry (ITC), GFP / Myc-Trap pull-down, and immunoprecipitation. 2-9. Pulldown Assay 6×His-Ecm29 bound to Ni-NTA beads were incubated with Caco2 / MYO1D cell lysate and MYO1Di-B68 (10 mM) in pulldown buffer (50 mM Tris-Cl, pH 7.5; 1 mM DTT; 4% glycerol; 0.1 mg / mL BSA; 5 mM MgCl₂; 1 mM ATP; 50 mM NaCl) at 4°C for 2 hours. Afterward, the samples were thoroughly washed with a wash buffer (pulldown buffer + 300 mM NaCl), and the proteins bound to the beads were separated by SDS-PAGE, followed by immunoblot analysis with His antibody. 2-10. Preparation of MYO1Di-Immobilized Affigel-10 Affigel-10 with the MYO1Di compound immobilized was prepared according to the following reaction scheme 39. [Reaction Equation 39] Reagents and conditions: (a) K2CO3, CAN, 80°C, (b) 10% TFA in Dichloromethane, (c) Affigel-10 in DMSO 2-10-1. Synthesis of MYO1Di-TG Linker Tert-butyl (2-(2-(2-(methylsulfonyl)ethoxy)ethoxy)ethyl) carbamate and potassium carbonate were added to an acetonitrile (ACN) solution in which MYO1Di-B66 was dissolved, and the mixture was stirred in a round-bottom flask at 80°C for 8 hours. The reaction mixture was filtered and concentrated, then purified by chromatography to obtain MYO1Di-B66 with a piperazine TG linker attached. Subsequently, 10% TFA (trifluoroacetic acid) was added to the MYO1Di-B66 solution with the piperazine TG linker attached at 0°C, stirred at room temperature (RT) for 30 minutes, and the solvent was evaporated to obtain the amine-form MYO1Di-B66-TG linker. 2-10-2. Synthesis of MYO1Di-Immunized Affigel-10 Affigel-10 was transferred to a 3 mL cartridge containing polyethylene frit, the supernatant was removed, and the mixture was washed with DMSO. Next, an amine-form MYO1Di-B66 linker and DIEA (N,N-diisopropylethylamine) were dissolved in DMSO and added to the gel. The cartridge was shaken well and reacted at room temperature (RT) for 3 hours. After the reaction, the slurry was discharged, and the gel was washed with DMSO. The loading level (90%) was determined by analyzing the effluent mixed with an internal standard using LCMS and comparing it to the initial reaction mixture. Subsequently, an ethanolamine solution and DIEA were dissolved in DMSO and added to the reaction cartridge, and the mixture was shaken well and reacted at room temperature for 3 hours. After the reaction, the slurry was discharged, and the gel was washed with DMSO, water, and a 2% aqueous sodium aziride (NaN3) solution. The final Affigel product was stored in a 2% aqueous sodium aziride solution at 4°C. 2-11. Acrylamide Gel Staining and PMF Analysis Proteins separated by SDS-PAGE were visualized using Coomassie Brilliant Blue G-250 staining. Briefly, the gel was fixed by shaking in a fixative (30% ethanol, water containing 2% phosphoric acid) for 30 minutes. Subsequently, it was washed with a washing solution (water containing 2% phosphoric acid) and treated to equilibrate in an equilibrium solution (18% ethanol, 15% ammonium sulfate, water containing 2% phosphoric acid) for 30 minutes. The stained protein bands were excised for in-gel digestion, followed by MALDI-TOF mass spectrometry. All digested peptides were identified via peptide mass fingerprinting (PMF) analysis (Genomine, Korea). 2-12. Analysis of the Luciferase Reporter 293T cells (1 × 10⁶ 4) was inoculated into 24-well plates, and TOP-flash, pRenillaTK, and the indicated plasmid (total DNA 200 ng) were transformed using FuGENE 6. After 48 hours, the cells were treated according to experimental conditions, and 16 hours later, a dual luciferase reporter assay (Promega) was performed using an automated GloMax luminometer (Promega). Luciferase activity was calculated by normalizing to the Renilla value. All experiments were repeated three times, with a minimum of two repetitions. 2-13. In vivo allograft colorectal cancer (CRC) tumor growth model All animal experiments were conducted in accordance with the guidelines of the Committee on Institutional Animal Ethics at Chonnam National University College of Medicine (CNU IACUC-H-2024-57), and the experimental protocols were approved. Allogeneic mouse tumor models are useful for evaluating the anticancer effects of candidate substances in the short term (Lee et al., 2005). In this experiment, the in vivo effects of the MYO1Di compound on colorectal cancer tumor formation were evaluated using a CT-26 cell / allogeneic mouse model. Six-week-old male Balb / c mice (Orientbio, Seongnam, Korea) were purchased and acclimatized for one week, then CT-26 / KITENIN cells (1×10⁶ 5 ) was suspended in 100 μL of PBS and administered by subcutaneous injection. The MYO1Di compound was administered by intraperitoneal injection (ip) at a dose of 20 or 40 mg / kg for 14 consecutive days starting 7 days after inoculation. Tumor volume (V) was calculated using the following formula: V = 1 / 2 × a × b 2 (a: longest diameter of the tumor, b: shortest diameter, in mm). Tumor volume was measured every other day for 28 days, and on the 30th day, all mice were sacrificed, and the tumors were resected and weighed. 2-14. In vivo model of liver metastasis of colorectal cancer (CRC) 5-6 week old Balb / c mice (Orientbio, Seongnam, Korea) were purchased and reared in metal cages with a free supply of water and feed. A colorectal cancer liver metastasis (CLM) model was established by injecting tumor cells into the portal vein via intrasplenic injection (Bae et al., 2021). Briefly, CT-26 / KITENIN-iRFP expressing cells (1 × 10⁶ 5 CLM was induced by injecting cells / mouse) into the spleen, and splenectomy was performed 10 minutes later. The abdomen and skin were sutured, and tumor growth inhibition experiments were conducted. Mice were randomized into four groups: Vehicle (0.1% DMSO), 5-FU alone (allogeneic mice: 100 mg / kg, nude mice: 50 mg / kg), and MYO1Di-B68 alone (allogeneic mice: 20 or 40 mg / kg). 5-FU was administered once intraperitoneally for 2 weeks, and MYO1Di-B68 was administered daily intraperitoneally for 2 weeks starting on day 14. To evaluate liver metastasis, iRFP fluorescence signals from liver nodules were captured using FOBI (Cellgentek, Korea), and the total fluorescence emitted from the liver nodules was compared between groups. 2-15. In vivo 4T1 triple-negative breast cancer (TNBC) in situ allograft model 4T1 cells (1 × 10⁶) in 6-week-old Balb / c female mice 5 or 5 × 10 5 MYO1Di-B68 was orthotopically transplanted into the fourth mammary gland fat pad. After 14 days, mice were randomized into the experimental group. MYO1Di-B68 was administered intraperitoneally daily for 14 days at a dose of 20 mg / kg or 40 mg / kg. Cisplatin (5 mg / kg) was administered intraperitoneally once a week as a positive control, and the vehicle treatment group was used as a negative control. Tumor size and body weight were monitored during the treatment period. Tumor volume was calculated using the following formula: V = 1 / 2 × a × b2 On day 28, mice were sacrificed, and tumors were resected and weighed. For lung metastasis analysis, the lungs were inflated by injecting India ink and fixed in Fekete's solution. Subsequently, surface metastatic nodules were counted using a dissecting microscope. Experimental Example 3: Experimental Results 3-1. Compound library screening for the search for small molecule compounds inhibiting MYO1D-EGFR interactions NanoBiT (NanoLuc Binary Technology) is a system capable of monitoring protein interactions (PPIs) within living cells using a structural complementarity-based approach, and is utilized for screening small molecule compounds to discover PPI inhibitors (Azad et al., 2014; Dixon et al., 2016). NanoBiT fuses Large BiT (LgBiT; 17.6 kDa) and Small BiT (SmBiT; 1.3 kDa), which are inactivating subunits of NanoLuc luciferase, to proteins of interest, respectively; upon interaction between the two proteins, luciferase activity is restored, generating a luminescence signal in the presence of a furimazine substrate (Dixon et al., 2016). To establish an optimal NanoBiT analysis system for searching for small molecule compounds that inhibit MYO1D-EGFR interactions, eight types of vectors were first designed by fusing LgBiT or SmBiT subunits to the N- or C-terminus of the TH domain of MYO1D and the kinase domain of EGFR, respectively. As a result of evaluating the luminescence activity after transient transfection of these eight MYO1D / EGFR combinations into HEK293T cells, the highest luminescence signal was observed in the MYO1D-LgBiT-N / EGFR-SmBiT-C combination (Fig. 1). Accordingly, to search for compounds capable of inhibiting MYO1D-LgBiT-N / EGFR-SmBiT-C reporter activity in HEK293T cells, screening was performed using a library of 8,000 small molecule compounds containing compounds 1) to 142) according to the present invention (see Table 1 and Figure 2). Compound Name Cell Viability (IC 50)Target1 binding (MYO1D)Target2 degradation (GFRs)1MYO1Di-A001>80--2MYO1Di-A002>80++3MYO1Di-A003>80-+4MYO1Di-A00448.09 μM--5MYO1Di-A005>80-+6MYO1Di-A006>80--7MYO1Di-A007>80--8MYO1Di-A00877.46 μM--9MYO1Di-A00945.19 μM-+10MYO1Di-A01054.31 μM--11MYO1Di-A01158.41 μM--12MYO1Di-A01242.09 μM--13MYO1Di-A01347.31 μM--14MYO1Di-A01451.90 μM+++15MYO1Di-A01542.27 μM--16MYO1Di-A01634.61 μM-+17MYO1Di-A01731.60 μM+-18MYO1Di-A01836.70 μM+-19MYO1Di-A01953.73 μM--20MYO1Di-A02049.56 μM--21MYO1Di-A02153.20 μM++22MYO1Di-A02275.67 μM-+23MYO1Di-A023>80-+24MYO1Di-A02456.84 μM--25MYO1Di-A02528.33 μM--26MYO1Di-A02652.17 μM--27MYO1Di-A027>80--28MYO1Di-A02854.10 μM--29MYO1Di-A02967.44 μM-+30MYO1Di-A03048.03 μM+-31MYO1Di-A03161.55 μM-+32MYO1Di-B002>80-+33MYO1Di-B003>80--34MYO1Di-B004>80--35MYO1Di-B005>80-++36MYO1Di-B00677.16 μM--37MYO1Di-B007>80++38MYO1Di-B008>80--39MYO1Di-B00940.26 μM++40MYO1Di-B010>80-+41MYO1Di-B01157.42 μM++42MYO1Di-B01274.79 μM++43MYO1Di-B013>80-+44MYO1Di-B01416.65 μM+++45MYO1Di-B01581.92 μM+-46MYO1Di-B01646.69 μM+-47MYO1Di-B017>80++48MYO1Di-B01846.69 μM+-49MYO1Di-B01950.21 μM+-50MYO1Di-B02070.98 μM+-51MYO1Di-B021>80+++52MYO1Di-B02220.75 μM-+53MYO1Di-B023>80--54MYO1Di-B024>80--55MYO1Di-B02518.06 μM-+56MYO1Di-B02632.03 μM--57MYO1Di-B02752.30 μM--58MYO1Di-B02844.36 μM--59MYO1Di-B029>80--60MYO1Di-B03068.72 μM--61MYO1Di-B03125.01 μM--62MYO1Di-B03221.45 μM+-63MYO1Di-B033>80+-64MYO1Di-B034>80--65MYO1Di-B03547.75 μM--66MYO1Di-B036>80--67MYO1Di-B037>80++68MYO1Di-B03815.74 μM+++69MYO1Di-B03959.50 μM+-70MYO1Di-B04027.52 μM+++71MYO1Di-B0418.45 μM++72MYO1Di-B04222.11 μM--73MYO1Di-B043>80--74MYO1Di-B044>80--75MYO1Di-B04557.11 μM--76MYO1Di-B046>80--77MYO1Di-B04758.41 μM-+78MYO1Di-B04856.99 μM--79MYO1Di-B04961.93 μM--80MYO1Di-B05063.45 μM+-81MYO1Di-B051>80--82MYO1Di-B052>80--83MYO1Di-B053>80--84MYO1Di-B05462.68 μM+++85MYO1Di-B055>80+++86MYO1Di-B05639.59 μM--87MYO1Di-B05765.12 μM--88MYO1Di-B058>80--89MYO1Di-B059>80+-90MYO1Di-B06050.31 μM+++91MYO1Di-B061>80++92MYO1Di-B06261.83 μM+-93MYO1Di-B063>80+-94MYO1Di-B064>80--95MYO1Di-B065>80--96MYO1Di-B06621.06 μM+++97MYO1Di-B067>80--98MYO1Di-B06810.33 μM++98-1MYO1Di-B68 / NA12.93 μM+++99MYO1Di-B06951.41 μM--100MYO1Di-B070>80--101MYO1Di-B07175.8 μM-+102MYO1Di-B07281.69 μM--103MYO1Di-B07320.2 μM++104MYO1Di-B07423.26 μM-+105MYO1Di-B075>80--106MYO1Di-B076>80-+107MYO1Di-B07742.55 μM--108MYO1Di-B07843.91 μM--109MYO1Di-B079>80--110MYO1Di-B080>80++111MYO1Di-B08134.75 μM+-112MYO1Di-B082>80--113MYO1Di-B08359.14 μM--114MYO1Di-B08458.24 μM--115MYO1Di-B08555.73 μM--116MYO1Di-B08646.98 μM-+117MYO1Di-B087<1 μM+++118MYO1Di-B08843.42 μM+++119MYO1Di-B089>80+-120MYO1Di-B09044.80 μM+-121MYO1Di-B091>80++122MYO1Di-B09247.69 μM--123MYO1Di-B09313.54 μM-+124MYO1Di-B09469.50 μM-+125MYO1Di-B095>80+-126MYO1Di-B0961.11 μM-+127MYO1Di-B097>80--128MYO1Di-B098>80+++129MYO1Di-B09949.88 μM++130MYO1Di-B10031.78 μM+++131MYO1Di-B101>80--132MYO1Di-B10233.16 μM+-133MYO1Di-B10327.06 μM-+134MYO1Di-B1048.70 μM-+135MYO1Di-B10534.39 μM++136MYO1Di-B10619.58 μM+-137MYO1Di-B107<1 μM+++138MYO1Di-B108>80++139MYO1Di-B109>80--140MYO1Di-B1104.03 μM++141MYO1Di-B111>80--142MYO1Di-B11214.44 μM++. Twelve compounds were selected based on their inhibitory ranking of reporter activity and their inhibitory effect on the invasiveness of Caco2 / MYO1D cells. Among these, MYO1Di-B014 not only excellently inhibited reporter activity in 293T cells (Fig. 2), but also significantly inhibited cell invasion (Fig. 3) and cell survival (Fig. 4) increased by MYO1D in Caco2 colorectal cancer cells. In addition, to determine whether the selected MYO1Di compound affects GFR expression levels as if it were knocking down MYO1D, various GFR expressions were analyzed after treating Caco2 colorectal cancer cells with MYO1Di-B014 (1 or 5 μM) for 48 or 72 hours. As a result, treatment with MYO1Di-B014 reduced the protein levels of EGFR, HER2, c-Met, VEGFR1, as well as MYO1D (Fig. 5). This reduction effect tended to be proportional to the treatment concentration and treatment time. 3-2. Inhibitory Effects of MYO1Di Compound on Survival and Mobility of Mutant GFR-Expressing Cancer Cells To determine whether the MYO1Di compound affects the survival and motility of NSCLC cells resistant to TKIs such as osimertinib, similar to MYO1D knockdown, cell signals, cell proliferation, and motility were evaluated by performing MTT, invasion, and immunoblot analyses on H1975 / OR cells. Treatment with MYO1Di-B014 reduced the expression levels of EGFR and HER2 similarly to MYO1D knockdown (see right diagram in Fig. 6) and also inhibited EGFR downstream signaling pathways such as p-AKT and p-ERK (see right diagram in Fig. 6). These signaling pathways are associated with cell proliferation and motility. Additionally, treatment with MYO1Di-B014 reduced cell invasiveness (Fig. 7). In the MTT assay, H1975 cell proliferation was inhibited upon treatment with osimertinib or MYO1Di-B014 (upper diagram in Fig. 8); however, in H1975 / OR cells, viability was significantly reduced upon treatment with 5 μM MYO1Di-B014, whereas no such change was observed upon treatment with 10 μM osimertinib (lower diagram in Fig. 8). The reduction effect tended to be proportional to the compound concentration and treatment time. Next, to determine whether the MYO1Di compound affects the survival of cancer cells expressing mutant EGFRs, MTT and clonogenic analyses were performed on Caco2 / EGFR-C797S, U87 / EGFR-vIII, BaF3 / mutant EGFRs, and H1975 / HER2 cells. Additionally, the effects of the MYO1Di compound were compared with treatments of afatinib or osimertinib. In Caco2 / EGFR-L858R-T790M-C797S cells, cell proliferation was significantly inhibited in a concentration-dependent manner after 72 hours (Fig. 9). In U87 / EGFR-vIII glioblastoma cells, some resistance to afatinib was observed, but MYO1Di-B014 showed an inhibitory effect after 72 hours at concentrations of 20 μM or higher (Fig. 10). BaF3 / EGFR-L858R-T790M-C797S cells were resistant to osimertinib, but MYO1Di-B014 significantly inhibited cell proliferation after 72 hours at concentrations of 5 μM or higher and also reduced the expression level of mutant EGFR (Fig. 11). On the other hand, in BaF3 / EGFR-Δ19-T790M and BaF3 / EGFR-L858R-T790M cells, osimertinib and MYO1Di-B014 similarly inhibited proliferation (Fig. 11). ErbB2 (HER2 / neu) plays an important role in the pathophysiology of some breast and ovarian cancers, and ErbB2 overexpression and gene mutations have also been reported in about 20% of lung cancers (Bunn et al., 2001; McLoughlin and Gentzler, 2020). When the effects of the MYO1Di compound were confirmed in these wild-type EGFR and ErbB2 overexpressing lung cancer cells, H1975 / HER2 cells showed almost no change in proliferation upon treatment with 10 μM osimertinib, but cell proliferation was further reduced upon treatment with MYO1Di-B014 (Fig. 12). In clonal analysis, MYO1Di-B014 reduced the long-term survival of cancer cells expressing the mutant EGFR, namely the EGFR-L858R-T790M-C797S mutation, and also reduced the expression levels of EGFR, c-Met, and MYO1D (Fig. 13). These results indicate that the reduction in wild-type and mutant GFR in MYO1Di-B014-treated cells is caused by a reduction in MYO1D, which leads to reduced cell viability and motility. In summary, these results suggest that the MYO1Di compound can inhibit cell survival and motility through a mechanism in which it reduces MYO1D—similar to MYO1D knockdown—thereby blocking the interaction between MYO1D and EGFR, and thereby downregulating GFRs in the plasma membrane of cancer cells. 3-3. Ecm29 is a protein that binds to MYO1Di-B014. To identify candidate proteins that bind to the MYO1Di compound and mediate its anticancer activity, such as the reduction of MYO1D and the subsequent downregulation of GFR, chemical probes were constructed by attaching Affigel beads to the MYO1Di compound. Since the MYO1Di-B014 compound does not possess a site for direct linker attachment, several synthetic derivatives derived from MYO1Di-B014 were designed, and their inhibitory activity against cell invasion in Caco2 / MYO1D cells was evaluated (Fig. 14). The optimal candidate compound suitable for Affigel bead binding was selected by comparing its activity with that of MYO1Di-B014. As a result, MYO1Di-B66 exhibited a MYO1D-induced inhibitory effect similar to that of MYO1Di-B014 (Fig. 15) and also possessed a structure capable of linker attachment. MYO1Di-B66 not only inhibited the proliferation of Caco2 / MYO1D cells in a concentration-dependent manner (Fig. 16), but also reduced the expression levels of EGFR, ErbB4, c-Met, and MYO1D to the same extent as with MYO1Di-B014 treatment (Fig. 17, right vs. left). This suggests that MYO1Di-B014 and MYO1Di-B66 have the same mechanism of action. The chemical structure of MYO1Di-B66 is presented in Fig. 18, and the linker attachment site is indicated by an arrow. As shown in Fig. 18, treatment with 1 μM MYO1Di-B66-linker-Ac inhibited the invasiveness of Caco2 / MYO1D cells to a level similar to that of free MYO1Di-B66 treatment, which implies that it exhibits the same activity regardless of linker attachment. Therefore, MYO1Di-B66 bound to Affigel beads was used in subsequent experiments. The fabricated chemical probe (B66-Affigel) was mixed with Caco2 / MYO1D cell lysate to pull down compound-binding proteins, which were then separated by 10% SDS-PAGE and subjected to Coomassie blue staining (Fig. 19, left). Bands distinct from the control group (Affigel alone) were excised and subjected to MALDI-TOF Mass Spectrometry (MS), which identified several candidate proteins (Fig. 19, right). Among the proteins binding to MYO1Di-B66 (MYO1Di-B014), we selected Ecm29 as the most likely mediating protein. Ecm29 (Extracellular Mutant 29) is an adapter protein that binds to a portion of the 26S proteasome and links it to an Ecm29-binding protein. This aligns with the mechanism by which the MYO1Di compound induces MYO1D reduction and the subsequent downregulation of GFR. Subsequently, when the protein pulled down by the chemical probe was blotted with a specific antibody, it was confirmed that not only Ecm29 but also MYO1D binds to MYO1Di-B66 (Fig. 20). Next, we aimed to verify whether the inhibitory effect of MYO1Di-B014 on colorectal cancer cell proliferation is dependent on Ecm29 expression. To this end, we analyzed the expression levels of Ecm29 and MYO1D in various CRC cells. The results showed that Caco2 and SW480 cells expressed high levels of endogenous Ecm29, and SW480 cells also exhibited relatively high expression of MYO1D (Fig. 21). Considering transformation efficiency and proliferation rate, we selected Caco2 cells as the experimental subjects. Interestingly, Ecm29 knockdown using si-Ecm29 RNA significantly restored the proliferation of Caco2 / MYO1D cells inhibited by MYO1Di-B014 (Fig. 22), and the expression levels of EGFR and MYO1D also recovered to basal levels upon Ecm29 knockdown, as the effect of MYO1Di-B014 treatment was offset (Fig. 23). These results imply that the inhibitory effect of MYO1Di-B014 on proliferation disappears when Ecm29 is deficient. In conclusion, since Ecm29 and MYO1D are partner proteins that bind to MYO1Di-B014, and the deficiency of Ecm29 nullifies the effect of MYO1Di-B014 in inhibiting the increase in cell proliferation induced by MYO1D, Ecm29 and MYO1D are considered sub-molecules involved in the regulation of cell proliferation along the same axis. 3-4. MYO1Di-B014 primarily binds to the 5th-7th HEAT repeat region in the N-terminal half of Ecm29. Ecm29 is known to act as an adapter protein that binds to a portion of the 26S proteasome (Gorbea et al., 2004). The C-terminal half of human Ecm29 binds to myosin and kinesin, while the N-terminal region binds to endocytosis-associated proteins such as Vps11, Rab11-FIP4, and rabaptin. The full-length FLAG-Ecm29, the C-terminal half, and the central fragment remain bound to the 26S proteasome separated by a glycerol gradient, whereas the N-terminal half does not. Therefore, it is presumed that Ecm29 acts as an adapter protein that links the 26S proteasome with the Ecm29 binding protein (Gorbea et al., 2010). Since Ecm29 and MYO1D were identified as binding partners to MYO1Di-B66 (Fig. 20), we wanted to determine whether MYO1D interacts with Ecm29 in normal cells not treated with MYO1Di. As a result, it was confirmed that MYO1D and Ecm29 do not bind in Caco2 / p or Caco2 / MYO1D cells not treated with the MYO1Di compound (Fig. 24). In addition, as previous reports have identified myosins and kinesins (Myo10, Myh7, Myh10, Myo1B, KIF1B, KIF5B, etc.) as Ecm29-binding proteins (Gorbea et al., 2010), we investigated whether MYO1Di-B014 affects the expression levels of MYO1B and MYO10 in addition to MYO1D. As shown in Figure 25, treatment with MYO1Di-B014 up to 20 μM gradually reduced MYO1D expression but did not affect the expression of MYO10 and MYO1B. This suggests that MYO1D is selectively recruited to and binds to Ecm29 only after administration of the MYO1Di compound. Next, to identify the precise binding site of MYO1Di-B014 to Ecm29, Ecm29 deletion mutants were cloned into a bacterial expression vector containing a His tag and purified by Ni-NTA affinity chromatography. These proteins were reacted with Affigel alone or with a chemical probe (B66-Affigel), and then immunoblotting was performed with an anti-His antibody to confirm whether MYO1Di-B014 binds to the Ecm29 deletion mutants. As a result, a positive band was observed in the N-terminal half of Ecm29 (amino acids 1-881) and specifically in the 308-648 amino acid range, whereas the C-terminal half (882-1846) did not bind (Figs. 26 and 27). This suggests that MYO1D, which anchors GFRs to the membrane, and Ecm29, which links 26S proteasomes to Ecm29-binding proteins in the cytoplasm, can form a functional complex after MYO1Di administration. Currently, surface plasmon resonance (SPR) analysis is underway to support the binding of MYO1Di-B014 to the 5th–7th HEAT repeats in the N-terminal half (numbers 308–648) of Ecm29 (Gorbea et al., 2004). Additionally, research is underway to identify the type of E3 ligase that binds to the functional Ecm29 / 26S proteasome complex after MYO1Di administration. Synthesizing these results, it is presumed that after treatment with MYO1Di-B014, the continuous HEAT repeat region of Ecm29 forms a solenoid structure to encapsulate binding partners or collapses into a single domain to bind to various proteins such as MYO1D and the E3 ligase / 26S proteasome complex (Gorbea et al., 2010). 3-5. MYO1Di-B014 first degrades Ecm29 and molecular motor MYO1D, and then removes various GFRs immobilized on the plasma membrane through the degrade of MYO1D. Since the inhibitory effect of MYO1Di-B014 on GFR function is presumed to be due to its specific binding to the central N-terminal half of Ecm29 (including the 5th–7th HEAT repeats), the inventors further investigated the temporal effects of MYO1Di-B014 on the expression levels of Ecm29, MYO1D, and GFR. After treating Caco2 cells with 10 μM MYO1Di-B014 once daily for 3 days, the expression levels of various GFRs, including EGFR, c-Met, VEGFR1 / 2 / 3, IGF1R, and FGFR, were analyzed daily (at 24, 48, and 72 hours). As a result, Ecm29 expression decreased on the 1st day after treatment, a decrease in MYO1D levels was observed on the 2nd day, and a decrease in the expression of GFRs (EGFR, c-Met, VEGFR1 / 2 / 3, etc.) was observed on the 3rd day (Fig. 28). In addition, it was confirmed that Ecm29 and MYO1D were ubiquitinated after treatment with MYO1Di-B014 (Fig. 29), and it was confirmed that the target proteins were degraded in the order of Ecm29, MYO1D, and GFR during a 3-day daily treatment period (Fig. 30). These results can be summarized as follows: After treatment with the MYO1Di compound, MYO1Di-B014 first bound to Ecm29 to recruit the molecular motor MYO1D to the E3 ligase / 26S proteasome complex, and by degrading MYO1D, disintegrated various GFRs such as EGFR, HER2, c-Met, and VEGFR1 / 2 / 3 from the plasma membrane, subsequently induced proteasome degradation of these GFRs. Therefore, based on in vitro experimental results, the inventors propose the following mechanism of action: the MYO1Di compound first binds to Ecm29 like MGD (molecular adhesive), targets and degrades MYO1D, and then secondarily degrades GFRs dissociated from the plasma membrane through the proteasome (Fig. 31). 3-6. MYO1Di-B014 inhibits tumor growth in an in vivo mouse model. To confirm whether the compound MYO1Di-B014 has an in vivo antitumor effect, the inventors used a syngeneic tumor model using colorectal adenocarcinoma cell lines derived from BALB / c mice and CT-26 mice. CT-26 / iRFP cells were subcutaneously injected into the right flank of BALB / c mice, and the tumors grew to a size that allowed for measurement on day 6 after injection. The dosage of MYO1Di-B014 (20, 40 mg / kg) was designed to maintain blood concentrations above the minimum effective in vitro concentration (5 μM), and was administered by intraperitoneal injection daily for 12 days starting 7 days after cell injection (Fig. 32). As shown in Fig. 33, tumor volume was significantly reduced after treatment with MYO1Di-B014, and tumor weight (Figs. 34 and 35) and total tumor fluorescence emitted from CT-26 / iRFP cells (Figs. 34 and 36) also decreased in proportion to the administered dose of MYO1Di-B014. No change in body weight was observed during the MYO1Di-B014 treatment period, and no significant abnormalities were observed (Fig. 37). These results indicate that MYO1Di-B014 effectively inhibits tumor growth in an in vivo allograft mouse model, and furthermore, suggest that the MYO1Di compound may act as a potential therapeutic agent to inhibit the progression of colorectal cancer. 3-7. MYO1Di-B68 inhibits tumor growth and liver metastasis of colorectal cancer in vivo. Since MYO1Di-B014 was administered daily at a relatively high dose (40 mg / kg) in an allograft tumor model (Fig. 32), we sought to find a new MYO1Di compound that possesses stronger cytotoxic activity at a lower dose. Accordingly, the inventors redesigned a series of derivatives based on the structure of MYO1Di-B014 and compared the inhibitory effects of these candidate substances on MYO1D and EGFR expression, as well as on the inhibition of cell viability in Caco2 / MYO1D cells, with those of MYO1Di-B014 (Figs. 38 and 39). Among them, MYO1Di-B38 and MYO1Di-B68 were selected as candidate substances. MYO1Di-B68 showed an inhibitory effect on Caco2 / MYO1D cell proliferation (Fig. 40; IC 50 : MYO1Di-B014 = 16.65 μM vs. MYO1Di-B68 = 10.33 μM), showed superior activity compared to MYO1Di-B014 in the inhibition of 4T1 cell proliferation (Fig. 39) and the inhibition of invasiveness in H1975 / OR cells (at 5 μM treatment, Fig. 41). Immunoblot analysis revealed that the expression of MYO1D and EGFR in Caco2 / MYO1D cells was reduced in both MYO1Di-B38 and MYO1Di-B68 treatments, similar to MYO1Di-B014 treatment (Fig. 40). This indicates that MYO1Di-B38 and MYO1Di-B68 share the same mechanism of action as MYO1Di-B014. Therefore, the inventors used these two compounds in subsequent in vivo experiments. In in vivo experiments using MYO1Di-B68 or MYO1Di-B38, the inventors reduced the maximum dose to 20 mg / kg (Fig. 42) and administered the drugs via intraperitoneal injection daily for two weeks, starting seven days after cell injection. After two weeks, mice were sacrificed and tumors were analyzed. During the experimental period, tumor volume gradually decreased upon treatment with the MYO1Di compounds (Fig. 43), and no change in body weight was observed (Fig. 44). When MYO1Di-B68 or MYO1Di-B38 was administered daily for two weeks, total tumor fluorescence (Fig. 45) and tumor weight (Fig. 46) were significantly reduced compared to the control group. Among them, the 20 mg / kg MYO1Di-B68 administration group showed the most superior inhibitory effect. In addition, the tumor expression levels of various growth factor receptors (GFRs), including EGFR, HER2, c-Met, VEGFR1, and VEGFR2, were clearly reduced in the 20 mg / kg MYO1Di-B68 treatment group compared to the control group, and the expression of MYO1D and Ecm29 was also reduced (Fig. 47). These in vivo data after MYO1Di-B68 administration showed a pattern similar to the in vitro GFR reduction trend previously observed in Caco2 cells after MYO1Di-B014 treatment (Fig. 28). The inventors also evaluated the antitumor effect of MYO1Di-B68 using a colorectal cancer liver metastasis model. CT-26 / KITENIN-iRFP-expressing cells were intrasplenically injected into the spleen of allogeneic mice, followed by splenectomy 10 minutes later to allow the cells to migrate to the liver via the portal vein, and the mice were allowed to recover for 2 weeks (Bae et al., 2021). Subsequently, the mice were treated with 5-FU 100 mg / kg once every 2 weeks via intraperitoneal injection, MYO1Di-B38 or B68 10 or 20 mg / kg daily via intraperitoneal injection, or as a vehicle-treated control group (Fig. 48). Liver metastasis was assessed through the total fluorescence signal emitted from tumor nodules expressing iRFP (Fig. 49). The fluorescence intensity of liver nodules was significantly reduced in the 5-FU alone group or the 20 mg / kg MYO1Di-B68 treatment group compared to the control group (Fig. 50). On the other hand, 10 mg / kg MYO1Di-B38 or MYO1Di-B68 did not inhibit liver metastasis (Fig. 50). Therefore, 20 mg / kg MYO1Di-B68 showed a superior inhibitory effect on liver metastasis compared to 5-FU. This inhibitory effect of MYO1Di-B68 is likely due to the degradation of various GFRs that regulate cell proliferation and invasiveness, whereas the effect of 5-FU is likely due to cytotoxicity. 3-8. MYO1Di-B68 treatment inhibits tumor growth and lung metastasis of TNBC in vivo. Recently, it has been suggested that MYO1D expression is increased in tumor tissues of triple-negative breast cancer (TNBC) patients and that MYO1D could be a new target gene for TNBC treatment. The inventors first evaluated the antitumor effects of MYO1Di compounds in vitro using various human and mouse TNBC cell lines. MYO1Di-B014 inhibited cell proliferation in MDA-MB-231, MDA-MB-468, HCC1806 cells (Fig. 51) and 4T1 cells (Fig. 39), and also inhibited the clonogenic survival of MDA-MB-231 cells (Fig. 51). In addition, MYO1Di-B68 also inhibited proliferation in MDA-MB-231, HCC1806 (Fig. 52), and 4T1 cells (Fig. 39). After treatment with MYO1Di-B014, the expression of MYO1D, EGFR, and VEGFR1 / 2 was reduced in TNBC cells (Fig. 51), which was similar to the results observed in colon cancer cells treated with MYO1Di-B014 (Fig. 28). To obtain a novel compound with higher PBS solubility for in vivo use, we synthesized MYO1Di-B68-Na, a structural derivative of MYO1Di-B68. This compound improved PBS solubility by substituting a hydrogen (H) in the middle of the structure with sodium (Na). In subsequent analyses, the inhibitory effect on cell proliferation after treatment with MYO1Di-B68 and B68-Na was found to be at similar levels in human TNBC cells (Figs. 52 and 53), mouse 4T1 TNBC cells (Fig. 54), and Caco2 colon cancer cells (Fig. 53). Additionally, a decrease in the expression of MYO1D, EGFR, HER2, and VEGFR1 was observed in TNBC cells after treatment with MYO1Di-B68-Na (Fig. 52), which was similar to the decrease in GFR expression in tumor tissues in vivo by MYO1Di-B68 (Fig. 47). Therefore, the inventors used MYO1Di-B68-Na in subsequent in vivo experiments on TNBC. The inventors tested the in vivo antitumor effects of MYO1Di-B68-Na against TNBC using a BALB / c mouse allograft model and a 4T1 breast cancer cell line. 4T1 cells (5×10⁶ 5MYO1Di-B68-Na was orthotopically injected into the fourth mammary gland fat pad of mice, and after 10 days, the tumor had grown sufficiently to be measurable. Cisplatin, one of the drugs currently used to treat TNBC, was selected as the reference anticancer agent, and cisplatin (5 mg / kg) was administered intraperitoneally once a week for 2 weeks (Pal et al., 2011; Gupta et al., 2020). Doses of MYO1Di-B68-Na (10, 20, 40 mg / kg) were determined based on previous experiments, and it was administered intraperitoneally five times a week for 2 weeks starting 14 days after cell injection (Fig. 55). According to Fig. 56, tumor volume gradually decreased after treatment with cisplatin or MYO1Di-B68-Na. The well-known tumor-suppressing effect of cisplatin was also observed in tumor weight (Figs. 57 and 58) and spleen weight (Fig. 14E). MYO1Di-B68-Na (40 mg / kg) also reduced tumor and spleen weights compared to the control group, but this was not statistically significant (Figs. 58 and 59). On the other hand, 10 mg / kg and 20 mg / kg MYO1Di-B68-Na did not inhibit tumor progression (Figs. 56 and 58). There was no change in body weight during MYO1Di-B68-Na treatment, but body weight decreased significantly after cisplatin treatment (Fig. 60). Interestingly, the number of lung metastatic nodules was significantly reduced in the cisplatin-alone treatment (5 mg / kg) or 40 mg / kg MYO1Di-B68-Na treatment groups (Figs. 61 and 62). This demonstrates that MYO1Di-B68-Na (40 mg / kg), in combination with cisplatin, clearly inhibits lung metastasis of TNBC. 3-9. Combined administration of MYO1Di-B68 and cisplatin effectively inhibits tumor growth of TNBC in vivo. An appropriate amount of 4T1 cells (5×10 5Since tumor and spleen weights decreased slightly after treatment with 40 mg / kg MYO1Di-B68-Na in an allogeneic TNBC inoculation model (injected into 4T1 cells), the inventors re-examined the antitumor effect of MYO1Di in a model with a lower cell count condition injecting 1 × 10⁶ 4T1 cells (Fig. 63). Considering the rapid decrease in body weight after treatment with 5 mg / kg cisplatin in the previous experiment (Fig. 61), the dose of cisplatin was adjusted to 4 mg / kg once a week for 3 weeks, and the doses of MYO1Di-B68-Na (20, 40 mg / kg) were also adjusted according to the previous results and administered daily via intraperitoneal injection for 3 weeks starting 9 days after cell injection (Fig. 63). According to Fig. 64, the 40 mg / kg MYO1Di-B68-Na treatment group showed a slightly superior tumor suppression effect compared to cisplatin during the early and mid-stages of the experiment. Overall, after 3 weeks of treatment, both 40 mg / kg MYO1Di-B68-Na and 4 mg / kg cisplatin showed similar and significant antiproliferative effects (Figs. 65, 66, and 67). In addition, compared to the control group, the number of lung metastatic nodules decreased in the groups treated with 4 mg / kg cisplatin or 40 mg / kg MYO1Di-B68-Na (Figs. 68 and 69), which was similar to previous results (Figs. 61 and 62). No changes in body weight were observed during treatment with MYO1Di-B68-Na or cisplatin alone (Fig. 70), and in the tumor tissue of the 40 mg / kg MYO1Di-B68-Na treatment group, the expression of EGFR, HER2, c-Met, VEGFR1, VEGFR2, as well as MYO1D and Ecm29, was significantly reduced compared to the control group (Fig. 71). This shows that the decreasing trend in GFR observed after MYO1Di-B68-Na treatment in TNBC (Fig. 71) is similar to the decreasing trend in GFR after MYO1Di-B68 treatment in colorectal cancer (Fig. 47). Since both 40 mg / kg MYO1Di-B68-Na and 4 mg / kg cisplatin showed similar antiproliferative effects (Figs. 65 to 68), the inventors subsequently evaluated the in vivo inhibitory effect on TNBC progression when these two drugs were administered in combination (same model as Fig. 63). Cisplatin (4 mg / kg, once a week) or cisplatin (4 mg / kg, once a week) and MYO1Di-B68-Na (40 mg / kg, daily) were administered by intraperitoneal injection for 3 weeks starting 15 days after cell injection (Fig. 72). According to Fig. 73, the combination therapy group showed a significantly greater tumor-inhibiting effect throughout the experimental period compared to cisplatin alone or the control group. Compared to the control group, tumor weight (Figs. 74 and 75) and spleen weight (Fig. 76) were significantly reduced in the combination therapy group. No change in body weight was observed in the combination therapy group (Fig. 77). Consequently, tumor progression in TNBC was more strongly inhibited when administered in combination with MYO1Di-B68-Na than with cisplatin alone. Therefore, the results of this study suggest that MYO1Di-B68-Na has great potential as an anticancer candidate that effectively inhibits tumor growth in a mouse allograft in situ TNBC model and can further effectively inhibit TNBC progression when combined with cisplatin.

Claims

1. A compound, its optical isomer, solvate, or pharmaceutically acceptable salt selected from the group consisting of the following compounds: 1) 5-(dimethylamino)-N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 4) 5-(dimethylamino)-N-(3-methoxyphenyl)naphthalene-1-sulfonamide; 5) N-(2,3-dihydro-1H-indene-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide; 6) 5-(dimethylamino)-N-(3-phenoxyphenyl)naphthalene-1-sulfonamide; 8) 5-(dimethylamino)-N-(3-isopropoxyphenyl)naphthalene-1-sulfonamide; 9) N-(benzo[d][1,3]dioxol-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide; 10) 5-(dimethylamino)-N-(thiazole-2-yl)naphthalene-1-sulfonamide; 11) 5-(dimethylamino)-N-(quinoline-3-yl)naphthalene-1-sulfonamide; 12) 5-(dimethylamino)-N-(3-fluorobenzyl)naphthalene-1-sulfonamide; 14) 5-(dimethylamino)-N-(4-fluorobenzyl)naphthalene-1-sulfonamide; 16) 5-(dimethylamino)-N-(2-(pyrrolidine-1-yl)ethyl)naphthalene-1-sulfonamide; 17) 5-(dimethylamino)-N-(2-(piperidine-1-yl)ethyl)naphthalene-1-sulfonamide; 20) 5-(dimethylamino)-N-(tetrahydro-2H-pyran-4-yl)naphthalene-1-sulfonamide; 21) tert-butyl (2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-λ 2 - Azanecarboxylate; 22) tert-butyl 4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-carboxylate; 24) N-(3-aminopropyl)-5-(dimethylamino)naphthalene-1-sulfonamide; 25) N-(3-((5-(dimethylamino)naphthalene)-1-sulfonamido)propyl)cyclobutanecarboxamide; 27) 1-(4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-yl)-2-phenylethane-1-one; 28) Cyclobutyl(4-((5-(dimethylamino)naphthalene-1-yl)sulfonyl)piperazine-1-yl)methanone; 29) N-(2-aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide hydrochloride; 30) N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-4-methylbenzamide; 31) N-(2-((5-(dimethylamino)naphthalene)-1-sulfonamido)ethyl)-2-(p-tolyl)acetamide; 33) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(3-chlorophenyl)methanone; 34) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(3-(trifluoromethyl)phenyl)methanone; 35) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(4-nitrophenyl)methanone; 36) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(pyrazine-2-yl)methanone; 37) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(thiophene-2-yl)methanone; 38) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(1H-indole-3-yl)methanone; 39) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(5-nitro-1H-pyrazol-3-yl)methanone; 40) (4-((5-bromothiophene-2-yl)sulfonyl)piperazine-1-yl)(1H-indole-4-yl)methanone; 43) 5-Bromo-N-(3-fluoro-2-methoxyphenyl)thiophene-2-sulfonamide; 44) 5-Bromo-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 53) 5-Bromo-N-(3-methylpyridine-2-yl)thiophene-2-sulfonamide; 54) 5-Bromo-N-(4-methylpyridine-2-yl)thiophene-2-sulfonamide; 55) 5-Bromo-N-(quinoline-3-yl)thiophene-2-sulfonamide; 56) 5-Bromo-N-(6-(trifluoromethyl)pyridine-3-yl)thiophene-2-sulfonamide; 57) 5-Bromo-N-(3-methoxyphenyl)thiophene-2-sulfonamide; 58) 5-Bromo-N-(2,3-Dihydro-1H-Indene-5-yl)thiophene-2-sulfonamide; 59) 5-Bromo-N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)thiophene-2-sulfonamide; 60) 5-Bromo-N-(3-isopropoxyphenyl)thiophene-2-sulfonamide; 61) 5-Bromo-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 62) 5-Bromo-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 63) N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 64) N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 65) N-(4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 66) N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 67) N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 68) 5-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 69) 5-chloro-N-(4-chloro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 71) 5-chloro-N-(2-chloro-4-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 72) 5-chloro-N-(2-fluoro-5-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 73) N-(2-fluoro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 74) N-(4-chloro-3-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 75) 3,4-Dimethoxy-N-(4-(trifluoromethyl)phenyl)benzenesulfonamide; 76) N-(2-chloro-4-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 77) N-(2-fluoro-5-(trifluoromethyl)phenyl)-3,4-dimethoxybenzenesulfonamide; 78) N-(2-fluoro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 79) N-(4-chloro-3-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 80) N-(4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 81) N-(2-chloro-4-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 82) N-(2-fluoro-5-(trifluoromethyl)phenyl)naphthalene-1-sulfonamide; 83) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-phenylthiophene-2-sulfonamide; 84) 5-(2,4-difluorophenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 85) 5-([1,1'-biphenyl]-2-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 86) 5-(4-(tert-butyl)phenyl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 87) 5-(benzo[d][1,3]dioxol-4-yl)-N-(2-fluoro-3-(trifluoromethyl)phenyl)thiophene-2-sulfonamide; 88) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-morpholinothiophene-2-sulfonamide; 89) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperidine-1-yl)thiophene-2-sulfonamide; 90) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(pyrrolidin-1-yl)thiophene-2-sulfonamide; 91) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-phenylpiperazine-1-yl)thiophene-2-sulfonamide; 92) (S)-N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(3-hydroxypyrrolidine-1-yl)thiophene-2-sulfonamide; 93) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(piperidine-1-yl)piperazine-1-yl)thiophene-2-sulfonamide; 94) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(4-(2-fluorophenyl)piperazine-1-yl)thiophene-2-sulfonamide; 95) tert-butyl 4-(5-(N-(2-fluoro-3-(trifluoromethyl)phenyl)sulfamoyl)thiophene-2-yl)piperazine-1-carboxylate; 96) N-(2-fluoro-3-(trifluoromethyl)phenyl)-5-(piperazine-1-yl)thiophene-2-sulfonamide; 97) N-(2-fluoro-3-(trifluoromethyl)phenyl)pyridine-3-sulfonamide; 98) 2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 99) 2,4-difluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 100) 2-fluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 101) N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-methoxybenzenesulfonamide; 102) N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 103) 4-chloro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 104) N-(2-fluoro-3-(trifluoromethyl)phenyl)-4-nitrobenzenesulfonamide; 105) N-phenylthiophene-2-sulfonamide; 106) N-phenylpyridine-3-sulfonamide; 107) 3,4-Dimethoxy-N-phenylbenzenesulfonamide; 108) 2,3,4-trifluoro-N-phenylbenzenesulfonamide; 109) 2,4-difluoro-N-phenylbenzenesulfonamide; 110) 2-fluoro-N-phenylbenzenesulfonamide; 111) 4-methoxy-N-phenylbenzenesulfonamide; 113) 4-chloro-N-phenylbenzenesulfonamide; 114) 4-nitro-N-phenylbenzenesulfonamide; 115) N-(benzo[d][1,3]dioxol-5-yl)-2,3,4-trifluorobenzenesulfonamide; 116) N-(benzo[d][1,3]dioxol-5-yl)-3,4,5-trifluorobenzenesulfonamide; 117) N-(benzo[d][1,3]dioxol-5-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide; 118) N-((3s,5s,7s)-adamantan-1-yl)-2,3,4-trifluorobenzenesulfonamide; 119) N-((3s,5s,7s)-adamantan-1-yl)-3,4,5-trifluorobenzenesulfonamide; 121) 1-(pyridine-2-yl)-4-((2,3,4-trifluorophenyl)sulfonyl)piperazine; 122) 1-(pyridine-2-yl)-4-((3,4,5-trifluorophenyl)sulfonyl)piperazine; 123) 1-((perfluorophenyl)sulfonyl)-4-(pyridine-2-yl)piperazine; 124) 2,3,4-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)benzenesulfonamide; 125) 3,4,5-trifluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)benzenesulfonamide; 126) 2,3,4,5,6-pentafluoro-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazole-5-yl)benzenesulfonamide; 127) N-(2,6-dioxopiperidin-3-yl)-2,3,4-trifluorobenzenesulfonamide; 128) N-(2,6-dioxopiperidin-3-yl)-3,4,5-trifluorobenzenesulfonamide; 129) N-(2,6-dioxopiperidin-3-yl)-2,3,4,5,6-pentafluorobenzenesulfonamide; 130) (S)-1'-((2,3,4-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine; 131) (S)-1'-((3,4,5-trifluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine; 132) 2,3,4-trifluoro-N-(1H-indole-7-yl)benzenesulfonamide; 133) 3,4,5-trifluoro-N-(1H-indole-7-yl)benzenesulfonamide; 134) 2,3,4,5,6-pentafluoro-N-(1H-indole-7-yl)benzenesulfonamide; 135) 2,3,4-trifluoro-N-(1H-indole-6-yl)benzenesulfonamide; 136) 3,4,5-trifluoro-N-(1H-indole-6-yl)benzenesulfonamide; 137) 2,3,4,5,6-pentafluoro-N-(1H-indole-6-yl)benzenesulfonamide; 138) N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxosoidolindolin-5-yl)-2,3,4-trifluorobenzenesulfonamide; 139) N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxosoidolindolin-5-yl)-3,4,5-trifluorobenzenesulfonamide; 140) 2,3,4,5,6-pentafluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzenesulfonamide; 141) 2,3,4-trifluoro-N-(2-fluoro-3-(trifluoromethyl)phenyl)benzamide; and 142) (S)-1'-((perfluorophenyl)sulfonyl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine; 2. A pharmaceutical composition for the prevention or treatment of cancer comprising the MYO1D activity-inhibiting compound of claim 1, or a stereoisomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.

3. In paragraph 2, the above cancer is pseudomyxoma, intrahepatic cholangiocarcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, oropharyngeal tonsil cancer, oropharyngeal hypopharyngeal cancer, mycosis fungoides, acute myeloid leukemia, acute lymphoblastic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell tumor, male breast cancer, brain tumor, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphoblastic leukemia, retinoblastoma, choroidal melanoma, diffuse large B-cell lymphoma, ampulla of Vater cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, rhinosinus cancer, non-small cell lung cancer, non-Hodgkin lymphoma, tongue cancer, genital cord stromal tumor, astrocytoma, Small cell lung cancer, pediatric brain tumor, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, neuroblastoma, renal pelvis cancer, kidney cancer, heart cancer, duodenal cancer, malignant bone tumor, malignant lymphoma, malignant soft tissue tumor, malignant mesothelioma, malignant melanoma, eye tumor, vulvar cancer, ureteral cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric carcinoid tumor, gastrointestinal stromal tumor, Wilms tumor, breast cancer, triple-negative breast cancer (TNBC), sarcoma, penile cancer, gestational trophoblastic disease, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone tumor, metastatic brain tumor, mediastinal cancer, rectal neuroendocrine tumor, rectal cancer, vaginal cancer, spinal cord tumor, acoustic neuroma, pancreatic cancer, salivary gland cancer, Kaposi sarcoma, Paget's disease, squamous cell carcinoma, A pharmaceutical composition that is lung adenocarcinoma, lung cancer, squamous cell carcinoma of the lung, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, or thymic cancer.

4. A pharmaceutical composition according to paragraph 2, wherein the cancer is a primary tumor or a metastatic tumor derived therefrom.

5. In paragraph 2, the pharmaceutical composition is a pharmaceutical composition applied to a patient having a GFR mutation.

6. A pharmaceutical composition according to paragraph 2, wherein the pharmaceutical composition replaces or combines with an anticancer agent targeting GFR or GFR mutations.

7. A pharmaceutical composition according to paragraph 2, wherein the pharmaceutical composition replaces or combines an anti-PD-1 immune checkpoint inhibitor.

8. A pharmaceutical composition for the prevention or treatment of diseases or disorders caused by the overexpression of GFR, such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, wet macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, psoriasis, rheumatoid arthritis, encephalomatosis, infantile hemangioma, telangiectasia, proteinuria, renal failure, placenta previa, eclampsia, or arteriovenous malformations, comprising the MYO1D activity-inhibiting compound of claim 1, or a stereoisomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition for the prevention or treatment of degenerative brain diseases comprising the MYO1D activity-inhibiting compound of claim 1, or a stereoisomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, A pharmaceutical composition in which the above-mentioned degenerative brain disease is Parkinson's disease, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, or Huntington's disease.